UniProtAccMutation	uniprot_acc	UniProtGeneMutation	gene	status	variant_or_mutagen	Orig_AA	Position	Mut_AA	info	match	type	uniprot_id	inclusion	comments(A/DECREASE/LOSS)		
Q13131/V307G	Q13131	PRKAA1/V307G	PRKAA1	Reviewed;	MUTAGEN	V	307	G	Q: Activates the kinase activity."";/evidence=""ECO:0000269|PubMed:17088252""	activating	A	AAPK1				
P00519/A337T	P00519	ABL1/A337T	ABL1	Reviewed;	VARIANT	A	337	T	in CHDSKM; increases kinase activity; no;effect on protein levels; dbSNP:rs1060499548)"";/evidence=""ECO:0000269|PubMed:28288113"";/id=""VAR_079483""	activating	A	ABL1	increase			
P00519/Y226C	P00519	ABL1/Y226C	ABL1	Reviewed;	VARIANT	Y	226	C	in CHDSKM; increases kinase activity; no;effect on protein levels; dbSNP:rs1060499547)"";/evidence=""ECO:0000269|PubMed:28288113"";/id=""VAR_079482""	activating	A	ABL1	increase			
Q07912/L487F	Q07912	TNK2/L487F	TNK2	Reviewed;	MUTAGEN	L	487	F	Constantly active kinase."";/evidence=""ECO:0000269|PubMed:16288044""	activating	A	ACK1				
Q07912/V365R	Q07912	TNK2/V365R	TNK2	Reviewed;	MUTAGEN	V	365	R	Increased autophosphorylation at Y-284."";/evidence=""ECO:0000269|PubMed:20110370""	activating	A	ACK1	increase			
P36896/L40A	P36896	ACVR1B/L40A	ACVR1B	Reviewed;	MUTAGEN	L	40	A	Increases binding to activin."";/evidence=""ECO:0000269|PubMed:12665502""	activating	A	ACV1B	exclude	Remove		
P36896/T206V	P36896	ACVR1B/T206V	ACVR1B	Reviewed;	MUTAGEN	T	206	V	Leads to constitutive activation."";/evidence=""ECO:0000269|PubMed:8622651""	activating	A	ACV1B				
P36896/V73A	P36896	ACVR1B/V73A	ACVR1B	Reviewed;	MUTAGEN	V	73	A	Increases binding to activin."";/evidence=""ECO:0000269|PubMed:12665502""	activating	A	ACV1B	exclude	Remove		
P31749/E17K	P31749	AKT1/E17K	AKT1	Reviewed;	VARIANT	E	17	K	(in PROTEUSS and breast cancer; also detected;in colorectal and ovarian cancer; somatic mutation; results;in increased phosphorylation at T-308 and higher basal;ubiquitination; the mutant protein is more efficiently;recruited to the plasma membrane; alters;phosphatidylinositiol phosphates lipid specificity of the;AKT1 PH domain; dbSNP:rs121434592)"";/evidence=""ECO:0000269|PubMed:17611497,;ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527,;ECO:0000269|PubMed:21793738"";/id=""VAR_055422""	activating	A	AKT1	increase			
Q9Y243/E17K	Q9Y243	AKT3/E17K	AKT3	Reviewed;	VARIANT	E	17	K	(in MPPH2 and melanoma; results in activation;of AKT; dbSNP:rs397514606)"";/evidence=""ECO:0000269|PubMed:18813315,;ECO:0000269|PubMed:22500628, ECO:0000269|PubMed:22729223"";/id=""VAR_065830""	activating	A	AKT3				
Q9UM73/F1174L	Q9UM73	ALK/F1174L	ALK	Reviewed;	VARIANT	F	1174	L	(in NBLST3; somatic mutation; constitutively;activated; retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs863225281)"";/evidence=""ECO:0000269|PubMed:18923523,;ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"";/id=""VAR_063857""	activating	A	ALK				
Q9UM73/F1174V	Q9UM73	ALK/F1174V	ALK	Reviewed;	VARIANT	F	1174	V	(in NBLST3; somatic mutation; constitutively;activated; retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs281864719)"";/evidence=""ECO:0000269|PubMed:18923523,;ECO:0000269|PubMed:21242967"";/id=""VAR_063858""	activating	A	ALK				
Q9UM73/R1275Q	Q9UM73	ALK/R1275Q	ALK	Reviewed;	VARIANT	R	1275	Q	(in NBLST3; constitutively activated;;retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs113994087)"";/evidence=""ECO:0000269|PubMed:18724359,;ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525,;ECO:0000269|PubMed:21242967, ECO:0000269|PubMed:22932897"";/id=""VAR_063865""	activating	A	ALK				
O14965/I57V	O14965	AURKA/I57V	AURKA	Reviewed;	VARIANT	I	57	V	(increased kinase activity; dbSNP:rs1047972)"";/evidence=""ECO:0000269|PubMed:15489334,;ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231,;ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714"";/id=""VAR_030842""	activating	A	AURKA	increase	For reference: This is definitely just a natural variant (while many others are excluded)		
O14965/T288D	O14965	AURKA/T288D	AURKA	Reviewed;	MUTAGEN	T	288	D	Mimics phosphorylation state and increases;kinase activity."";/evidence=""ECO:0000269|PubMed:11039908""	activating	A	AURKA	increase			
O14965/V174M	O14965	AURKA/V174M	AURKA	Reviewed;	VARIANT	V	174	M	(in a metastatic melanoma sample; somatic;mutation; constitutively enhanced kinase activity)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:19801554"";/id=""VAR_041129""	activating	A	AURKA				
Q13873/R899P	Q13873	BMPR2/R899P	BMPR2	Reviewed;	VARIANT	R	899	P	(in PPH1; leads to constitutive activation of;the MAPK14 pathway; dbSNP:rs137852752)"";/evidence=""ECO:0000269|PubMed:15965979"";/id=""VAR_033111""	activating	A	BMPR2				
P15056/G464V	P15056	BRAF/G464V	BRAF	Reviewed;	VARIANT	G	464	V	(in a colorectal cancer cell line; elevated;kinase activity; efficiently induces cell transformation;;dbSNP:rs121913348)"";/evidence=""ECO:0000269|PubMed:12068308"";/id=""VAR_018616""	activating	A	BRAF	increase			
P15056/G469A	P15056	BRAF/G469A	BRAF	Reviewed;	VARIANT	G	469	A	(in NHL; also in a lung adenocarcinoma;sample; somatic mutation; elevated kinase activity;;efficiently induces cell transformation;;dbSNP:rs121913355)"";/evidence=""ECO:0000269|PubMed:12068308,;ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846"";/id=""VAR_018620""	activating	A	BRAF	increase			
P15056/L597V	P15056	BRAF/L597V	BRAF	Reviewed;	VARIANT	L	597	V	(in NS7; also in a lung adenocarcinoma;sample; somatic mutation; elevated kinase activity;;efficiently induces cell transformation;;dbSNP:rs121913369)"";/evidence=""ECO:0000269|PubMed:12068308,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169"";/id=""VAR_018627""	activating	A	BRAF	increase			
P15056/R671K	P15056	BRAF/R671K	BRAF	Reviewed;	MUTAGEN	R	671	K	Increased kinase activity and stability in;response to EGF treatment."";/evidence=""ECO:0000269|PubMed:21917714""	activating	A	BRAF	increase			
Q8IWQ3/T174E	Q8IWQ3	BRSK2/T174E	BRSK2	Reviewed;	MUTAGEN	T	174	E	Constitutively activated."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:22798068""	activating	A	BRSK2				
Q8IWQ3/T443A	Q8IWQ3	BRSK2/T443A	BRSK2	Reviewed;	MUTAGEN	T	443	A	Constitutively activated. Promotes formation;of actin stress fibers."";/evidence=""ECO:0000269|PubMed:22669945""	activating	A	BRSK2				
Q9BWU1/Y32H	Q9BWU1	CDK19/Y32H	CDK19	Reviewed;	VARIANT	Y	32	H	(in DEE87; fails to rescue neurologic;phenotypes in a Drosophila model system; increased protein;kinase activity; dbSNP:rs1236246272)"";/evidence=""ECO:0000269|PubMed:32330417,;ECO:0000269|PubMed:33134521, ECO:0000269|PubMed:33495529"";/id=""VAR_084395""	activating	A	CDK19	increase			
P24941/T14A	P24941	CDK2/T14A	CDK2	Reviewed;	MUTAGEN	T	14	A	2-fold increase in activity."";/evidence=""ECO:0000269|PubMed:1396589""	activating	A	CDK2	increase			
P24941/Y15F	P24941	CDK2/Y15F	CDK2	Reviewed;	MUTAGEN	Y	15	F	2-fold increase in activity."";/evidence=""ECO:0000269|PubMed:1396589""	activating	A	CDK2	increase			
P50750/S175A	P50750	CDK9/S175A	CDK9	Reviewed;	MUTAGEN	S	175	A	Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:21533037""	activating	A	CDK9				
P50750/T186D	P50750	CDK9/T186D	CDK9	Reviewed;	MUTAGEN	T	186	D	Mimics autophosphorylation; constitutive;kinase activity, independently of calcium signaling."";/evidence=""ECO:0000269|PubMed:11145967,;ECO:0000269|PubMed:18566585, ECO:0000269|PubMed:21448926""	activating	A	CDK9				
P07333/L301S	P07333	CSF1R/L301S	CSF1R	Reviewed;	MUTAGEN	L	301	S	Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:15117969""	activating	A	CSF1R				
Q08345/N211A	Q08345	DDR1/N211A	DDR1	Reviewed;	MUTAGEN	N	211	A	Phosphorylates regardless of collagen;presence, collagen addition does not alter significantly;the levels of constitutive phosphorylation."";/evidence=""ECO:0000269|PubMed:24509848""	activating	A	DDR1				
Q08345/S213A	Q08345	DDR1/S213A	DDR1	Reviewed;	MUTAGEN	S	213	A	Phosphorylates regardless of collagen;presence, collagen addition does not alter significantly;the levels of constitutive phosphorylation."";/evidence=""ECO:0000269|PubMed:24509848""	activating	A	DDR1				
Q16832/L610P	Q16832	DDR2/L610P	DDR2	Reviewed;	VARIANT	L	610	P	(in WRCN; increased autophosphorylation in;patient fibroblasts)"";/evidence=""ECO:0000269|PubMed:30449416"";/id=""VAR_081931""	activating	A	DDR2	increase			
Q16832/Y740C	Q16832	DDR2/Y740C	DDR2	Reviewed;	VARIANT	Y	740	C	(in WRCN; increased autophosphorylation in;patient fibroblasts)"";/evidence=""ECO:0000269|PubMed:30449416"";/id=""VAR_081932""	activating	A	DDR2	increase			
Q9Y463/H90P	Q9Y463	DYRK1B/H90P	DYRK1B	Reviewed;	VARIANT	H	90	P	(in AOMS3; expression of glucose-6-;phosphatase is significantly higher than wild-type;;dbSNP:rs587777380)"";/evidence=""ECO:0000269|PubMed:24827035"";/id=""VAR_071773""	activating	A	DYR1B	increase	Variant R102C is also activating (main variant from the same paper)		
O43781/S350E	O43781	DYRK3/S350E	DYRK3	Reviewed;	MUTAGEN	S	350	E	D: Phosphomimetic mutant; increased stability;of the protein."";/evidence=""ECO:0000269|PubMed:29634919""	activating	A	DYRK3	increase	Also S350D (seems to be an error in parsing)	Is 'increased stability' considered activating? I guess? not catalytic tho	
P19525/G130R	P19525	EIF2AK2/G130R	EIF2AK2	Reviewed;	VARIANT	G	130	R	(in DYT33; gain-of-function variant resulting;in increased levels of phosphorylated EIF2AK2 and EIF2A in;patient cells compared to controls)"";/evidence=""ECO:0000269|PubMed:33236446,;ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068"";/id=""VAR_086716""	activating	A	E2AK2	increase			
P19525/N32T	P19525	EIF2AK2/N32T	EIF2AK2	Reviewed;	VARIANT	N	32	T	(in DYT33; unknown pathological significance;;gain-of-function variant resulting in increased levels of;phosphorylated EIF2AK2 and EIF2A in patient cells compared;to controls)"";/evidence=""ECO:0000269|PubMed:33236446"";/id=""VAR_086715""	activating	A	E2AK2	increase			
P00533/E709G	P00533	EGFR/E709G	EGFR	Reviewed;	VARIANT	E	709	G	(found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs397517085)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628"";/id=""VAR_069498""	activating	A	EGFR				
P00533/G719S	P00533	EGFR/G719S	EGFR	Reviewed;	VARIANT	G	719	S	(found in a lung cancer sample; somatic;mutation; strongly increased kinase activity;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs28929495)"";/evidence=""ECO:0000269|PubMed:15118125,;ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628,;ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"";/id=""VAR_019297""	activating	A	EGFR				
P00533/L858R	P00533	EGFR/L858R	EGFR	Reviewed;	VARIANT	L	858	R	(found in a lung cancer sample; somatic;mutation; constitutively activated enzyme with strongly;increased kinase activity; more sensitive to gefitinib than;wild-type; dbSNP:rs121434568)"";/evidence=""ECO:0000269|PubMed:15118125,;ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628,;ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"";/id=""VAR_019298""	activating	A	EGFR				
P00533/L861Q	P00533	EGFR/L861Q	EGFR	Reviewed;	VARIANT	L	861	Q	(found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs121913444)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793"";/id=""VAR_026102""	activating	A	EGFR				
P00533/S768I	P00533	EGFR/S768I	EGFR	Reviewed;	VARIANT	S	768	I	(found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs121913465)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628"";/id=""VAR_069502""	activating	A	EGFR				
P00533/T693A	P00533	EGFR/T693A	EGFR	Reviewed;	MUTAGEN	T	693	A	Increased phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	activating	A	EGFR	exclude	inconclusive		
P00533/T790M	P00533	EGFR/T790M	EGFR	Reviewed;	VARIANT	T	790	M	(found in a lung cancer sample; increased;kinase activity; dbSNP:rs121434569)"";/evidence=""ECO:0000269|PubMed:16533793,;ECO:0000269|PubMed:18227510"";/id=""VAR_026098""	activating	A	EGFR	increase			
P00533/V689M	P00533	EGFR/V689M	EGFR	Reviewed;	MUTAGEN	V	689	M	Constitutively activated kinase."";/evidence=""ECO:0000269|PubMed:19560417""	activating	A	EGFR		Maybe we can add 2 more mutations: See Mutagenesis 1005-1006 ED -> RK 'constitutively activated kinase'		
P29317/R721Q	P29317	EPHA2/R721Q	EPHA2	Reviewed;	VARIANT	R	721	Q	(in CTRCT6; retained in the cytoplasm and;constitutively active it alters EPHA2 signaling;;dbSNP:rs116506614)"";/evidence=""ECO:0000269|PubMed:19649315"";/id=""VAR_062532""	activating	A	EPHA2				
P21860/A1337T	P21860	ERBB3/A1337T	ERBB3	Reviewed;	VARIANT	A	1337	T	(in FERLK; risk factor for erythroleukemia;;results in increased ERBB-mediated signaling; results in a;block of erythroid differentiation and increased cell;proliferation; dbSNP:rs755855285)"";/evidence=""ECO:0000269|PubMed:27416908"";/id=""VAR_081641""	activating	A	ERBB3	increase			
Q15303/I947R	Q15303	ERBB4/I947R	ERBB4	Reviewed;	MUTAGEN	I	947	R	Constitutively autophosphorylated."";/evidence=""ECO:0000269|PubMed:18287036""	activating	A	ERBB4				
Q15303/Q646C	Q15303	ERBB4/Q646C	ERBB4	Reviewed;	MUTAGEN	Q	646	C	Constitutively activated kinase."";/evidence=""ECO:0000269|PubMed:17120616""	activating	A	ERBB4				
P07332/L145P	P07332	FES/L145P	FES	Reviewed;	MUTAGEN	L	145	P	Constitutively activated kinase that can act;as oncogene. Promotes myeloid cell survival and;proliferation."";/evidence=""ECO:0000269|PubMed:11509660,;ECO:0000269|PubMed:15485904""	activating	A	FES				
P21802/C278F	P21802	FGFR2/C278F	FGFR2	Reviewed;	VARIANT	C	278	F	(in CS, JWS and PS; forms disulfide-linked;dimers with constitutive kinase activity, is retained in an;intracellular compartment and not detected at the cell;surface; dbSNP:rs776587763)"";/evidence=""ECO:0000269|PubMed:11173845,;ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:16844695,;ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057"";/id=""VAR_004121""	activating	A	FGFR2				
P21802/E565A	P21802	FGFR2/E565A	FGFR2	Reviewed;	MUTAGEN	E	565	A	Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17803937""	activating	A	FGFR2				
P21802/E565G	P21802	FGFR2/E565G	FGFR2	Reviewed;	VARIANT	E	565	G	(in PS; constitutive kinase activity;;dbSNP:rs121918506)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017277""	activating	A	FGFR2				
P21802/K526E	P21802	FGFR2/K526E	FGFR2	Reviewed;	VARIANT	K	526	E	(in FSPC; constitutive kinase activity;;dbSNP:rs121918507)"";/evidence=""ECO:0000269|PubMed:16061565,;ECO:0000269|PubMed:17803937"";/id=""VAR_023788""	activating	A	FGFR2				
P21802/K641R	P21802	FGFR2/K641R	FGFR2	Reviewed;	VARIANT	K	641	R	(in PS; constitutive kinase activity;;dbSNP:rs1057519047)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017278""	activating	A	FGFR2				
P21802/K659N	P21802	FGFR2/K659N	FGFR2	Reviewed;	VARIANT	K	659	N	(in craniosynostosis; constitutive kinase;activity; dbSNP:rs1589722765)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017279""	activating	A	FGFR2				
P21802/N549H	P21802	FGFR2/N549H	FGFR2	Reviewed;	VARIANT	N	549	H	(in CS; constitutive kinase activity;;dbSNP:rs1057519045)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017276""	activating	A	FGFR2				
P21802/N549T	P21802	FGFR2/N549T	FGFR2	Reviewed;	MUTAGEN	N	549	T	Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17803937""	activating	A	FGFR2				
P22607/G380R	P22607	FGFR3/G380R	FGFR3	Reviewed;	VARIANT	G	380	R	in keratinocytic non-epidermolytic nevus and;ACH; very common mutation; constitutively activated kinase;with impaired internalization and degradation, resulting in;prolonged FGFR3 signaling; dbSNP:rs28931614)"";/evidence=""ECO:0000269|PubMed:10611230,;ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:16841094,;ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:7847369,;ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935"";/id=""VAR_004155""	activating	A	FGFR3				
P22607/K650D	P22607	FGFR3/K650D	FGFR3	Reviewed;	MUTAGEN	K	650	D	Constitutively activated kinase.""	activating	A	FGFR3				
P22607/K650E	P22607	FGFR3/K650E	FGFR3	Reviewed;	VARIANT	K	650	E	in KERSEB, TD2, TGCT and BLC; bladder;transitional cell carcinoma; somatic mutation;;constitutively activated kinase with impaired;internalization and degradation, resulting in prolonged;FGFR3 signaling; dbSNP:rs78311289)"";/evidence=""ECO:0000269|PubMed:10471491,;ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:12297284,;ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:15772091,;ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19855393,;ECO:0000269|PubMed:7773297, ECO:0000269|PubMed:8754806,;ECO:0000269|PubMed:9207791"";/id=""VAR_004160""	activating	A	FGFR3		K600M (natural variant) is missing. Same effect	Also K650Q	
P22607/K650L	P22607	FGFR3/K650L	FGFR3	Reviewed;	MUTAGEN	K	650	L	Constitutively activated kinase.""	activating	A	FGFR3				
P22607/R248C	P22607	FGFR3/R248C	FGFR3	Reviewed;	VARIANT	R	248	C	(in KERSEB, BLC, keratinocytic non-;epidermolytic nevus and TD1; severe and lethal; also found;as somatic mutation in one patient with multiple myeloma;;constitutive dimerization and kinase activation;;dbSNP:rs121913482)"";/evidence=""ECO:0000269|PubMed:10360402,;ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11529856,;ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094,;ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:7773297,;ECO:0000269|PubMed:8845844"";/id=""VAR_004148""	activating	A	FGFR3				
P22607/Y373C	P22607	FGFR3/Y373C	FGFR3	Reviewed;	VARIANT	Y	373	C	(in KERSEB and TD1; disulfide-linked dimer;with constitutive kinase activation; dbSNP:rs121913485)"";/evidence=""ECO:0000269|PubMed:10360402,;ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076,;ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9207791"";/id=""VAR_004153""	activating	A	FGFR3				
P09769/Y523F	P09769	FGR/Y523F	FGR	Reviewed;	MUTAGEN	Y	523	F	Strongly increased catalytic activity.;Functions as oncogene."";/evidence=""ECO:0000269|PubMed:1737799""	activating	A	FGR	increase			
P36888/D835E	P36888	FLT3/D835E	FLT3	Reviewed;	VARIANT	D	835	E	(in acute lymphoblastic leukemia patients and;acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913487)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:14504097"";/id=""VAR_065679""	activating	A	FLT3				
P36888/D835H	P36888	FLT3/D835H	FLT3	Reviewed;	VARIANT	D	835	H	(in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"";/id=""VAR_065680""	activating	A	FLT3				
P36888/D835N	P36888	FLT3/D835N	FLT3	Reviewed;	VARIANT	D	835	N	(in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608"";/id=""VAR_065681""	activating	A	FLT3				
P36888/D835V	P36888	FLT3/D835V	FLT3	Reviewed;	VARIANT	D	835	V	(in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121909646)"";/evidence=""ECO:0000269|PubMed:11290608"";/id=""VAR_065682""	activating	A	FLT3				
P36888/D835Y	P36888	FLT3/D835Y	FLT3	Reviewed;	VARIANT	D	835	Y	(in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"";/id=""VAR_065683""	activating	A	FLT3				
P49841/S9A	P49841	GSK3B/S9A	GSK3B	Reviewed;	MUTAGEN	S	9	A	oss of phosphorylation; abolished inhibition;of activity, leading to constitutively active."";/evidence=""ECO:0000269|PubMed:17050006,;ECO:0000269|PubMed:28992046, ECO:0000269|PubMed:7980435""	activating	A	GSK3B				
P25092/S840I	P25092	GUCY2C/S840I	GUCY2C	Reviewed;	VARIANT	S	840	I	(in DIAR6; activating mutation; exposure of;the mutant receptor to its ligands results in markedly;increased production of cyclic guanosine monophosphate;;dbSNP:rs587776871)"";/evidence=""ECO:0000269|PubMed:22436048"";/id=""VAR_067724""	activating	A	GUC2C	increase	D387G should be included as deactivating (currently not included)		
Q96GX5/K72M	Q96GX5	MASTL/K72M	MASTL	Reviewed;	MUTAGEN	K	72	M	Hyperactive form."";/evidence=""ECO:0000269|PubMed:21164014""	activating	A	GWL				
P08631/Y522F	P08631	HCK/Y522F	HCK	Reviewed;	MUTAGEN	Y	522	F	Constitutively activated kinase, leading to;cellular transformation."";/evidence=""ECO:0000269|PubMed:10092522,;ECO:0000269|PubMed:11896602""	activating	A	HCK				
O15111/S176E	O15111	CHUK/S176E	CHUK	Reviewed;	MUTAGEN	S	176	E	Full activation."";/evidence=""ECO:0000269|PubMed:9346484,;ECO:0000269|PubMed:9520446""	activating	A	IKKA				
O14920/K171E	O14920	IKBKB/K171E	IKBKB	Reviewed;	MUTAGEN	K	171	E	Increased activation of NF-kappa-B signaling."";/evidence=""ECO:0000269|PubMed:30337470""	activating	A	IKKB	increase	Activating mutations missing: O14920/S177E; O14920/S181E		
O14920/V203I	O14920	IKBKB/V203I	IKBKB	Reviewed;	VARIANT	V	203	I	(in IMD15A; gain-of-function mutation;resulting in increased activation of NF-kappa-B signaling;pathway; dbSNP:rs1563340753)"";/evidence=""ECO:0000269|PubMed:30337470"";/id=""VAR_081275""	activating	A	IKKB	increase			
P06213/Y1011A	P06213	INSR/Y1011A	INSR	Reviewed;	MUTAGEN	Y	1011	A	Increases kinase activity."";/evidence=""ECO:0000269|PubMed:12707268""	activating	A	INSR	increase			
P23458/A634D	P23458	JAK1/A634D	JAK1	Reviewed;	VARIANT	A	634	D	in AIIDE; constitutive gain of function;resulting in increased receptor signaling pathway via JAK-;STAT; no effect on protein abundance)"";/evidence=""ECO:0000269|PubMed:28111307"";/id=""VAR_084991""	activating	A	JAK1				
P23458/V658F	P23458	JAK1/V658F	JAK1	Reviewed;	MUTAGEN	V	658	F	Constitutively active. Increased receptor;signaling pathway via JAK-STAT."";/evidence=""ECO:0000269|PubMed:16239216""	activating	A	JAK1		Activating mut missing: P23458/S703I		
P52333/C759R	P52333	JAK3/C759R	JAK3	Reviewed;	VARIANT	C	759	R	(in T(-)B(+)NK(-) SCID; constitutive;phosphorylation)"";/evidence=""ECO:0000269|PubMed:9354668"";/id=""VAR_010497""	activating	A	JAK3				
P17612/L206R	P17612	PRKACA/L206R	PRKACA	Reviewed;	VARIANT	L	206	R	(in PPNAD4; somatic mutation; the mutation;results in cAMP-independent basal protein kinase activity;and constitutive activation of protein kinase A;;dbSNP:rs386352352)"";/evidence=""ECO:0000269|PubMed:24571724,;ECO:0000269|PubMed:24700472, ECO:0000269|PubMed:24747643,;ECO:0000269|PubMed:24855271"";/id=""VAR_071707""	activating	A	KAPCA		Several potential activating muts missing		
Q9UQM7/P212Q	Q9UQM7	CAMK2A/P212Q	CAMK2A	Reviewed;	VARIANT	P	212	Q	(in MRD53; increased basal;autophosphorylation)"";/evidence=""ECO:0000269|PubMed:29560374"";/id=""VAR_081160""	activating	A	KCC2A	increase			
Q13555/R292P	Q13555	CAMK2G/R292P	CAMK2G	Reviewed;	VARIANT	R	292	P	(in MRD59; gain-of-function variant affecting;regulation of neurite formation and arborization; results;in constitutive autophosphorylation; dbSNP:rs397514627)"";/evidence=""ECO:0000269|PubMed:23033978,;ECO:0000269|PubMed:30184290"";/id=""VAR_069390""	activating	A	KCC2G				
Q13976/R177Q	Q13976	PRKG1/R177Q	PRKG1	Reviewed;	VARIANT	R	177	Q	in AAT8; impairs cGMP binding; the mutant;protein is constitutively active; dbSNP:rs397515330)"";/evidence=""ECO:0000269|PubMed:23910461"";/id=""VAR_070434""	activating	A	KGP1				
P10721/D816F	P10721	KIT/D816F	KIT	Reviewed;	VARIANT	D	816	F	(in MASTC; sporadic case; somatic mutation;;requires 2 nucleotide substitutions; constitutively;activated and is much more rapidly autophosphorylated than;wild type)"";/evidence=""ECO:0000269|PubMed:9990072"";/id=""VAR_033133""	activating	A	KIT		Activating missing: S741A, S746A (Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation); D816V (same as the others)		
P10721/D816H	P10721	KIT/D816H	KIT	Reviewed;	VARIANT	D	816	H	(in a testicular tumor; seminoma; somatic;mutation; constitutively activated; dbSNP:rs121913506)"";/evidence=""ECO:0000269|PubMed:10362788,;ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452"";/id=""VAR_033134""	activating	A	KIT				
P10721/D816I	P10721	KIT/D816I	KIT	Reviewed;	VARIANT	D	816	I	(in MASTC; somatic mutation; constitutively;activated; requires 2 nucleotide substitutions;;dbSNP:rs1057519709)"";/evidence=""ECO:0000269|PubMed:19865100"";/id=""VAR_081064""	activating	A	KIT				
P10721/D816Y	P10721	KIT/D816Y	KIT	Reviewed;	VARIANT	D	816	Y	(in MASTSYS and MASTC; also found in acute;myeloid leukemia and a germ cell tumor of the testis;;somatic mutation; constitutively activated;;dbSNP:rs121913506)"";/evidence=""ECO:0000269|PubMed:16175573,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100,;ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072"";/id=""VAR_023828""	activating	A	KIT				
P10721/N822I	P10721	KIT/N822I	KIT	Reviewed;	VARIANT	N	822	I	(in MASTC; constitutively activated;;dbSNP:rs993022333)"";/evidence=""ECO:0000269|PubMed:21689725"";/id=""VAR_081065""	activating	A	KIT				
Q15139/Y463E	Q15139	PRKD1/Y463E	PRKD1	Reviewed;	MUTAGEN	Y	463	E	Constitutive activation and constitutive;phosphorylation of S-738 and S-742."";/evidence=""ECO:0000269|PubMed:12637538""	activating	A	KPCD1				
Q04759/A148E	Q04759	PRKCQ/A148E	PRKCQ	Reviewed;	MUTAGEN	A	148	E	Constitutively active form."";/evidence=""ECO:0000269|PubMed:10652356""	activating	A	KPCT				
O75676/F709A	O75676	RPS6KA4/F709A	RPS6KA4	Reviewed;	MUTAGEN	F	709	A	Strongly elevates basal activity."";/evidence=""ECO:0000269|PubMed:11035004""	activating	A	KS6A4	increase			
P43405/A353T	P43405	SYK/A353T	SYK	Reviewed;	VARIANT	A	353	T	(in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085996""	activating	A	KSYK				
P43405/M450I	P43405	SYK/M450I	SYK	Reviewed;	VARIANT	M	450	I	(in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085997""	activating	A	KSYK				
P43405/P342T	P43405	SYK/P342T	SYK	Reviewed;	VARIANT	P	342	T	(in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085995""	activating	A	KSYK				
P43405/S550F	P43405	SYK/S550F	SYK	Reviewed;	VARIANT	S	550	F	(in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085998""	activating	A	KSYK				
P43405/S550Y	P43405	SYK/S550Y	SYK	Reviewed;	VARIANT	S	550	Y	(in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085999""	activating	A	KSYK				
P53667/T508E	P53667	LIMK1/T508E	LIMK1	Reviewed;	MUTAGEN	T	508	E	Phosphomimetic mutant; enhances kinase;activity."";/evidence=""ECO:0000269|PubMed:22328514""	activating	A	LIMK1	increase			
P53667/T508EE	P53667	LIMK1/T508EE	LIMK1	Reviewed;	MUTAGEN	T	508	EE	: Enhances kinase activity."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	activating	A	LIMK1	exclude	Remove, redundant		
P53671/T505E	P53671	LIMK2/T505E	LIMK2	Reviewed;	MUTAGEN	T	505	E	Phosphomimetic mutant; enhances kinase;activity."";/evidence=""ECO:0000269|PubMed:11018042,;ECO:0000269|PubMed:22328514""	activating	A	LIMK2	increase			
Q5S007/H2391D	Q5S007	LRRK2/H2391D	LRRK2	Reviewed;	MUTAGEN	H	2391	D	Increases kinase activity."";/evidence=""ECO:0000269|PubMed:30635421""	activating	A	LRRK2	increase			
Q5S007/I2020T	Q5S007	LRRK2/I2020T	LRRK2	Reviewed;	VARIANT	I	2020	T	in PARK8; significant increase in;autophosphorylation of about 40% in comparison to wild-type;protein in vitro; shows a progressive reduction in neurite;length and branching; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs35870237)"";/evidence=""ECO:0000269|PubMed:15541309,;ECO:0000269|PubMed:15880653, ECO:0000269|PubMed:16172858,;ECO:0000269|PubMed:16251215, ECO:0000269|PubMed:16321986,;ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:26824392,;ECO:0000269|PubMed:29212815"";/id=""VAR_024959""	activating	A	LRRK2	increase			
Q5S007/R1441G	Q5S007	LRRK2/R1441G	LRRK2	Reviewed;	VARIANT	R	1441	G	in PARK8; shows a progressive reduction in;neurite length and branching; shows an increase in activity;in phosphorylation of RAB8A and RAB10; decreases;phosphorylation-dependent binding to YWHAG;;dbSNP:rs33939927)"";/evidence=""ECO:0000269|PubMed:15541308,;ECO:0000269|PubMed:15925109, ECO:0000269|PubMed:16172858,;ECO:0000269|PubMed:16533964, ECO:0000269|PubMed:17114044,;ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718,;ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29212815,;ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421"";/id=""VAR_024946""	activating	A	LRRK2	increase	Also activating: R1441C, R1441H, Y1699C, G2019S,		
Q5S007/R1728H	Q5S007	LRRK2/R1728H	LRRK2	Reviewed;	VARIANT	R	1728	H	(in PARK8; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs145364431)"";/evidence=""ECO:0000269|PubMed:18213618,;ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:29212815"";/id=""VAR_054744""	activating	A	LRRK2	increase			
Q5S007/R2394E	Q5S007	LRRK2/R2394E	LRRK2	Reviewed;	MUTAGEN	R	2394	E	ecreases WD domain homodimerization.;Increases kinase activity and autophosphorylation at Ser-;1292."";/evidence=""ECO:0000269|PubMed:30635421""	activating	A	LRRK2	exclude	Conflicting?		
Q5S007/T2031S	Q5S007	LRRK2/T2031S	LRRK2	Reviewed;	VARIANT	T	2031	S	(in PARK8; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs78029637)"";/evidence=""ECO:0000269|PubMed:26824392,;ECO:0000269|PubMed:29212815"";/id=""VAR_082047""	activating	A	LRRK2	increase			
P29376/E763K	P29376	LTK/E763K	LTK	Reviewed;	VARIANT	E	763	K	(may possibly contribute to susceptibility to;systemic lupus erythematosus; increases autophosphorylation;and interaction with PI3-kinase subunit p85;;dbSNP:rs76282169)"";/evidence=""ECO:0000269|PubMed:14695357"";/id=""VAR_065465""	activating	A	LTK	increase			
P29376/G750E	P29376	LTK/G750E	LTK	Reviewed;	MUTAGEN	G	750	E	Increases autophosphorylation and interaction;with PI3-kinase subunit p85 (demonstrated with chimeric;EGFR-LTK)."";/evidence=""ECO:0000269|PubMed:14695357""	activating	A	LTK	increase			
P07948/Y508F	P07948	LYN/Y508F	LYN	Reviewed;	MUTAGEN	Y	508	F	bolishes autoinhibition and thereby increases;kinase activity."";/evidence=""ECO:0000269|PubMed:16920712""	activating	A	LYN	increase			
Q13233/L189P	Q13233	MAP3K1/L189P	MAP3K1	Reviewed;	VARIANT	L	189	P	(in SRXY6; increases phosphorylation of the;downstream target MAPK3/MAPK1 compared to wild-type and;enhances binding of RHOA to the mutant MAP3K1 complex;;dbSNP:rs387906788)"";/evidence=""ECO:0000269|PubMed:21129722"";/id=""VAR_065504""	activating	A	M3K1	increase			
Q13233/L189R	Q13233	MAP3K1/L189R	MAP3K1	Reviewed;	VARIANT	L	189	R	(in SRXY6; increases phosphorylation of the;downstream targets MAPK14 and MAPK3/MAPK1 compared to wild-;type and enhances binding of RHOA to the mutant MAP3K1;complex; dbSNP:rs387906788)"";/evidence=""ECO:0000269|PubMed:21129722"";/id=""VAR_065505""	activating	A	M3K1	increase			
Q56UN5/T161E	Q56UN5	MAP3K19/T161E	MAP3K19	Reviewed;	MUTAGEN	T	161	E	Constitutively active kinase with normal;accumulation in the nucleus."";/evidence=""ECO:0000269|PubMed:26443375""	activating	A	M3K19	exclude	This is wrong. Not in uniprot. 161 not a T		
Q99683/S1033A	Q99683	MAP3K5/S1033A	MAP3K5	Reviewed;	MUTAGEN	S	1033	A	Enhanced induction of apoptosis and increased;kinase activity."";/evidence=""ECO:0000269|PubMed:15094778""	activating	A	M3K5	increase			
O43318/P512L	O43318	MAP3K7/P512L	MAP3K7	Reviewed;	VARIANT	P	512	L	(in FMD2; does not affect interaction with;TAB2; does not affect homodimerization; increases;autophosphorylation; increases MAPK signaling; increases;NF-kappa-B signaling; dbSNP:rs886039230)"";/evidence=""ECO:0000269|PubMed:27426733"";/id=""VAR_077347""	activating	A	M3K7	increase			
Q92918/T355A	Q92918	MAP4K1/T355A	MAP4K1	Reviewed;	MUTAGEN	T	355	A	Retains kinase activity. Not degraded by the;Cul7-RING ubiquitin-protein ligase complex containing;FBXW8."";/evidence=""ECO:0000269|PubMed:24362026""	activating	A	M4K1				
P49137/K353R	P49137	MAPKAPK2/K353R	MAPKAPK2	Reviewed;	MUTAGEN	K	353	R	nduces decreased sumoylation and increase in;protein kinase activity."";/evidence=""ECO:0000269|PubMed:21131586""	activating	A	MAPK2	increase			
P49137/S272D	P49137	MAPKAPK2/S272D	MAPKAPK2	Reviewed;	MUTAGEN	S	272	D	Mimicks phosphorylation state, leading to;slight increase of basal kinase activity."";/evidence=""ECO:0000269|PubMed:8846784""	activating	A	MAPK2	increase			
P49137/T222D	P49137	MAPKAPK2/T222D	MAPKAPK2	Reviewed;	MUTAGEN	T	222	D	Mimicks phosphorylation state, leading to;slight increase of basal kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	activating	A	MAPK2	increase			
P49137/T334D	P49137	MAPKAPK2/T334D	MAPKAPK2	Reviewed;	MUTAGEN	T	334	D	E: Mimicks phosphorylation state, leading to;elevated basal kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	activating	A	MAPK2	increase	Also T334E		
Q16644/K73M	Q16644	MAPKAPK3/K73M	MAPKAPK3	Reviewed;	MUTAGEN	K	73	M	Higher affinity toward PCH2."";/evidence=""ECO:0000269|PubMed:15563468""	activating	A	MAPK3	loss	is this activating?	Gurdeep: Correct, this should be loss. Highly conserved Lys	
Q8IW41/L337G	Q8IW41	MAPKAPK5/L337G	MAPKAPK5	Reviewed;	MUTAGEN	L	337	G	Induces constitutive protein kinase activity."";/evidence=""ECO:0000269|PubMed:21329882""	activating	A	MAPK5				
Q8IW41/S212D	Q8IW41	MAPKAPK5/S212D	MAPKAPK5	Reviewed;	MUTAGEN	S	212	D	Mimicks phosphorylation state and displays a;slightly higher protein kinase activity."";/evidence=""ECO:0000269|PubMed:12808055""	activating	A	MAPK5	increase			
Q8IW41/T182D	Q8IW41	MAPKAPK5/T182D	MAPKAPK5	Reviewed;	MUTAGEN	T	182	D	Mimicks phosphorylation state and induces;constitutive protein kinase activity."";/evidence=""ECO:0000269|PubMed:12808055,;ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:9628874""	activating	A	MAPK5				
Q9P0L2/T215E	Q9P0L2	MARK1/T215E	MARK1	Reviewed;	MUTAGEN	T	215	E	Constitutively active."";/evidence=""ECO:0000269|PubMed:14976552""	activating	A	MARK1		DEactivating T215A missing		
Q96L34/T214E	Q96L34	MARK4/T214E	MARK4	Reviewed;	MUTAGEN	T	214	E	imicks phosphorylation state, leading to;increased activity. Decreases mTORC1 activity."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:23184942""	activating	A	MARK4	increase	DEactivating T214A missing		
Q14680/T167D	Q14680	MELK/T167D	MELK	Reviewed;	MUTAGEN	T	167	D	E: Phosphomimetic mutant that has similar;kinase activity as wild-type."";/evidence=""ECO:0000269|PubMed:14976552""	activating	A	MELK	exclude	Also T167E		
P08581/H1094L	P08581	MET/H1094L	MET	Reviewed;	VARIANT	H	1094	L	(in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines)"";/evidence=""ECO:0000269|PubMed:10327054"";/id=""VAR_032486""	activating	A	MET				
P08581/H1094Y	P08581	MET/H1094Y	MET	Reviewed;	VARIANT	H	1094	Y	(in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines;;dbSNP:rs121913244)"";/evidence=""ECO:0000269|PubMed:10327054"";/id=""VAR_032488""	activating	A	MET				
P08581/H1106D	P08581	MET/H1106D	MET	Reviewed;	VARIANT	H	1106	D	(in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines)"";/evidence=""ECO:0000269|PubMed:10327054,;ECO:0000269|PubMed:10433944"";/id=""VAR_032489""	activating	A	MET				
P08581/V1092I	P08581	MET/V1092I	MET	Reviewed;	VARIANT	V	1092	I	(in RCCP; constitutive autophosphorylation;;dbSNP:rs786202724)"";/evidence=""ECO:0000269|PubMed:10327054,;ECO:0000269|PubMed:10417759, ECO:0000269|PubMed:10433944"";/id=""VAR_032485""	activating	A	MET				
P08581/Y1230D	P08581	MET/Y1230D	MET	Reviewed;	VARIANT	Y	1230	D	(in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines)"";/evidence=""ECO:0000269|PubMed:10327054,;ECO:0000269|PubMed:10433944"";/id=""VAR_032491""	activating	A	MET				
P53778/D179A	P53778	MAPK12/D179A	MAPK12	Reviewed;	MUTAGEN	D	179	A	Emulation of the active state."";/evidence=""ECO:0000269|PubMed:15284239""	activating	A	MK12				
Q9BUB5/T385D	Q9BUB5	MKNK1/T385D	MKNK1	Reviewed;	MUTAGEN	T	385	D	Constitutively active."";/evidence=""ECO:0000269|PubMed:11463832""	activating	A	MKNK1				
Q9HBH9/T379D	Q9HBH9	MKNK2/T379D	MKNK2	Reviewed;	MUTAGEN	T	379	D	Constitutively active."";/evidence=""ECO:0000269|PubMed:11463832""	activating	A	MKNK2				
Q02750/K57N	Q02750	MAP2K1/K57N	MAP2K1	Reviewed;	VARIANT	K	57	N	(in MEL; somatic mutation; results in;increased MAPK signal transduction; dbSNP:rs869025608)"";/evidence=""ECO:0000269|PubMed:29643386"";/id=""VAR_084454""	activating	A	MP2K1	increase			
Q02750/M219V	Q02750	MAP2K1/M219V	MAP2K1	Reviewed;	MUTAGEN	M	219	V	Increases interaction with KSR1 and BRAF."";/evidence=""ECO:0000269|PubMed:29433126""	activating	A	MP2K1	increase			
Q02750/N221Y	Q02750	MAP2K1/N221Y	MAP2K1	Reviewed;	MUTAGEN	N	221	Y	Increases interaction with KSR1 and BRAF."";/evidence=""ECO:0000269|PubMed:29433126""	activating	A	MP2K1	increase			
P36507/P128Q	P36507	MAP2K2/P128Q	MAP2K2	Reviewed;	VARIANT	P	128	Q	(in CFC4; results in increased kinase;activity; dbSNP:rs267607230)"";/evidence=""ECO:0000269|PubMed:20358587"";/id=""VAR_069782""	activating	A	MP2K2	increase			
P46734/S218E	P46734	MAP2K3/S218E	MAP2K3	Reviewed;	MUTAGEN	S	218	E	Constitutive activation."";/evidence=""ECO:0000269|PubMed:8622669""	activating	A	MP2K3		Inactivating missing: S218A (literally is tagged with 'inactivation' only, so why?)		
P46734/T222E	P46734	MAP2K3/T222E	MAP2K3	Reviewed;	MUTAGEN	T	222	E	Constitutive activation."";/evidence=""ECO:0000269|PubMed:8622669""	activating	A	MP2K3		Inactivating missing: T222A (literally is tagged with 'inactivation' only, so why?)		
P52564/S207E	P52564	MAP2K6/S207E	MAP2K6	Reviewed;	MUTAGEN	S	207	E	Constitutive activation according to;PubMed:8622669, but not to PubMed:8621675.""	activating	A	MP2K6		Inactivating missing: S207A (literally is tagged with 'inactivation' only, so why?)		
P52564/T211E	P52564	MAP2K6/T211E	MAP2K6	Reviewed;	MUTAGEN	T	211	E	Constitutive activation according to;PubMed:8622669, but not to PubMed:8621675.""	activating	A	MP2K6		Inactivating missing: T211A (literally is tagged with 'inactivation' only, so why?)		
Q5VT25/D478A	Q5VT25	CDC42BPA/D478A	CDC42BPA	Reviewed;	MUTAGEN	D	478	A	revents cleavage by CASP3, impairs the;increase of its kinase activity and impairs extrusion;apical actin ring assembly."";/evidence=""ECO:0000269|PubMed:29162624""	activating	A	MRCKA	loss	deactivating		
Q5VT25/S222L	Q5VT25	CDC42BPA/S222L	CDC42BPA	Reviewed;	MUTAGEN	S	222	L	Increase in autophosphorylation but not kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	activating	A	MRCKA	exclude	not really activating (neutral?)		
P42345/A1459D	P42345	MTOR/A1459D	MTOR	Reviewed;	VARIANT	A	1459	D	(in FCORD2; somatic mutation; increased TOR;signaling)"";/evidence=""ECO:0000269|PubMed:26018084"";/id=""VAR_078828""	activating	A	MTOR	increase			
P42345/A431T	P42345	MTOR/A431T	MTOR	Reviewed;	MUTAGEN	A	431	T	Does not completely restore mitochondrial DNA-;dependent respiratory chain activities in respiration-;defective mutant cells."";/evidence=""ECO:0000269|PubMed:22608499""	activating	A	MTOR	exclude	not in Uniprot		
P42345/C1483R	P42345	MTOR/C1483R	MTOR	Reviewed;	VARIANT	C	1483	R	(in FCORD2; somatic mutation; increased TOR;signaling; increased kinase activity; dbSNP:rs1057519914)"";/evidence=""ECO:0000269|PubMed:25799227"";/id=""VAR_078831""	activating	A	MTOR	increase	Missing activating: S2159D, T2164E		
P42345/E1799K	P42345	MTOR/E1799K	MTOR	Reviewed;	VARIANT	E	1799	K	(in SKS; results in increased mTOR signaling;;dbSNP:rs863225264)"";/evidence=""ECO:0000269|PubMed:25851998,;ECO:0000269|PubMed:26542245"";/id=""VAR_075072""	activating	A	MTOR	increase			
P42345/L1460P	P42345	MTOR/L1460P	MTOR	Reviewed;	VARIANT	L	1460	P	(in FCORD2; somatic mutation; increased TOR;signaling; dbSNP:rs1057519779)"";/evidence=""ECO:0000269|PubMed:26018084,;ECO:0000269|PubMed:27830187"";/id=""VAR_078830""	activating	A	MTOR	increase			
P42345/L2427P	P42345	MTOR/L2427P	MTOR	Reviewed;	VARIANT	L	2427	P	(in FCORD2; somatic mutation; increased TOR;signaling; increased kinase activity; dbSNP:rs1085307113)"";/evidence=""ECO:0000269|PubMed:25799227"";/id=""VAR_078841""	activating	A	MTOR	increase			
P42345/L2427Q	P42345	MTOR/L2427Q	MTOR	Reviewed;	VARIANT	L	2427	Q	(in FCORD2; somatic mutation; increased TOR;signaling; increased kinase activity; dbSNP:rs1085307113)"";/evidence=""ECO:0000269|PubMed:25799227"";/id=""VAR_078842""	activating	A	MTOR	increase			
P42345/S2215F	P42345	MTOR/S2215F	MTOR	Reviewed;	VARIANT	S	2215	F	(in FCORD2; somatic mutation; increased TOR;signaling; dbSNP:rs587777894)"";/evidence=""ECO:0000269|PubMed:25799227,;ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187"";/id=""VAR_078839""	activating	A	MTOR	increase			
P42345/S2215Y	P42345	MTOR/S2215Y	MTOR	Reviewed;	VARIANT	S	2215	Y	(in FCORD2; also found in a colorectal;adenocarcinoma sample; somatic mutation; increased TOR;signaling; dbSNP:rs587777894)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187"";/id=""VAR_041543""	activating	A	MTOR	increase			
P42345/T2173A	P42345	MTOR/T2173A	MTOR	Reviewed;	MUTAGEN	T	2173	A	Increased mTOR kinase activity."";/evidence=""ECO:0000269|PubMed:24247430""	activating	A	MTOR	increase			
P51955/S171D	P51955	NEK2/S171D	NEK2	Reviewed;	MUTAGEN	S	171	D	Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	activating	A	NEK2	increase			
P51955/T170E	P51955	NEK2/T170E	NEK2	Reviewed;	MUTAGEN	T	170	E	Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	activating	A	NEK2	increase			
P51955/T175E	P51955	NEK2/T175E	NEK2	Reviewed;	MUTAGEN	T	175	E	Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	activating	A	NEK2	increase			
Q9HC98/Y108A	Q9HC98	NEK6/Y108A	NEK6	Reviewed;	MUTAGEN	Y	108	A	Increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	activating	A	NEK6	increase			
Q8TDX7/Y97A	Q8TDX7	NEK7/Y97A	NEK7	Reviewed;	MUTAGEN	Y	97	A	5-fold increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	activating	A	NEK7	increase			
Q8TDX7/Y97F	Q8TDX7	NEK7/Y97F	NEK7	Reviewed;	MUTAGEN	Y	97	F	L: Moderate increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	activating	A	NEK7	increase	Missing activating: K96E, Y97L	K96E is predicted to be A by activark as of now. This is cool coz it is one the cases where mutation occurs next to p-site (Y97), which is known to deactivate the kinase (if mutated), and that Activark can predict this	
Q8TD19/I167T	Q8TD19	NEK9/I167T	NEK9	Reviewed;	VARIANT	I	167	T	(in NC; increased autophosphorylation at T-;210; dbSNP:rs879253775)"";/evidence=""ECO:0000269|PubMed:27153399"";/id=""VAR_077801""	activating	A	NEK9	increase			
Q8TD19/I573T	Q8TD19	NEK9/I573T	NEK9	Reviewed;	VARIANT	I	573	T	(in NC; increased autophosphorylation at T-;210; dbSNP:rs1555352529)"";/evidence=""ECO:0000269|PubMed:27153399"";/id=""VAR_077802""	activating	A	NEK9	increase			
Q13153/L107F	Q13153	PAK1/L107F	PAK1	Reviewed;	MUTAGEN	L	107	F	bolishes autoinhibition, leading to;constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	activating	A	PAK1		Missing activating: Y131C, Y429C		
Q13153/T423E	Q13153	PAK1/T423E	PAK1	Reviewed;	MUTAGEN	T	423	E	Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	activating	A	PAK1				
O96013/S445N	O96013	PAK4/S445N	PAK4	Reviewed;	MUTAGEN	S	445	N	Approximately 30-fold increased;autophosphorylation (constitutively active mutant)."";/evidence=""ECO:0000269|PubMed:11313478""	activating	A	PAK4				
O96013/S474E	O96013	PAK4/S474E	PAK4	Reviewed;	MUTAGEN	S	474	E	Approximately 3-fold increased;autophosphorylation."";/evidence=""ECO:0000269|PubMed:11313478""	activating	A	PAK4	increase			
Q96RG2/A1151K	Q96RG2	PASK/A1151K	PASK	Reviewed;	MUTAGEN	A	1151	K	Induces lower protein kinase activity and;ability to autophosphorylate."";/evidence=""ECO:0000269|PubMed:20943661""	activating	A	PASK	exclude	REMOVE. It is already present as 'decrease'		
Q96RG2/R1058A	Q96RG2	PASK/R1058A	PASK	Reviewed;	MUTAGEN	R	1058	A	Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	activating	A	PASK	exclude	REMOVE. It is already present as 'decrease'		
Q96RG2/Y1152F	Q96RG2	PASK/Y1152F	PASK	Reviewed;	MUTAGEN	Y	1152	F	Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	activating	A	PASK	exclude	REMOVE. It is already present as 'decrease'		
O15530/A277V	O15530	PDPK1/A277V	PDPK1	Reviewed;	MUTAGEN	A	277	V	3-fold increase in kinase activity."";/evidence=""ECO:0000269|PubMed:10364160""	activating	A	PDPK1	increase			
O15530/T513E	O15530	PDPK1/T513E	PDPK1	Reviewed;	MUTAGEN	T	513	E	Enhanced kinase activity towards PKB."";/evidence=""ECO:0000269|PubMed:20978239""	activating	A	PDPK1	increase			
P16234/D842V	P16234	PDGFRA/D842V	PDGFRA	Reviewed;	VARIANT	D	842	V	(in a GIST sample; imatinib resistant,;constitutively activated kinase; dbSNP:rs121908585)"";/evidence=""ECO:0000269|PubMed:12522257,;ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453"";/id=""VAR_066471""	activating	A	PGFRA				
P16234/D842Y	P16234	PDGFRA/D842Y	PDGFRA	Reviewed;	VARIANT	D	842	Y	(in a GIST sample; imatinib sensitive,;constitutively activated kinase; dbSNP:rs121913265)"";/evidence=""ECO:0000269|PubMed:15928335"";/id=""VAR_066472""	activating	A	PGFRA				
P16234/H650Q	P16234	PDGFRA/H650Q	PDGFRA	Reviewed;	VARIANT	H	650	Q	(in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066465""	activating	A	PGFRA				
P16234/N659K	P16234	PDGFRA/N659K	PDGFRA	Reviewed;	VARIANT	N	659	K	(in GIST sample; constitutively activated;kinase; dbSNP:rs1057519700)"";/evidence=""ECO:0000269|PubMed:15928335"";/id=""VAR_066466""	activating	A	PGFRA				
P16234/N659S	P16234	PDGFRA/N659S	PDGFRA	Reviewed;	VARIANT	N	659	S	(in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066467""	activating	A	PGFRA				
P16234/R748G	P16234	PDGFRA/R748G	PDGFRA	Reviewed;	VARIANT	R	748	G	(in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066469""	activating	A	PGFRA				
P16234/V561D	P16234	PDGFRA/V561D	PDGFRA	Reviewed;	VARIANT	V	561	D	(in a GIST sample; constitutively activated;kinase; dbSNP:rs121908586)"";/evidence=""ECO:0000269|PubMed:12522257,;ECO:0000269|PubMed:15928335"";/id=""VAR_066462""	activating	A	PGFRA				
P16234/Y555C	P16234	PDGFRA/Y555C	PDGFRA	Reviewed;	VARIANT	Y	555	C	(in GISTPS; increased platelet-derived growth;factor alpha-receptor activity; constitutively activated;kinase; dbSNP:rs121908589)"";/evidence=""ECO:0000269|PubMed:17087943"";/id=""VAR_083158""	activating	A	PGFRA				
P16234/Y849S	P16234	PDGFRA/Y849S	PDGFRA	Reviewed;	VARIANT	Y	849	S	(in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066475""	activating	A	PGFRA				
P09619/V665A	P09619	PDGFRB/V665A	PDGFRB	Reviewed;	VARIANT	V	665	A	(in PENTT; gain of function in protein;tyrosine kinase activity; shows ligand-independent;constitutive signaling; dbSNP:rs1554108211)"";/evidence=""ECO:0000269|PubMed:26279204"";/id=""VAR_075866""	activating	A	PGFRB				
P11309/H68Y	P11309	PIM1/H68Y	PIM1	Reviewed;	MUTAGEN	H	68	Y	Increased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	activating	A	PIM1	increase			
P53350/K492R	P53350	PLK1/K492R	PLK1	Reviewed;	MUTAGEN	K	492	R	Severe mitotic defects leading to prometaphase;delay. Increased localization at kinetochores leading to;increased levels of phosphorylated BUBR1."";/evidence=""ECO:0000269|PubMed:23455478""	activating	A	PLK1	exclude	Affects localization, rather than activity. Remove?		
P53350/S137D	P53350	PLK1/S137D	PLK1	Reviewed;	MUTAGEN	S	137	D	Increases activity. Results in a block in;G1/S."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:18615013""	activating	A	PLK1	increase			
P53350/T210D	P53350	PLK1/T210D	PLK1	Reviewed;	MUTAGEN	T	210	D	Increases activity and restores recovery after;DNA damage checkpoint."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,;ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	activating	A	PLK1	increase			
O00444/T170D	O00444	PLK4/T170D	PLK4	Reviewed;	MUTAGEN	T	170	D	Activating mutant."";/evidence=""ECO:0000269|PubMed:18239451,;ECO:0000269|PubMed:19164942""	activating	A	PLK4				
Q13882/W184A	Q13882	PTK6/W184A	PTK6	Reviewed;	MUTAGEN	W	184	A	Abrogates interaction between PTK6-domain;kinase and PTK6-linker. Abrogates autophosphorylation and;phosphorylation of KHDRBS1."";/evidence=""ECO:0000269|PubMed:15961400""	activating	A	PTK6	loss	loss		
P04049/A237T	P04049	RAF1/A237T	RAF1	Reviewed;	VARIANT	A	237	T	(in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs587777588)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071844""	activating	A	RAF1	increase			
P04049/H626R	P04049	RAF1/H626R	RAF1	Reviewed;	VARIANT	H	626	R	(in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs1553609795)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071848""	activating	A	RAF1	increase			
P04049/L613V	P04049	RAF1/L613V	RAF1	Reviewed;	VARIANT	L	613	V	(in NS5 and LPRD2; shows in vitro greater;kinase activity and enhanced MAPK1 activation than wild-;type; dbSNP:rs80338797)"";/evidence=""ECO:0000269|PubMed:17603482,;ECO:0000269|PubMed:17603483"";/id=""VAR_037821""	activating	A	RAF1	increase			
P04049/P261A	P04049	RAF1/P261A	RAF1	Reviewed;	VARIANT	P	261	A	(in NS5; shows in vitro greater kinase;activity and enhanced MAPK1 activation than wild-type;;dbSNP:rs121434594)"";/evidence=""ECO:0000269|PubMed:17603482"";/id=""VAR_037812""	activating	A	RAF1	increase			
P04049/P261L	P04049	RAF1/P261L	RAF1	Reviewed;	VARIANT	P	261	L	(in NS5; shows greater kinase activity and;enhanced MAPK1 activation than wild-type;;dbSNP:rs397516828)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037813""	activating	A	RAF1	increase			
P04049/P261S	P04049	RAF1/P261S	RAF1	Reviewed;	VARIANT	P	261	S	(in NS5; shows in vitro greater kinase;activity and enhanced MAPK1 activation than wild-type;;dbSNP:rs121434594)"";/evidence=""ECO:0000269|PubMed:17603482,;ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980"";/id=""VAR_037814""	activating	A	RAF1	increase			
P04049/P332A	P04049	RAF1/P332A	RAF1	Reviewed;	VARIANT	P	332	A	(in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs1057403865)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071846""	activating	A	RAF1	increase			
P04049/R563K	P04049	RAF1/R563K	RAF1	Reviewed;	MUTAGEN	R	563	K	oss of methylation. Increased stability and;catalytic activity in response to EGF treatment."";/evidence=""ECO:0000269|PubMed:21917714""	activating	A	RAF1	increase	should be 'resistance'?		
P04049/S257L	P04049	RAF1/S257L	RAF1	Reviewed;	VARIANT	S	257	L	(in NS5 and LPRD2; shows in vitro greater;kinase activity and enhanced ERK activation than wild-type;;dbSNP:rs80338796)"";/evidence=""ECO:0000269|PubMed:17603482,;ECO:0000269|PubMed:17603483"";/id=""VAR_037808""	activating	A	RAF1	increase			
P04049/S259A	P04049	RAF1/S259A	RAF1	Reviewed;	VARIANT	S	259	A	(in an ovarian serous carcinoma sample;;somatic mutation; increased ERK activation;;dbSNP:rs3730271)"";/evidence=""ECO:0000269|PubMed:16630891,;ECO:0000269|PubMed:17344846"";/id=""VAR_041037""	activating	A	RAF1	increase			
P04049/T310A	P04049	RAF1/T310A	RAF1	Reviewed;	VARIANT	T	310	A	(in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs778155315)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071845""	activating	A	RAF1	increase			
P04049/T641M	P04049	RAF1/T641M	RAF1	Reviewed;	VARIANT	T	641	M	(in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs587777587)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071849""	activating	A	RAF1	increase			
P04049/V263A	P04049	RAF1/V263A	RAF1	Reviewed;	VARIANT	V	263	A	(in NS5; shows in vitro greater kinase;activity and enhanced MAPK1 activation than wild-type;;dbSNP:rs397516830)"";/evidence=""ECO:0000269|PubMed:17603482"";/id=""VAR_037815""	activating	A	RAF1	increase			
P07949/G894S	P07949	RET/G894S	RET	Reviewed;	VARIANT	G	894	S	(in a patient with renal agenesis; unknown;pathological significance; constitutively phosphorylated;;expressed only the immature intracellular form)"";/evidence=""ECO:0000269|PubMed:18252215"";/id=""VAR_044396""	activating	A	RET				
P07949/V376A	P07949	RET/V376A	RET	Reviewed;	VARIANT	V	376	A	(in a patient with renal agenesis; unknown;pathological significance; constitutively phosphorylated;;expressed only the immature intracellular form)"";/evidence=""ECO:0000269|PubMed:18252215"";/id=""VAR_044393""	activating	A	RET				
P07949/V778I	P07949	RET/V778I	RET	Reviewed;	VARIANT	V	778	I	(in a patient with renal agenesis; unknown;pathological significance; constitutively phosphorylated;;dbSNP:rs75686697)"";/evidence=""ECO:0000269|PubMed:18252215"";/id=""VAR_044395""	activating	A	RET				
Q13546/D324H	Q13546	RIPK1/D324H	RIPK1	Reviewed;	VARIANT	D	324	H	(in AIEFL; prevents cleavage by CASP8;;increased kinase activity; increased inflammatory;response)"";/evidence=""ECO:0000269|PubMed:31827280,;ECO:0000269|PubMed:31827281"";/id=""VAR_083518""	activating	A	RIPK1	increase			
Q13546/D324V	Q13546	RIPK1/D324V	RIPK1	Reviewed;	VARIANT	D	324	V	(in AIEFL; prevents cleavage by CASP8;;increased kinase activity; increased inflammatory;response)"";/evidence=""ECO:0000269|PubMed:31827280"";/id=""VAR_084135""	activating	A	RIPK1	increase			
Q05823/H583A	Q05823	RNASEL/H583A	RNASEL	Reviewed;	MUTAGEN	H	583	A	No change in enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	activating	A	RN5A	exclude	neutral; remove		
Q05823/P584A	Q05823	RNASEL/P584A	RNASEL	Reviewed;	MUTAGEN	P	584	A	No change in enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	activating	A	RN5A	exclude	neutral; remove		
Q05823/W632A	Q05823	RNASEL/W632A	RNASEL	Reviewed;	MUTAGEN	W	632	A	No change in enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	activating	A	RN5A	exclude	neutral; remove		
Q01974/D482G	Q01974	ROR2/D482G	ROR2	Reviewed;	MUTAGEN	D	482	G	Slight increase in kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	activating	A	ROR2	increase			
O00141/S422D	O00141	SGK1/S422D	SGK1	Reviewed;	MUTAGEN	S	422	D	10-fold activation."";/evidence=""ECO:0000269|PubMed:10191262,;ECO:0000269|PubMed:11696533, ECO:0000269|PubMed:12911626,;ECO:0000269|PubMed:15040001""	activating	A	SGK1	increase			
Q9HBY8/S356D	Q9HBY8	SGK2/S356D	SGK2	Reviewed;	MUTAGEN	S	356	D	Increased activation."";/evidence=""ECO:0000269|PubMed:10548550""	activating	A	SGK2	increase			
Q96BR1/S486D	Q96BR1	SGK3/S486D	SGK3	Reviewed;	MUTAGEN	S	486	D	Increased activation."";/evidence=""ECO:0000269|PubMed:10548550""	activating	A	SGK3	increase			
Q9H0K1/T175E	Q9H0K1	SIK2/T175E	SIK2	Reviewed;	MUTAGEN	T	175	E	Constitutively active."";/evidence=""ECO:0000269|PubMed:14976552""	activating	A	SIK2		Missing: T175A as 'loss'		
P12931/E527K	P12931	SRC/E527K	SRC	Reviewed;	VARIANT	E	527	K	in THC6; increased protein tyrosine kinase;activity; increased autophosphorylation at Y-419; causes;defective megakaryopoiesis associated with increased;overall tyrosine phosphorylation in megakaryocytes;;dbSNP:rs879255268)"";/evidence=""ECO:0000269|PubMed:26936507"";/id=""VAR_076919""	activating	A	SRC	increase			
Q15831/K48R	Q15831	STK11/K48R	STK11	Reviewed;	MUTAGEN	K	48	R	Enhanced phosphorylation at Thr-336 and Ser-;428, enhanced cytoplasmic localization and increased kinase;activity."";/evidence=""ECO:0000269|PubMed:18687677""	activating	A	STK11	increase			
P49842/D89N	P49842	STK19/D89N	STK19	Reviewed;	VARIANT	D	89	N	(recurrent gain-of-function variant found in;metastatic melanoma; promotes NRAS signaling; somatic;mutation; dbSNP:rs267600971)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:30712867"";/id=""VAR_042361""	activating	A	STK19	increase			
P36897/T204D	P36897	TGFBR1/T204D	TGFBR1	Reviewed;	MUTAGEN	T	204	D	Constitutive activation."";/evidence=""ECO:0000269|PubMed:7774578""	activating	A	TGFR1				
Q02763/A925S	Q02763	TEK/A925S	TEK	Reviewed;	VARIANT	A	925	S	(in VMCM; increased ligand-independent;autophosphorylation and kinase activation)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066610""	activating	A	TIE2	increase			
Q02763/K1100N	Q02763	TEK/K1100N	TEK	Reviewed;	VARIANT	K	1100	N	(in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066611""	activating	A	TIE2	increase			
Q02763/L914F	Q02763	TEK/L914F	TEK	Reviewed;	VARIANT	L	914	F	(found in patients with solitary and multiple;sporadic venous malformations; increased ligand-independent;autophosphorylation; novel location at endoplasmic;reticulum and Golgi apparatus; partially retained at;endoplasmic reticulum and Golgi apparatus;;dbSNP:rs1825682849)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078051""	activating	A	TIE2	increase			
Q02763/R849W	Q02763	TEK/R849W	TEK	Reviewed;	VARIANT	R	849	W	in VMCM; increased ligand-independent;autophosphorylation and kinase activation; no effect on;location at membrane; dbSNP:rs80338908)"";/evidence=""ECO:0000269|PubMed:10369874,;ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299,;ECO:0000269|PubMed:8980225"";/id=""VAR_006352""	activating	A	TIE2	increase			
Q02763/R915C	Q02763	TEK/R915C	TEK	Reviewed;	VARIANT	R	915	C	(found in a patient with solitary sporadic;venous malformations; increased ligand-independent;autophosphorylation; dbSNP:rs1825682922)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078052""	activating	A	TIE2	increase			
Q02763/R915H	Q02763	TEK/R915H	TEK	Reviewed;	VARIANT	R	915	H	(in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs387906745)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066607""	activating	A	TIE2	increase			
Q02763/R918C	Q02763	TEK/R918C	TEK	Reviewed;	VARIANT	R	918	C	(in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs1825683100)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066608""	activating	A	TIE2	increase			
Q02763/S917I	Q02763	TEK/S917I	TEK	Reviewed;	VARIANT	S	917	I	(found in a patient with solitary sporadic;venous malformations; increased ligand-independent;autophosphorylation)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078054""	activating	A	TIE2	increase			
Q02763/V919L	Q02763	TEK/V919L	TEK	Reviewed;	VARIANT	V	919	L	(in VMCM; increased ligand-independent;autophosphorylation and kinase activation)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066609""	activating	A	TIE2	increase			
Q02763/Y897C	Q02763	TEK/Y897C	TEK	Reviewed;	VARIANT	Y	897	C	(in VMCM; increased ligand-independent;autophosphorylation and kinase activation;;dbSNP:rs80338909)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066606""	activating	A	TIE2	increase	Y897F also		
Q02763/Y897H	Q02763	TEK/Y897H	TEK	Reviewed;	VARIANT	Y	897	H	(found in a patient with solitary sporadic;venous malformations; increased ligand-independent;autophosphorylation)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078050""	activating	A	TIE2	increase			
Q02763/Y897S	Q02763	TEK/Y897S	TEK	Reviewed;	VARIANT	Y	897	S	(in VMCM; also found in a patient with;solitary sporadic venous malformations; increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs80338909)"";/evidence=""ECO:0000269|PubMed:10369874,;ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299"";/id=""VAR_008716""	activating	A	TIE2	increase			
Q86UE8/S617A	Q86UE8	TLK2/S617A	TLK2	Reviewed;	MUTAGEN	S	617	A	Increase in autophosphorylation."";/evidence=""ECO:0000269|PubMed:29955062""	activating	A	TLK2	increase			
O75962/P1461L	O75962	TRIO/P1461L	TRIO	Reviewed;	VARIANT	P	1461	L	(in MRD63; slightly increased occipitofrontal;circumference; slightly increased RAC1-mediated signaling;;slightly increased neurite outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083921""	activating	A	TRIO	increase			
O75962/R1078G	O75962	TRIO/R1078G	TRIO	Reviewed;	VARIANT	R	1078	G	(in MRD63; increased activation of RAC1-;mediated signaling; increased neurite outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083917""	activating	A	TRIO	increase			
O75962/R1078Q	O75962	TRIO/R1078Q	TRIO	Reviewed;	VARIANT	R	1078	Q	(in MRD63; increased activation of RAC1-;mediated signaling; increased neurite outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083918""	activating	A	TRIO	increase			
O75962/R1078W	O75962	TRIO/R1078W	TRIO	Reviewed;	VARIANT	R	1078	W	(in MRD63; increased activation of RAC1-;mediated signaling; increased neurite outgrowth;;dbSNP:rs1554065887)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083919""	activating	A	TRIO	increase	Also activating: N1080I ("(Thr1075Ile, Arg1078Trp/Gly/Gln, and Asn1080Ile) have a strong TRIO-activating effect, inducing hyperactivation of RAC1"		
Q9BXA7/T174E	Q9BXA7	TSSK1B/T174E	TSSK1B	Reviewed;	MUTAGEN	T	174	E	Constitutively active."";/evidence=""ECO:0000269|PubMed:15733851""	activating	A	TSSK1				
P17948/N1050D	P17948	FLT1/N1050D	FLT1	Reviewed;	MUTAGEN	N	1050	D	Strongly increases kinase activity. Increases;activity in promoting proliferation of endothelial cells."";/evidence=""ECO:0000269|PubMed:16286478""	activating	A	VGFR1	increase			
P35968/C1045A	P35968	KDR/C1045A	KDR	Reviewed;	MUTAGEN	C	1045	A	Significantly higher kinase activity."";/evidence=""ECO:0000269|PubMed:23199280""	activating	A	VGFR2	increase			
P43403/A141E	P43403	ZAP70/A141E	ZAP70	Reviewed;	MUTAGEN	A	141	E	Increased constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/D327P	P43403	ZAP70/D327P	ZAP70	Reviewed;	MUTAGEN	D	327	P	ncreases constitutive kinase activity on LAT;phosphorylation, strongly increases subcellular;localization of CD69 at the cell surface and decreases;autoinhibition conformation."";/evidence=""ECO:0000269|PubMed:26783323""	activating	A	ZAP70	increase			
P43403/K362E	P43403	ZAP70/K362E	ZAP70	Reviewed;	MUTAGEN	K	362	E	ncreases constitutive kinase activity on LAT;phosphorylation, strongly increases subcellular;localization of CD69 at the cell surface and decreases;autoinhibition conformation."";/evidence=""ECO:0000269|PubMed:26783323""	activating	A	ZAP70	increase			
P43403/L133A	P43403	ZAP70/L133A	ZAP70	Reviewed;	MUTAGEN	L	133	A	Increased constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/P147A	P43403	ZAP70/P147A	ZAP70	Reviewed;	MUTAGEN	P	147	A	Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/Q145A	P43403	ZAP70/Q145A	ZAP70	Reviewed;	MUTAGEN	Q	145	A	Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/S144A	P43403	ZAP70/S144A	ZAP70	Reviewed;	MUTAGEN	S	144	A	Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/V314A	P43403	ZAP70/V314A	ZAP70	Reviewed;	MUTAGEN	V	314	A	Increased constitutive kinase activity.""	activating	A	ZAP70	increase			
P43403/W131A	P43403	ZAP70/W131A	ZAP70	Reviewed;	MUTAGEN	W	131	A	Increased constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/Y292F	P43403	ZAP70/Y292F	ZAP70	Reviewed;	MUTAGEN	Y	292	F	Induces constitutive TCR stimulation-;independent NFAT induction."";/evidence=""ECO:0000269|PubMed:8943331""	activating	A	ZAP70	increase			
P43403/Y492F	P43403	ZAP70/Y492F	ZAP70	Reviewed;	MUTAGEN	Y	492	F	Increases kinase activity."";/evidence=""ECO:0000269|PubMed:7781602""	activating	A	ZAP70	increase			
P43403/Y597A	P43403	ZAP70/Y597A	ZAP70	Reviewed;	MUTAGEN	Y	597	A	Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
P43403/Y598A	P43403	ZAP70/Y598A	ZAP70	Reviewed;	MUTAGEN	Y	598	A	Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A	ZAP70	increase			
Q07912/K158R	Q07912	TNK2/K158R	TNK2	Reviewed;	MUTAGEN	K	158	R	Loss of autophosphorylation at Y-284."";/evidence=""ECO:0000269|PubMed:16288044,;ECO:0000269|PubMed:20110370""	loss	D	ACK1				
Q8NER5/K222R	Q8NER5	ACVR1C/K222R	ACVR1C	Reviewed;	MUTAGEN	K	222	R	Loss of response to NODAL and SMAD2;phosphorylation."";/evidence=""ECO:0000269|PubMed:12063393,;ECO:0000269|PubMed:15531507""	loss	D	ACV1C				
P37023/C41G	P37023	ACVRL1/C41G	ACVRL1	Reviewed;	VARIANT	C	41	G	(in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075231""	loss	D	ACVL1				
P37023/C41Y	P37023	ACVRL1/C41Y	ACVRL1	Reviewed;	VARIANT	C	41	Y	(in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum; dbSNP:rs1184716348)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075232""	loss	D	ACVL1				
P37023/C46G	P37023	ACVRL1/C46G	ACVRL1	Reviewed;	VARIANT	C	46	G	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075233""	loss	D	ACVL1				
P37023/R47P	P37023	ACVRL1/R47P	ACVRL1	Reviewed;	VARIANT	R	47	P	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs774389618)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075234""	loss	D	ACVL1				
P37023/H66Y	P37023	ACVRL1/H66Y	ACVRL1	Reviewed;	VARIANT	H	66	Y	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1480110873)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075235""	loss	D	ACVL1				
P37023/C77F	P37023	ACVRL1/C77F	ACVRL1	Reviewed;	VARIANT	C	77	F	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1330837892)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075236""	loss	D	ACVL1				
P37023/G211D	P37023	ACVRL1/G211D	ACVRL1	Reviewed;	VARIANT	G	211	D	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs28936687)"";/evidence=""ECO:0000269|PubMed:14684682,;ECO:0000269|PubMed:26176610"";/id=""VAR_026788""	loss	D	ACVL1				
P37023/G211S	P37023	ACVRL1/G211S	ACVRL1	Reviewed;	VARIANT	G	211	S	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075238""	loss	D	ACVL1				
P37023/A306P	P37023	ACVRL1/A306P	ACVRL1	Reviewed;	VARIANT	A	306	P	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:15024723,;ECO:0000269|PubMed:26176610"";/id=""VAR_026795""	loss	D	ACVL1				
P37023/L313V	P37023	ACVRL1/L313V	ACVRL1	Reviewed;	VARIANT	L	313	V	(in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075240""	loss	D	ACVL1				
P37023/H314Y	P37023	ACVRL1/H314Y	ACVRL1	Reviewed;	VARIANT	H	314	Y	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1565594311)"";/evidence=""ECO:0000269|PubMed:15024723,;ECO:0000269|PubMed:26176610"";/id=""VAR_026796""	loss	D	ACVL1				
P37023/P378S	P37023	ACVRL1/P378S	ACVRL1	Reviewed;	VARIANT	P	378	S	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs959973779)"";/evidence=""ECO:0000269|PubMed:20414677,;ECO:0000269|PubMed:26176610"";/id=""VAR_070335""	loss	D	ACVL1				
P37023/E379D	P37023	ACVRL1/E379D	ACVRL1	Reviewed;	VARIANT	E	379	D	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075241""	loss	D	ACVL1				
P37023/E379K	P37023	ACVRL1/E379K	ACVRL1	Reviewed;	VARIANT	E	379	K	(in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1131691686)"";/evidence=""ECO:0000269|PubMed:15024723,;ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:26176610"";/id=""VAR_026803""	loss	D	ACVL1				
P37023/V404G	P37023	ACVRL1/V404G	ACVRL1	Reviewed;	VARIANT	V	404	G	(in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075242""	loss	D	ACVL1				
P37023/R411W	P37023	ACVRL1/R411W	ACVRL1	Reviewed;	VARIANT	R	411	W	(in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum; dbSNP:rs121909287)"";/evidence=""ECO:0000269|PubMed:11484689,;ECO:0000269|PubMed:15024723, ECO:0000269|PubMed:15712270,;ECO:0000269|PubMed:26176610"";/id=""VAR_026809""	loss	D	ACVL1				
P31749/K14Q	P31749	AKT1/K14Q	AKT1	Reviewed;	MUTAGEN	K	14	Q	Substantial reduction of phosphorylation at T-;308 and S-473, loss of AKT activation, and loss of binding;to PIP3 as well as IGF1-induced membrane recruitment."";/evidence=""ECO:0000269|PubMed:12176338,;ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285""	decrease	D	AKT1				
P31749/K179M	P31749	AKT1/K179M	AKT1	Reviewed;	MUTAGEN	K	179	M	Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:33594058""	loss	D	AKT1				
P31749/T305Y	P31749	AKT1/T305Y	AKT1	Reviewed;	MUTAGEN	T	305	Y	Abolishes phosphorylation at Thr-308."";/evidence=""ECO:0000269|PubMed:22629392""	loss	D	AKT1				
P31749/T312Y	P31749	AKT1/T312Y	AKT1	Reviewed;	MUTAGEN	T	312	Y	Abolishes phosphorylation at Thr-308."";/evidence=""ECO:0000269|PubMed:22629392""	loss	D	AKT1				
Q9Y243/S472A	Q9Y243	AKT3/S472A	AKT3	Reviewed;	MUTAGEN	S	472	A	67% decrease of activity after pervanadate;treatment."";/evidence=""ECO:0000269|PubMed:10092583""	decrease	D	AKT3				
Q96QP1/K1067M	Q96QP1	ALPK1/K1067M	ALPK1	Reviewed;	MUTAGEN	K	1067	M	Abolishes the serine/threonine-protein kinase;and ability to initiate the innate immune response."";/evidence=""ECO:0000269|PubMed:30111836""	loss	D	ALPK1				
P20594/W115G	P20594	NPR2/W115G	NPR2	Reviewed;	VARIANT	W	115	G	(in AMD1; markedly deficient activity;;dbSNP:rs28931582)"";/evidence=""ECO:0000269|PubMed:15146390"";/id=""VAR_022584""	decrease	D	ANPRB				
P20594/T297M	P20594	NPR2/T297M	NPR2	Reviewed;	VARIANT	T	297	M	(in AMD1; markedly deficient activity;;dbSNP:rs1313765432)"";/evidence=""ECO:0000269|PubMed:15146390"";/id=""VAR_022586""	decrease	D	ANPRB				
P20594/G413E	P20594	NPR2/G413E	NPR2	Reviewed;	VARIANT	G	413	E	(in AMD1; markedly deficient activity)"";/evidence=""ECO:0000269|PubMed:15146390"";/id=""VAR_022589""	decrease	D	ANPRB				
P25098/K220R	P25098	GRK2/K220R	GRK2	Reviewed;	MUTAGEN	K	220	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:9892019""	loss	D	ARBK1				
P25098/D3A	P25098	GRK2/D3A	GRK2	Reviewed;	MUTAGEN	D	3	A	85% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	D	ARBK1				
P25098/D3N	P25098	GRK2/D3N	GRK2	Reviewed;	MUTAGEN	D	3	N	60% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	D	ARBK1				
P25098/L4K	P25098	GRK2/L4K	GRK2	Reviewed;	MUTAGEN	L	4	K	95% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	D	ARBK1				
P25098/E5A	P25098	GRK2/E5A	GRK2	Reviewed;	MUTAGEN	E	5	A	50% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	D	ARBK1				
Q13315/I323V	Q13315	ATM/I323V	ATM	Reviewed;	VARIANT	I	323	V	(in AT; loss of protein expression;;dbSNP:rs587781511)"";/evidence=""ECO:0000269|PubMed:10817650,;ECO:0000269|PubMed:27664052"";/id=""VAR_010803""	loss	D	ATM	exclude			
Q13315/L1046P	Q13315	ATM/L1046P	ATM	Reviewed;	VARIANT	L	1046	P	(in AT; loss of protein expression;;dbSNP:rs568461905)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077237""	loss	D	ATM	exclude			
Q13315/L1465P	Q13315	ATM/L1465P	ATM	Reviewed;	VARIANT	L	1465	P	(in AT; decreased phosphorylation of target;proteins; dbSNP:rs730881391)"";/evidence=""ECO:0000269|PubMed:10234507,;ECO:0000269|PubMed:19431188"";/id=""VAR_010826""	decrease	D	ATM				
Q13315/G2023R	Q13315	ATM/G2023R	ATM	Reviewed;	VARIANT	G	2023	R	(in AT; loss of protein expression;;dbSNP:rs11212587)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077238""	loss	D	ATM	exclude			
Q13315/L2068S	Q13315	ATM/L2068S	ATM	Reviewed;	VARIANT	L	2068	S	(in AT; decreased protein abundance; loss of;DNA damage induced protein autophosphorylation;;dbSNP:rs1555114558)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077239""	decrease	D	ATM				
Q13315/Y2080D	Q13315	ATM/Y2080D	ATM	Reviewed;	VARIANT	Y	2080	D	(in AT; loss of DNA damage induced protein;autophosphorylation; dbSNP:rs1064795467)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077240""	loss	D	ATM				
Q13315/Y2627H	Q13315	ATM/Y2627H	ATM	Reviewed;	VARIANT	Y	2627	H	(in AT; loss of protein expression)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077241""	loss	D	ATM	exclude			
Q13315/F2827C	Q13315	ATM/F2827C	ATM	Reviewed;	VARIANT	F	2827	C	(in AT; mild; decreased phosphorylation of;target proteins; dbSNP:rs121434216)"";/evidence=""ECO:0000269|PubMed:19431188,;ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314"";/id=""VAR_010879""	decrease	D	ATM				
Q13315/F2834L	Q13315	ATM/F2834L	ATM	Reviewed;	VARIANT	F	2834	L	(in AT; decreased protein abundance)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077242""	decrease	D	ATM	exclude			
Q13315/N3003D	Q13315	ATM/N3003D	ATM	Reviewed;	VARIANT	N	3003	D	(in AT; decreased protein abundance;;dbSNP:rs1137889)"";/evidence=""ECO:0000269|PubMed:27664052,;ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678,;ECO:0000269|PubMed:8665503"";/id=""VAR_077243""	decrease	D	ATM	exclude			
Q13315/K1807E	Q13315	ATM/K1807E	ATM	Reviewed;	MUTAGEN	K	1807	E	Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	D	ATM				
Q13315/V1941L	Q13315	ATM/V1941L	ATM	Reviewed;	MUTAGEN	V	1941	L	Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	D	ATM				
Q13315/Y2019C	Q13315	ATM/Y2019C	ATM	Reviewed;	MUTAGEN	Y	2019	C	Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	D	ATM				
Q13315/E2039K	Q13315	ATM/E2039K	ATM	Reviewed;	MUTAGEN	E	2039	K	Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	D	ATM				
Q13315/L2338P	Q13315	ATM/L2338P	ATM	Reviewed;	MUTAGEN	L	2338	P	Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	D	ATM				
Q13315/S2394L	Q13315	ATM/S2394L	ATM	Reviewed;	MUTAGEN	S	2394	L	Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	D	ATM				
Q13315/L2452P	Q13315	ATM/L2452P	ATM	Reviewed;	MUTAGEN	L	2452	P	Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	D	ATM				
Q13315/P2699L	Q13315	ATM/P2699L	ATM	Reviewed;	MUTAGEN	P	2699	L	Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	D	ATM				
Q13315/D2708N	Q13315	ATM/D2708N	ATM	Reviewed;	MUTAGEN	D	2708	N	Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	D	ATM				
Q13315/Q2730P	Q13315	ATM/Q2730P	ATM	Reviewed;	MUTAGEN	Q	2730	P	Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	D	ATM				
Q13315/D2870A	Q13315	ATM/D2870A	ATM	Reviewed;	MUTAGEN	D	2870	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9733515""	loss	D	ATM				
Q13315/N2875K	Q13315	ATM/N2875K	ATM	Reviewed;	MUTAGEN	N	2875	K	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9733515""	loss	D	ATM				
Q13315/K3016R	Q13315	ATM/K3016R	ATM	Reviewed;	MUTAGEN	K	3016	R	Loss of DNA damage-inducible acetylation.;Retains constitutive kinase activity, but blocks DNA;damage-induced kinase activation. Disrupts dimer and;abolishes S-1981 autophosphorylation."";/evidence=""ECO:0000269|PubMed:17923702""	loss	D	ATM				
Q13315/R3047Q	Q13315	ATM/R3047Q	ATM	Reviewed;	MUTAGEN	R	3047	Q	Abolished interaction with PEX5 and;translocation to peroxisomes in response to reactive oxygen;species (ROS)."";/evidence=""ECO:0000269|PubMed:26344566""	loss	D	ATM				
Q13535/K2327R	Q13535	ATR/K2327R	ATR	Reviewed;	MUTAGEN	K	2327	R	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:11114888,;ECO:0000269|PubMed:12011431, ECO:0000269|PubMed:9925639""	loss	D	ATR				
Q13535/D2475A	Q13535	ATR/D2475A	ATR	Reviewed;	MUTAGEN	D	2475	A	Abolishes kinase activity; increases;sensitivity to IR and impairs translocation to nuclear foci;upon DNA damage."";/evidence=""ECO:0000269|PubMed:12814551,;ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9925639""	loss	D	ATR				
Q13535/D2494E	Q13535	ATR/D2494E	ATR	Reviewed;	MUTAGEN	D	2494	E	Abolishes kinase activity; reduces cell;viability, augments sensitivity to IR and UV."";/evidence=""ECO:0000269|PubMed:10597277,;ECO:0000269|PubMed:9636169""	decrease	D	ATR	loss	loss		
O14965/K162R	O14965	AURKA/K162R	AURKA	Reviewed;	MUTAGEN	K	162	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14702041""	loss	D	AURKA				
O14965/D274N	O14965	AURKA/D274N	AURKA	Reviewed;	MUTAGEN	D	274	N	Abolishes cilia disassembly and kinase;activity."";/evidence=""ECO:0000269|PubMed:14580337,;ECO:0000269|PubMed:17604723""	loss	D	AURKA				
O14965/T288A	O14965	AURKA/T288A	AURKA	Reviewed;	MUTAGEN	T	288	A	Reduces cilia disassembly and kinase;activity."";/evidence=""ECO:0000269|PubMed:17604723""	decrease	D	AURKA				
Q96GD4/K106R	Q96GD4	AURKB/K106R	AURKB	Reviewed;	MUTAGEN	K	106	R	Leads to loss of kinase activity and severely;impairs mitotic progression."";/evidence=""ECO:0000269|PubMed:12686604,;ECO:0000269|PubMed:12925766, ECO:0000269|PubMed:14722118,;ECO:0000269|PubMed:16179162""	loss	D	AURKB				
Q9UQB9/K72R	Q9UQB9	AURKC/K72R	AURKC	Reviewed;	MUTAGEN	K	72	R	Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:15316025,;ECO:0000269|PubMed:15499654""	decrease	D	AURKC				
Q9UQB9/D166Y	Q9UQB9	AURKC/D166Y	AURKC	Reviewed;	MUTAGEN	D	166	Y	Impairs kinase activity, and keeps AURKC with;the chromosomes until the end of mitosis."";/evidence=""ECO:0000269|PubMed:15938719""	decrease	D	AURKC				
Q9UQB9/T198A	Q9UQB9	AURKC/T198A	AURKC	Reviewed;	MUTAGEN	T	198	A	Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:15316025,;ECO:0000269|PubMed:15670791""	decrease	D	AURKC				
Q9UIG0/C338A	Q9UIG0	BAZ1B/C338A	BAZ1B	Reviewed;	MUTAGEN	C	338	A	Loss of tyrosine-protein kinase activity."";/evidence=""ECO:0000269|PubMed:19092802""	loss	D	BAZ1B				
O14874/R174G	O14874	BCKDK/R174G	BCKDK	Reviewed;	VARIANT	R	174	G	(in BCKDKD; partial loss of kinase activity)"";/evidence=""ECO:0000269|PubMed:24449431"";/id=""VAR_072184""	decrease	D	BCKD				
O14874/L389P	O14874	BCKDK/L389P	BCKDK	Reviewed;	VARIANT	L	389	P	(in BCKDKD; complete loss of kinase;activity)"";/evidence=""ECO:0000269|PubMed:24449431"";/id=""VAR_072185""	loss	D	BCKD				
Q13873/D485G	Q13873	BMPR2/D485G	BMPR2	Reviewed;	VARIANT	D	485	G	(in PPH1; complete loss of function;;dbSNP:rs137852745)"";/evidence=""ECO:0000269|PubMed:10973254,;ECO:0000269|PubMed:11115378"";/id=""VAR_013679""	loss	D	BMPR2				
P51813/Y566F	P51813	BMX/Y566F	BMX	Reviewed;	MUTAGEN	Y	566	F	Abolishes almost completely the SRC-induced;phosphorylation of BMX."";/evidence=""ECO:0000269|PubMed:10688651""	loss	D	BMX				
P15056/K483S	P15056	BRAF/K483S	BRAF	Reviewed;	MUTAGEN	K	483	S	Reduces kinase activity with MAP2K1."";/evidence=""ECO:0000269|PubMed:21441910""	decrease	D	BRAF				
O60885/S503A	O60885	BRD4/S503A	BRD4	Reviewed;	MUTAGEN	S	503	A	Impaired phosphorylation by CK2 and binding to;acetylated histones."";/evidence=""ECO:0000269|PubMed:23317504""	decrease	D	BRD4				
Q8TDC3/K59A	Q8TDC3	BRSK1/K59A	BRSK1	Reviewed;	MUTAGEN	K	59	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15150265""	loss	D	BRSK1				
Q8TDC3/G327A	Q8TDC3	BRSK1/G327A	BRSK1	Reviewed;	MUTAGEN	G	327	A	Abolishes activation of kinase activity."";/evidence=""ECO:0000269|PubMed:18339622""	loss	D	BRSK1				
Q8IWQ3/K48M	Q8IWQ3	BRSK2/K48M	BRSK2	Reviewed;	MUTAGEN	K	48	M	Loss of catalytic activity. Causes;disintegration of actin stress fibers."";/evidence=""ECO:0000269|PubMed:22669945,;ECO:0000269|PubMed:22798068""	loss	D	BRSK2				
Q8IWQ3/T260A	Q8IWQ3	BRSK2/T260A	BRSK2	Reviewed;	MUTAGEN	T	260	A	Decreased phosphorylation. Nearly abolishes;stimulation of insulin secretion."";/evidence=""ECO:0000269|PubMed:16870137,;ECO:0000269|PubMed:22669945""	decrease	D	BRSK2				
Q8IWQ3/G310A	Q8IWQ3	BRSK2/G310A	BRSK2	Reviewed;	MUTAGEN	G	310	A	Decreased activation of kinase activity."";/evidence=""ECO:0000269|PubMed:18339622""	decrease	D	BRSK2				
Q06187/R307G	Q06187	BTK/R307G	BTK	Reviewed;	VARIANT	R	307	G	(in XLA; loss of activity;;dbSNP:rs128621195)"";/evidence=""ECO:0000269|PubMed:8162056"";/id=""VAR_006231""	loss	D	BTK				
Q06187/K430E	Q06187	BTK/K430E	BTK	Reviewed;	VARIANT	K	430	E	(in XLA; loss of phosphorylation of GTF2I;;dbSNP:rs128620184)"";/evidence=""ECO:0000269|PubMed:7809124"";/id=""VAR_006242""	loss	D	BTK				
Q06187/Y223F	Q06187	BTK/Y223F	BTK	Reviewed;	MUTAGEN	Y	223	F	Loss of phosphorylation of GTF2I."";/evidence=""ECO:0000269|PubMed:8630736,;ECO:0000269|PubMed:9012831""	loss	D	BTK				
Q06187/R307K	Q06187	BTK/R307K	BTK	Reviewed;	MUTAGEN	R	307	K	Loss of phosphorylation of GTF2I."";/evidence=""ECO:0000269|PubMed:9012831""	loss	D	BTK				
Q06187/Y551F	Q06187	BTK/Y551F	BTK	Reviewed;	MUTAGEN	Y	551	F	Loss of phosphorylation of GTF2I."";/evidence=""ECO:0000269|PubMed:9012831""	loss	D	BTK				
O43683/K821A	O43683	BUB1/K821A	BUB1	Reviewed;	MUTAGEN	K	821	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:10198256""	loss	D	BUB1				
Q9NYV4/D877N	Q9NYV4	CDK12/D877N	CDK12	Reviewed;	MUTAGEN	D	877	N	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:24662513""	loss	D	CDK12				
O94921/K164R	O94921	CDK14/K164R	CDK14	Reviewed;	MUTAGEN	K	164	R	Abolishes protein kinase activity."";/evidence=""ECO:0000269|PubMed:17517622,;ECO:0000269|PubMed:19524571""	loss	D	CDK14				
Q00536/S12A	Q00536	CDK16/S12A	CDK16	Reviewed;	MUTAGEN	S	12	A	Abolishes phosphorylation by BRSK2. Abolishes;effect on insulin secretion."";/evidence=""ECO:0000269|PubMed:22798068""	loss	D	CDK16				
Q00536/K194A	Q00536	CDK16/K194A	CDK16	Reviewed;	MUTAGEN	K	194	A	Loss of kinase activity. Abolishes effect on;insulin secretion."";/evidence=""ECO:0000269|PubMed:22184064,;ECO:0000269|PubMed:22798068""	loss	D	CDK16				
Q00536/K194R	Q00536	CDK16/K194R	CDK16	Reviewed;	MUTAGEN	K	194	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:22184064,;ECO:0000269|PubMed:22798068""	loss	D	CDK16				
Q9BWU1/G28R	Q9BWU1	CDK19/G28R	CDK19	Reviewed;	VARIANT	G	28	R	(in DEE87; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:33495529"";/id=""VAR_084393""	decrease	D	CDK19				
Q8IZL9/T161A	Q8IZL9	CDK20/T161A	CDK20	Reviewed;	MUTAGEN	T	161	A	Impairs CDK2 T-160 phosphorylation and;activity."";/evidence=""ECO:0000269|PubMed:14597612""	decrease	D	CDK20				
P24941/K9F	P24941	CDK2/K9F	CDK2	Reviewed;	MUTAGEN	K	9	F	Reduced phosphorylation by CAK."";/evidence=""ECO:0000269|PubMed:17373709""	decrease	D	CDK2				
P24941/T160A	P24941	CDK2/T160A	CDK2	Reviewed;	MUTAGEN	T	160	A	Abolishes activity."";/evidence=""ECO:0000269|PubMed:1396589""	loss	D	CDK2				
P24941/L166R	P24941	CDK2/L166R	CDK2	Reviewed;	MUTAGEN	L	166	R	Reduced phosphorylation by CAK and reduced;kinase activity."";/evidence=""ECO:0000269|PubMed:17373709""	decrease	D	CDK2				
P50613/K41A	P50613	CDK7/K41A	CDK7	Reviewed;	MUTAGEN	K	41	A	Total loss of activity.""	loss	D	CDK7				
P50613/T170A	P50613	CDK7/T170A	CDK7	Reviewed;	MUTAGEN	T	170	A	Total loss of activity. Total loss of;transcriptional activity of the reconstituted TFIIH;complex."";/evidence=""ECO:0000269|PubMed:8069918,;ECO:0000269|PubMed:9832506""	loss	D	CDK7				
P49336/V27L	P49336	CDK8/V27L	CDK8	Reviewed;	VARIANT	V	27	L	(in IDDHBA; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083786""	decrease	D	CDK8				
P49336/R29G	P49336	CDK8/R29G	CDK8	Reviewed;	VARIANT	R	29	G	(in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593218885)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083787""	decrease	D	CDK8				
P49336/G30S	P49336	CDK8/G30S	CDK8	Reviewed;	VARIANT	G	30	S	(in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593218890)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083788""	decrease	D	CDK8				
P49336/S62L	P49336	CDK8/S62L	CDK8	Reviewed;	VARIANT	S	62	L	(in IDDHBA; decreased protein kinase;activity; dbSNP:rs1565977796)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083789""	decrease	D	CDK8				
P49336/R178Q	P49336	CDK8/R178Q	CDK8	Reviewed;	VARIANT	R	178	Q	(in IDDHBA; decreased protein kinase;activity; dbSNP:rs1418353379)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083791""	decrease	D	CDK8				
P49336/V193G	P49336	CDK8/V193G	CDK8	Reviewed;	VARIANT	V	193	G	(in IDDHBA; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083792""	decrease	D	CDK8				
P49336/I223M	P49336	CDK8/I223M	CDK8	Reviewed;	VARIANT	I	223	M	(in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593310364)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083793""	decrease	D	CDK8				
P50750/K44R	P50750	CDK9/K44R	CDK9	Reviewed;	MUTAGEN	K	44	R	Impaired kinase and transcriptional elongation;activities, but normal cyclin T1 and HEXIM1 binding."";/evidence=""ECO:0000269|PubMed:17452463""	decrease	D	CDK9				
P50750/K48Q	P50750	CDK9/K48Q	CDK9	Reviewed;	MUTAGEN	K	48	Q	Mimics acetylation; leading to impaired;protein kinase activity."";/evidence=""ECO:0000269|PubMed:28426094""	decrease	D	CDK9				
P50750/K48R	P50750	CDK9/K48R	CDK9	Reviewed;	MUTAGEN	K	48	R	Decreased acetylation; leading to enhanced;protein kinase activity."";/evidence=""ECO:0000269|PubMed:28426094""	decrease	D	CDK9	activating	A		
P50750/S175D	P50750	CDK9/S175D	CDK9	Reviewed;	MUTAGEN	S	175	D	Mimics phosphorylation, constitutive loss of;kinase activity."";/evidence=""ECO:0000269|PubMed:21533037""	loss	D	CDK9				
Q9Y5P4/S132A	Q9Y5P4	CERT1/S132A	CERT1	Reviewed;	MUTAGEN	S	132	A	Abolishes the phosphorylation. Strongly;reduces the interaction with phosphatidylinositol 4-;phosphate. Increases the ceramide transfer activity."";/evidence=""ECO:0000269|PubMed:17591919""	decrease	D	CERT	loss	loss		
O14757/K38R	O14757	CHEK1/K38R	CHEK1	Reviewed;	MUTAGEN	K	38	R	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:12446774,;ECO:0000269|PubMed:14681223""	loss	D	CHK1				
O14757/D130A	O14757	CHEK1/D130A	CHEK1	Reviewed;	MUTAGEN	D	130	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10673501,;ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:11535615,;ECO:0000269|PubMed:11821419, ECO:0000269|PubMed:12588868,;ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:15311285,;ECO:0000269|PubMed:9278511""	loss	D	CHK1				
O96017/H371Y	O96017	CHEK2/H371Y	CHEK2	Reviewed;	VARIANT	H	371	Y	(confers a moderate risk of breast cancer;;partially reduces kinase activity; dbSNP:rs531398630)"";/evidence=""ECO:0000269|PubMed:21618645"";/id=""VAR_066012""	decrease	D	CHK2				
O96017/T68A	O96017	CHEK2/T68A	CHEK2	Reviewed;	MUTAGEN	T	68	A	Loss of activation and phosphorylation."";/evidence=""ECO:0000269|PubMed:11901158,;ECO:0000269|PubMed:15342622""	loss	D	CHK2				
O96017/S73A	O96017	CHEK2/S73A	CHEK2	Reviewed;	MUTAGEN	S	73	A	Impaired activation, phosphorylation by ATM;and G2/M transition checkpoint."";/evidence=""ECO:0000269|PubMed:16481012""	decrease	D	CHK2				
O96017/D347A	O96017	CHEK2/D347A	CHEK2	Reviewed;	MUTAGEN	D	347	A	Loss of kinase activity and of the ability to;phosphorylate CDC25A."";/evidence=""ECO:0000269|PubMed:11298456,;ECO:0000269|PubMed:9836640""	loss	D	CHK2				
O96017/D368N	O96017	CHEK2/D368N	CHEK2	Reviewed;	MUTAGEN	D	368	N	Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	loss	D	CHK2				
O96017/T383A	O96017	CHEK2/T383A	CHEK2	Reviewed;	MUTAGEN	T	383	A	Loss of phosphorylation in response to;ionizing radiation."";/evidence=""ECO:0000269|PubMed:11390408""	loss	D	CHK2		could argue for R		
O96017/T387A	O96017	CHEK2/T387A	CHEK2	Reviewed;	MUTAGEN	T	387	A	Loss of phosphorylation in response to;ionizing radiation."";/evidence=""ECO:0000269|PubMed:11390408""	loss	D	CHK2		could argue for R		
Q9UPZ9/R272Q	Q9UPZ9	CILK1/R272Q	CILK1	Reviewed;	VARIANT	R	272	Q	(in ECO; significantly impairs kinase;activity; decreased localization at the ciliary tips;;impaired ciliogenesis; results in abnormally elongated;cilia; impairs mitosis, cell-cycle exit and radial;neuroblast migration, while promoting apoptosis, when;tested in a heterologous system; loss of nuclear;localization; dbSNP:rs118203918)"";/evidence=""ECO:0000269|PubMed:19185282,;ECO:0000269|PubMed:24797473, ECO:0000269|PubMed:24853502,;ECO:0000269|PubMed:29539279"";/id=""VAR_057994""	decrease	D	CILK1				
Q9HAZ1/K189R	Q9HAZ1	CLK4/K189R	CLK4	Reviewed;	MUTAGEN	K	189	R	Loss of function."";/evidence=""ECO:0000269|PubMed:11170754""	loss	D	CLK4				
P07333/P132L	P07333	CSF1R/P132L	CSF1R	Reviewed;	VARIANT	P	132	L	(in BANDDOS; impairs phosphorylation of JNK;kinases upon stimulation with CSF1; dbSNP:rs1351319114)"";/evidence=""ECO:0000269|PubMed:30982609"";/id=""VAR_083140""	decrease	D	CSF1R				
P07333/E633K	P07333	CSF1R/E633K	CSF1R	Reviewed;	VARIANT	E	633	K	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860269)"";/evidence=""ECO:0000269|PubMed:22197934"";/id=""VAR_067398""	decrease	D	CSF1R				
P07333/G765D	P07333	CSF1R/G765D	CSF1R	Reviewed;	VARIANT	G	765	D	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs690016566)"";/evidence=""ECO:0000269|PubMed:24336230"";/id=""VAR_083144""	decrease	D	CSF1R				
P07333/M766T	P07333	CSF1R/M766T	CSF1R	Reviewed;	VARIANT	M	766	T	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860270)"";/evidence=""ECO:0000269|PubMed:22197934,;ECO:0000269|PubMed:23408870"";/id=""VAR_067401""	decrease	D	CSF1R				
P07333/I775N	P07333	CSF1R/I775N	CSF1R	Reviewed;	VARIANT	I	775	N	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860273)"";/evidence=""ECO:0000269|PubMed:22197934"";/id=""VAR_067404""	decrease	D	CSF1R				
P07333/A781E	P07333	CSF1R/A781E	CSF1R	Reviewed;	VARIANT	A	781	E	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs587777247)"";/evidence=""ECO:0000269|PubMed:24336230"";/id=""VAR_083145""	decrease	D	CSF1R				
P07333/R782H	P07333	CSF1R/R782H	CSF1R	Reviewed;	VARIANT	R	782	H	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860281)"";/evidence=""ECO:0000269|PubMed:23408870"";/id=""VAR_083146""	decrease	D	CSF1R				
P07333/I794T	P07333	CSF1R/I794T	CSF1R	Reviewed;	VARIANT	I	794	T	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860274)"";/evidence=""ECO:0000269|PubMed:22197934,;ECO:0000269|PubMed:24336230"";/id=""VAR_067405""	decrease	D	CSF1R				
P07333/P824S	P07333	CSF1R/P824S	CSF1R	Reviewed;	VARIANT	P	824	S	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1)"";/evidence=""ECO:0000269|PubMed:24336230"";/id=""VAR_083147""	decrease	D	CSF1R				
P07333/M875T	P07333	CSF1R/M875T	CSF1R	Reviewed;	VARIANT	M	875	T	(in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860279)"";/evidence=""ECO:0000269|PubMed:22197934,;ECO:0000269|PubMed:23408870"";/id=""VAR_067410""	decrease	D	CSF1R				
P07333/Y809F	P07333	CSF1R/Y809F	CSF1R	Reviewed;	MUTAGEN	Y	809	F	Reduced kinase activity. Reduced interaction;with SRC, FYN and YES1."";/evidence=""ECO:0000269|PubMed:7681396""	decrease	D	CSF1R				
P07333/Y969F	P07333	CSF1R/Y969F	CSF1R	Reviewed;	MUTAGEN	Y	969	F	Abolishes down-regulation of activated CSF1R."";/evidence=""ECO:0000269|PubMed:15117969""	loss	D	CSF1R				
P41240/Y184F	P41240	CSK/Y184F	CSK	Reviewed;	MUTAGEN	Y	184	F	Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:9148770""	loss	D	CSK				
P41240/Y304F	P41240	CSK/Y304F	CSK	Reviewed;	MUTAGEN	Y	304	F	Decreases activity by two-thirds and alters;conformation."";/evidence=""ECO:0000269|PubMed:9148770""	decrease	D	CSK				
P41240/S364A	P41240	CSK/S364A	CSK	Reviewed;	MUTAGEN	S	364	A	Strong decrease of phosphorylation by PRKACA;(catalytic subunit of PKA)."";/evidence=""ECO:0000269|PubMed:11181701""	decrease	D	CSK				
O14578/G106V	O14578	CIT/G106V	CIT	Reviewed;	VARIANT	G	106	V	(in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037892)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077442""	decrease	D	CTRO				
O14578/K126Q	O14578	CIT/K126Q	CIT	Reviewed;	VARIANT	K	126	Q	(in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037893)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077443""	decrease	D	CTRO				
O14578/D230V	O14578	CIT/D230V	CIT	Reviewed;	VARIANT	D	230	V	(in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037894)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077444""	decrease	D	CTRO				
P53355/K42A	P53355	DAPK1/K42A	DAPK1	Reviewed;	MUTAGEN	K	42	A	Loss of activity, apoptotic function and of;autophosphorylation."";/evidence=""ECO:0000269|PubMed:11579085,;ECO:0000269|PubMed:7828849""	loss	D	DAPK1				
P53355/S289A	P53355	DAPK1/S289A	DAPK1	Reviewed;	MUTAGEN	S	289	A	Loss of phosphorylation and significant;increase in proapoptotic activity.""	loss	D	DAPK1	activating	A, phosphorylation inactivates kinase		
P53355/S308D	P53355	DAPK1/S308D	DAPK1	Reviewed;	MUTAGEN	S	308	D	Reduced Ca(2+)-calmodulin binding and Ca(2+)-;calmodulin-independent kinase activity. Decreases apoptotic;activity."";/evidence=""ECO:0000269|PubMed:11579085""	decrease	D	DAPK1				
Q9UIK4/K52A	Q9UIK4	DAPK2/K52A	DAPK2	Reviewed;	MUTAGEN	K	52	A	Loss of activity, apoptotic function and of;autophosphorylation."";/evidence=""ECO:0000269|PubMed:10376525,;ECO:0000269|PubMed:10629061, ECO:0000269|PubMed:11230133""	loss	D	DAPK2				
Q9UIK4/S318A	Q9UIK4	DAPK2/S318A	DAPK2	Reviewed;	MUTAGEN	S	318	A	Loss of Ca(2+)-calmodulin independent;phosphorylation, increase in apoptotic activity."";/evidence=""ECO:0000269|PubMed:11230133""	loss	D	DAPK2	activating	A, phosphorylation inactivates kinase		
O43293/T112M	O43293	DAPK3/T112M	DAPK3	Reviewed;	VARIANT	T	112	M	(in a colorectal adenocarcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation and cell survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040438""	decrease	D	DAPK3				
O43293/D161N	O43293	DAPK3/D161N	DAPK3	Reviewed;	VARIANT	D	161	N	(in an ovarian mucinous carcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation and cell survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040439""	decrease	D	DAPK3				
O43293/P216S	O43293	DAPK3/P216S	DAPK3	Reviewed;	VARIANT	P	216	S	(in a lung neuroendocrine carcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation, cell adhesion and cell;survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040440""	decrease	D	DAPK3				
O43293/K42A	O43293	DAPK3/K42A	DAPK3	Reviewed;	MUTAGEN	K	42	A	Loss of kinase activity at low concentrations;of ATP."";/evidence=""ECO:0000269|PubMed:17158456""	loss	D	DAPK3				
O43293/D161A	O43293	DAPK3/D161A	DAPK3	Reviewed;	MUTAGEN	D	161	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17158456""	loss	D	DAPK3				
O43293/T180A	O43293	DAPK3/T180A	DAPK3	Reviewed;	MUTAGEN	T	180	A	Greatly reduced kinase activity."";/evidence=""ECO:0000269|PubMed:21487036""	decrease	D	DAPK3				
O43293/T225A	O43293	DAPK3/T225A	DAPK3	Reviewed;	MUTAGEN	T	225	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17158456""	loss	D	DAPK3				
O43293/T265A	O43293	DAPK3/T265A	DAPK3	Reviewed;	MUTAGEN	T	265	A	Loss of phosphorylation by ROCK1,;catalytically inactive."";/evidence=""ECO:0000269|PubMed:17158456""	loss	D	DAPK3				
O43293/T299A	O43293	DAPK3/T299A	DAPK3	Reviewed;	MUTAGEN	T	299	A	Loss of phosphorylation by ROCK1."";/evidence=""ECO:0000269|PubMed:17158456""	loss	D	DAPK3				
Q16832/K608A	Q16832	DDR2/K608A	DDR2	Reviewed;	MUTAGEN	K	608	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:16186108""	loss	D	DDR2				
Q09013/K100A	Q09013	DMPK/K100A	DMPK	Reviewed;	MUTAGEN	K	100	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15598648""	loss	D	DMPK				
Q13627/K188R	Q13627	DYRK1A/K188R	DYRK1A	Reviewed;	MUTAGEN	K	188	R	Abolished protein kinase activity."";/evidence=""ECO:0000269|PubMed:23665168,;ECO:0000269|PubMed:25620562""	loss	D	DYR1A				
Q13627/Y321F	Q13627	DYRK1A/Y321F	DYRK1A	Reviewed;	MUTAGEN	Y	321	F	Mildly reduces kinase activity. Does not;abolish autophosphorylation on tyrosine residues."";/evidence=""ECO:0000269|PubMed:23665168""	decrease	D	DYR1A				
Q9Y463/K140R	Q9Y463	DYRK1B/K140R	DYRK1B	Reviewed;	MUTAGEN	K	140	R	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10910078""	loss	D	DYR1B	exclude	There are more (Y271F and Y273F)		
Q9Y463/D239A	Q9Y463	DYRK1B/D239A	DYRK1B	Reviewed;	MUTAGEN	D	239	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:32611815""	loss	D	DYR1B				
Q92630/T106A	Q92630	DYRK2/T106A	DYRK2	Reviewed;	MUTAGEN	T	106	A	Impaired ATM-mediated phosphorylation, reduced;affinity with MDM2 and altered MDM2-triggered;ubiquitination."";/evidence=""ECO:0000269|PubMed:19965871""	decrease	D	DYRK2	exclude	pubmed suggests that this may contribute to an escape mechanism to avoid ubiquitination by MDM2, hence escaping degradation. Hard to argue A or D here		
Q92630/K251R	Q92630	DYRK2/K251R	DYRK2	Reviewed;	MUTAGEN	K	251	R	Abolishes protein serine/threonine kinase;activity."";/evidence=""ECO:0000269|PubMed:23362280""	loss	D	DYRK2				
Q92630/S442A	Q92630	DYRK2/S442A	DYRK2	Reviewed;	MUTAGEN	S	442	A	Impaired ATM-mediated phosphorylation, reduced;affinity with MDM2 and altered MDM2-triggered;ubiquitination."";/evidence=""ECO:0000269|PubMed:19965871""	decrease	D	DYRK2	exclude	pubmed suggests that this may contribute to an escape mechanism to avoid ubiquitination by MDM2, hence escaping degradation. Hard to argue A or D here		
Q9NR20/K133R	Q9NR20	DYRK4/K133R	DYRK4	Reviewed;	MUTAGEN	K	133	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17292540""	loss	D	DYRK4				
Q9NR20/Y264F	Q9NR20	DYRK4/Y264F	DYRK4	Reviewed;	MUTAGEN	Y	264	F	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:21127067""	loss	D	DYRK4				
P19525/A67E	P19525	EIF2AK2/A67E	EIF2AK2	Reviewed;	MUTAGEN	A	67	E	Significant loss of activity; loss of dsRNA;binding and dimerization."";/evidence=""ECO:0000269|PubMed:11337501""	loss	D	E2AK2				
P19525/T258A	P19525	EIF2AK2/T258A	EIF2AK2	Reviewed;	MUTAGEN	T	258	A	Moderate loss of activity."";/evidence=""ECO:0000269|PubMed:11152499""	loss	D	E2AK2	decrease	decrease		
P19525/K296R	P19525	EIF2AK2/K296R	EIF2AK2	Reviewed;	MUTAGEN	K	296	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:11152499""	loss	D	E2AK2				
P19525/T446A	P19525	EIF2AK2/T446A	EIF2AK2	Reviewed;	MUTAGEN	T	446	A	Significant loss of activity and impairs;autophosphorylation of T-451."";/evidence=""ECO:0000269|PubMed:11337501""	loss	D	E2AK2	decrease	decrease		
P19525/T451A	P19525	EIF2AK2/T451A	EIF2AK2	Reviewed;	MUTAGEN	T	451	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:11337501""	loss	D	E2AK2				
Q9P2K8/K614A	Q9P2K8	EIF2AK4/K614A	EIF2AK4	Reviewed;	MUTAGEN	K	614	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:10026192""	loss	D	E2AK4				
O00418/S78A	O00418	EEF2K/S78A	EEF2K	Reviewed;	MUTAGEN	S	78	A	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:22216903""	decrease	D	EF2K				
O00418/T348A	O00418	EEF2K/T348A	EEF2K	Reviewed;	MUTAGEN	T	348	A	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:22216903""	decrease	D	EF2K				
O00418/S366A	O00418	EEF2K/S366A	EEF2K	Reviewed;	MUTAGEN	S	366	A	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:11500364,;ECO:0000269|PubMed:22216903""	decrease	D	EF2K				
P00533/G428D	P00533	EGFR/G428D	EGFR	Reviewed;	VARIANT	G	428	D	(in NISBD2; loss of function; the mutant does;not localize to the cell membrane; has diffuse cytoplasmic;localization; dbSNP:rs606231253)"";/evidence=""ECO:0000269|PubMed:24691054"";/id=""VAR_072435""	loss	D	EGFR				
P00533/R429E	P00533	EGFR/R429E	EGFR	Reviewed;	MUTAGEN	R	429	E	Abolishes autophosphorylation and activation;of downstream kinases."";/evidence=""ECO:0000269|PubMed:12297050""	loss	D	EGFR				
P00533/L688A	P00533	EGFR/L688A	EGFR	Reviewed;	MUTAGEN	L	688	A	Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417,;ECO:0000269|PubMed:19563760""	decrease	D	EGFR				
P00533/V689A	P00533	EGFR/V689A	EGFR	Reviewed;	MUTAGEN	V	689	A	Reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	D	EGFR				
P00533/E690A	P00533	EGFR/E690A	EGFR	Reviewed;	MUTAGEN	E	690	A	Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417,;ECO:0000269|PubMed:19563760""	decrease	D	EGFR				
P00533/L692A	P00533	EGFR/L692A	EGFR	Reviewed;	MUTAGEN	L	692	A	P: Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417,;ECO:0000269|PubMed:19563760""	decrease	D	EGFR		L->P missing		
P00533/T693D	P00533	EGFR/T693D	EGFR	Reviewed;	MUTAGEN	T	693	D	Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	D	EGFR				
P00533/P694A	P00533	EGFR/P694A	EGFR	Reviewed;	MUTAGEN	P	694	A	Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	D	EGFR				
P00533/P699A	P00533	EGFR/P699A	EGFR	Reviewed;	MUTAGEN	P	699	A	Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	D	EGFR				
P00533/N700A	P00533	EGFR/N700A	EGFR	Reviewed;	MUTAGEN	N	700	A	Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	D	EGFR				
P00533/L704A	P00533	EGFR/L704A	EGFR	Reviewed;	MUTAGEN	L	704	A	Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	D	EGFR				
P00533/R705A	P00533	EGFR/R705A	EGFR	Reviewed;	MUTAGEN	R	705	A	Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	D	EGFR				
P00533/I706A	P00533	EGFR/I706A	EGFR	Reviewed;	MUTAGEN	I	706	A	Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	D	EGFR				
P00533/K745A	P00533	EGFR/K745A	EGFR	Reviewed;	MUTAGEN	K	745	A	M: Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:19560417""	loss	D	EGFR		Also K->M is missing		
P00533/D974A	P00533	EGFR/D974A	EGFR	Reviewed;	MUTAGEN	D	974	A	Strongly reduced phosphorylation.""	decrease	D	EGFR				
P00533/R977A	P00533	EGFR/R977A	EGFR	Reviewed;	MUTAGEN	R	977	A	Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19563760""	decrease	D	EGFR				
P29317/K646M	P29317	EPHA2/K646M	EPHA2	Reviewed;	MUTAGEN	K	646	M	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:16236711""	loss	D	EPHA2				
P29317/S897A	P29317	EPHA2/S897A	EPHA2	Reviewed;	MUTAGEN	S	897	A	D: Loss of serum-induced phosphorylation by;PKB. Loss of serum-induced chemotaxis."";/evidence=""ECO:0000269|PubMed:19573808""	loss	D	EPHA2	exclude	Also S->D missing; I think this means p-site is lost and doesn't really say about activatiion or deactivation		
P29320/V133E	P29320	EPHA3/V133E	EPHA3	Reviewed;	MUTAGEN	V	133	E	Loss of EFNA5-binding ability and function."";/evidence=""ECO:0000269|PubMed:14660665""	loss	D	EPHA3				
P29320/F152L	P29320	EPHA3/F152L	EPHA3	Reviewed;	MUTAGEN	F	152	L	Loss of EFNA5-binding ability and function."";/evidence=""ECO:0000269|PubMed:14660665""	loss	D	EPHA3				
P54762/K651R	P54762	EPHB1/K651R	EPHB1	Reviewed;	MUTAGEN	K	651	R	Kinase-dead mutant. Unable to;autophosphorylate, to interact with SH2 domain-containing;interactors, to activate the MAPK/ERK and JUN signaling;cascades. Not ubiquitinated by CBL."";/evidence=""ECO:0000269|PubMed:18034775,;ECO:0000269|PubMed:9430661""	loss	D	EPHB1				
P54753/K665R	P54753	EPHB3/K665R	EPHB3	Reviewed;	MUTAGEN	K	665	R	Kinase-dead. Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:9674711""	loss	D	EPHB3				
P54760/K650N	P54760	EPHB4/K650N	EPHB4	Reviewed;	VARIANT	K	650	N	(in CMAVM2; highly decreased tyrosine;phosphorylation; highly decreased interaction with RASA1;;dbSNP:rs1584658113)"";/evidence=""ECO:0000269|PubMed:30578106"";/id=""VAR_081706""	decrease	D	EPHB4				
P54760/E664K	P54760	EPHB4/E664K	EPHB4	Reviewed;	VARIANT	E	664	K	(in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs1562969219)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081708""	loss	D	EPHB4				
P54760/R739Q	P54760	EPHB4/R739Q	EPHB4	Reviewed;	VARIANT	R	739	Q	(in LMPHM7; loss of kinase activity;;dbSNP:rs1057519263)"";/evidence=""ECO:0000269|PubMed:27400125"";/id=""VAR_078063""	loss	D	EPHB4				
P54760/I782S	P54760	EPHB4/I782S	EPHB4	Reviewed;	VARIANT	I	782	S	(in LMPHM7; loss of kinase activity;;dbSNP:rs1057519264)"";/evidence=""ECO:0000269|PubMed:27400125"";/id=""VAR_078064""	loss	D	EPHB4				
P54760/R838W	P54760	EPHB4/R838W	EPHB4	Reviewed;	VARIANT	R	838	W	(in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs764827256)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081719""	loss	D	EPHB4				
P54760/C845R	P54760	EPHB4/C845R	EPHB4	Reviewed;	VARIANT	C	845	R	(in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs1584653054)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081720""	loss	D	EPHB4				
P54760/R864W	P54760	EPHB4/R864W	EPHB4	Reviewed;	VARIANT	R	864	W	(in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs769965440)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081722""	loss	D	EPHB4				
P04626/A710V	P04626	ERBB2/A710V	ERBB2	Reviewed;	VARIANT	A	710	V	(in VSCN2; almost complete loss of ERBB2 and;ERBB3 phosphorylation in the presence or in the absence of;NRG1 stimulation, suggesting alteration of downstream;signaling; does not affect the subcellular localization at;the cell membrane)"";/evidence=""ECO:0000269|PubMed:33497358"";/id=""VAR_086107""	loss	D	ERBB2				
P21860/T787P	P21860	ERBB3/T787P	ERBB3	Reviewed;	VARIANT	T	787	P	(in VSCN1; almost complete loss of ERBB2 and;ERBB3 phosphorylation in the presence or in the absence of;NRG1 stimulation, suggesting alteration of downstream;signaling; does not affect the subcellular localization at;the cell membrane)"";/evidence=""ECO:0000269|PubMed:33497358"";/id=""VAR_086108""	loss	D	ERBB3				
P21860/V899M	P21860	ERBB3/V899M	ERBB3	Reviewed;	VARIANT	V	899	M	(in VSCN1; almost complete loss of ERBB2 and;ERBB3 phosphorylation in the presence or in the absence of;NRG1 stimulation, suggesting alteration of downstream;signaling; does not affect the subcellular localization at;the cell membrane)"";/evidence=""ECO:0000269|PubMed:33497358"";/id=""VAR_086110""	loss	D	ERBB3				
P21860/K742M	P21860	ERBB3/K742M	ERBB3	Reviewed;	MUTAGEN	K	742	M	Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:20351256""	decrease	D	ERBB3				
P21860/Y868E	P21860	ERBB3/Y868E	ERBB3	Reviewed;	MUTAGEN	Y	868	E	Strongly reduced tyrosine phosphorylation."";/evidence=""ECO:0000269|PubMed:20351256""	decrease	D	ERBB3				
Q15303/R927Q	Q15303	ERBB4/R927Q	ERBB4	Reviewed;	VARIANT	R	927	Q	(in ALS19; reduces autophosphorylation upon;NRG1 stimulation; dbSNP:rs397514262)"";/evidence=""ECO:0000269|PubMed:24119685"";/id=""VAR_070810""	decrease	D	ERBB4				
Q15303/R1275W	Q15303	ERBB4/R1275W	ERBB4	Reviewed;	VARIANT	R	1275	W	(in ALS19; reduces autophosphorylation upon;NRG1 stimulation; dbSNP:rs397514263)"";/evidence=""ECO:0000269|PubMed:24119685"";/id=""VAR_070811""	decrease	D	ERBB4				
Q15303/L710N	Q15303	ERBB4/L710N	ERBB4	Reviewed;	MUTAGEN	L	710	N	Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:18287036""	decrease	D	ERBB4				
Q15303/K751R	Q15303	ERBB4/K751R	ERBB4	Reviewed;	MUTAGEN	K	751	R	Abolishes kinase activity. Abolishes;phosphorylation, proteolytic processing and nuclear;localization."";/evidence=""ECO:0000269|PubMed:11390655,;ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867""	loss	D	ERBB4				
Q15303/M766R	Q15303	ERBB4/M766R	ERBB4	Reviewed;	MUTAGEN	M	766	R	Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:18287036""	decrease	D	ERBB4				
Q15303/D843N	Q15303	ERBB4/D843N	ERBB4	Reviewed;	MUTAGEN	D	843	N	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:16978839""	loss	D	ERBB4				
Q15303/D861Y	Q15303	ERBB4/D861Y	ERBB4	Reviewed;	MUTAGEN	D	861	Y	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19098003""	loss	D	ERBB4				
Q15303/L864R	Q15303	ERBB4/L864R	ERBB4	Reviewed;	MUTAGEN	L	864	R	Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:18287036""	decrease	D	ERBB4				
O75460/K599A	O75460	ERN1/K599A	ERN1	Reviewed;	MUTAGEN	K	599	A	Loss of autophosphorylation and of;endoribonuclease activity. Inhibition of growth arrest."";/evidence=""ECO:0000269|PubMed:11175748,;ECO:0000269|PubMed:9637683""	loss	D	ERN1				
Q76MJ5/K548A	Q76MJ5	ERN2/K548A	ERN2	Reviewed;	MUTAGEN	K	548	A	Loss of autophosphorylation, of induction of;apoptosis and of 28S rRNA cleavage, attenuation of;repression of protein synthesis."";/evidence=""ECO:0000269|PubMed:11175748""	loss	D	ERN2				
Q14289/K457A	Q14289	PTK2B/K457A	PTK2B	Reviewed;	MUTAGEN	K	457	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15166227""	loss	D	FAK2				
Q14289/Y881F	Q14289	PTK2B/Y881F	PTK2B	Reviewed;	MUTAGEN	Y	881	F	Loss of phosphorylation site. Strongly reduced;interaction with GRB2."";/evidence=""ECO:0000269|PubMed:20521079""	decrease	D	FAK2				
P16591/R483Q	P16591	FER/R483Q	FER	Reviewed;	MUTAGEN	R	483	Q	Abolishes kinase activity. Abolishes location;at microtubules."";/evidence=""ECO:0000269|PubMed:12972546""	loss	D	FER				
P16591/K591R	P16591	FER/K591R	FER	Reviewed;	MUTAGEN	K	591	R	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9722593""	loss	D	FER				
P07332/L334P	P07332	FES/L334P	FES	Reviewed;	MUTAGEN	L	334	P	Abolishes autophosphorylation."";/evidence=""ECO:0000269|PubMed:11509660""	loss	D	FES				
P07332/G463V	P07332	FES/G463V	FES	Reviewed;	MUTAGEN	G	463	V	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:18775312""	loss	D	FES				
P07332/K590E	P07332	FES/K590E	FES	Reviewed;	MUTAGEN	K	590	E	Abolishes kinase activity. Fails to inhibit;proliferation of melanoma cells."";/evidence=""ECO:0000269|PubMed:15485904,;ECO:0000269|PubMed:28463229""	loss	D	FES				
P07332/M704V	P07332	FES/M704V	FES	Reviewed;	MUTAGEN	M	704	V	Reduced autophosphorylation and strongly;reduced kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	decrease	D	FES				
P07332/Y713F	P07332	FES/Y713F	FES	Reviewed;	MUTAGEN	Y	713	F	Reduces kinase activity by over 90%."";/evidence=""ECO:0000269|PubMed:7687763""	decrease	D	FES				
P07332/V743M	P07332	FES/V743M	FES	Reviewed;	MUTAGEN	V	743	M	Strongly reduced autophosphorylation and;kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	decrease	D	FES				
P07332/S759F	P07332	FES/S759F	FES	Reviewed;	MUTAGEN	S	759	F	Reduced autophosphorylation and strongly;reduced kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	decrease	D	FES				
P11362/K618N	P11362	FGFR1/K618N	FGFR1	Reviewed;	VARIANT	K	618	N	(in HH2; some patients also carry GNRHR;mutations; impairs tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:19820032,;ECO:0000269|PubMed:23643382"";/id=""VAR_069293""	decrease	D	FGFR1				
P11362/K514A	P11362	FGFR1/K514A	FGFR1	Reviewed;	MUTAGEN	K	514	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15117958""	loss	D	FGFR1				
P11362/D623A	P11362	FGFR1/D623A	FGFR1	Reviewed;	MUTAGEN	D	623	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19224897""	loss	D	FGFR1				
P21802/M391R	P21802	FGFR2/M391R	FGFR2	Reviewed;	VARIANT	M	391	R	(in BBDS; the mutation selectively reduces;plasma-membrane levels of the protein and markedly;diminishes the receptor's responsiveness to extracellular;FGF; dbSNP:rs387906677)"";/evidence=""ECO:0000269|PubMed:22387015"";/id=""VAR_067978""	decrease	D	FGFR2				
P21802/A628T	P21802	FGFR2/A628T	FGFR2	Reviewed;	VARIANT	A	628	T	(in LADDS; strongly reduced kinase activity;;dbSNP:rs121918509)"";/evidence=""ECO:0000269|PubMed:16501574"";/id=""VAR_029884""	decrease	D	FGFR2				
P21802/Y769F	P21802	FGFR2/Y769F	FGFR2	Reviewed;	MUTAGEN	Y	769	F	Increases fibroblast proliferation. Decreases;phosphorylation of PLCG1 and FRS2. Decreases activation of;MAP kinases."";/evidence=""ECO:0000269|PubMed:15629145,;ECO:0000269|PubMed:19103595""	decrease	D	FGFR2				
P22607/K508A	P22607	FGFR3/K508A	FGFR3	Reviewed;	MUTAGEN	K	508	A	Loss of kinase activity. Abolishes;ubiquitination."";/evidence=""ECO:0000269|PubMed:12297284,;ECO:0000269|PubMed:16410555""	loss	D	FGFR3				
P22607/Y724F	P22607	FGFR3/Y724F	FGFR3	Reviewed;	MUTAGEN	Y	724	F	Strongly reduced kinase activity. Strongly;reduced mitogen activity."";/evidence=""ECO:0000269|PubMed:11294897""	decrease	D	FGFR3				
P22455/K503R	P22455	FGFR4/K503R	FGFR4	Reviewed;	MUTAGEN	K	503	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11433297,;ECO:0000269|PubMed:17311277""	loss	D	FGFR4				
P36888/K644A	P36888	FLT3/K644A	FLT3	Reviewed;	MUTAGEN	K	644	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15831474""	loss	D	FLT3				
P42685/K262R	P42685	FRK/K262R	FRK	Reviewed;	MUTAGEN	K	262	R	Loss of ability to phosphorylate PTEN."";/evidence=""ECO:0000269|PubMed:19345329""	loss	D	FRK				
Q15835/K219A	Q15835	GRK1/K219A	GRK1	Reviewed;	MUTAGEN	K	219	A	Loss of autophosphorylation and RHO;phosphorylation."";/evidence=""ECO:0000269|PubMed:15946941""	loss	D	GRK1				
P49841/L128A	P49841	GSK3B/L128A	GSK3B	Reviewed;	MUTAGEN	L	128	A	Abolishes activity toward AXIN1."";/evidence=""ECO:0000269|PubMed:11430833""	loss	D	GSK3B				
Q02846/F565S	Q02846	GUCY2D/F565S	GUCY2D	Reviewed;	VARIANT	F	565	S	(in LCA1; loss of activity;;dbSNP:rs61749755)"";/evidence=""ECO:0000269|PubMed:9888789"";/id=""VAR_009131""	loss	D	GUC2D				
Q8TF76/K282M	Q8TF76	HASPIN/K282M	HASPIN	Reviewed;	MUTAGEN	K	282	M	Loss of catalytic activity. Reduced nuclear;size in larval salivary glands."";/evidence=""ECO:0000269|PubMed:32750047""	decrease	D	HASP				
Q8TF76/E492A	Q8TF76	HASPIN/E492A	HASPIN	Reviewed;	MUTAGEN	E	492	A	Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D	HASP				
Q8TF76/K511A	Q8TF76	HASPIN/K511A	HASPIN	Reviewed;	MUTAGEN	K	511	A	Strongly reduced enzyme activity."";/evidence=""ECO:0000269|PubMed:19918057""	decrease	D	HASP				
Q8TF76/H651A	Q8TF76	HASPIN/H651A	HASPIN	Reviewed;	MUTAGEN	H	651	A	Strongly reduced enzyme activity, markedly;reduced affinity for histone H3."";/evidence=""ECO:0000269|PubMed:19918049,;ECO:0000269|PubMed:19918057""	decrease	D	HASP				
Q8TF76/D707L	Q8TF76	HASPIN/D707L	HASPIN	Reviewed;	MUTAGEN	D	707	L	Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D	HASP				
Q8TF76/D709N	Q8TF76	HASPIN/D709N	HASPIN	Reviewed;	MUTAGEN	D	709	N	Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D	HASP				
Q8TF76/G713F	Q8TF76	HASPIN/G713F	HASPIN	Reviewed;	MUTAGEN	G	713	F	Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D	HASP				
Q8TF76/D716L	Q8TF76	HASPIN/D716L	HASPIN	Reviewed;	MUTAGEN	D	716	L	Markedly reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D	HASP				
P08631/K290E	P08631	HCK/K290E	HCK	Reviewed;	MUTAGEN	K	290	E	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11896602""	loss	D	HCK				
P08631/E305A	P08631	HCK/E305A	HCK	Reviewed;	MUTAGEN	E	305	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10644735""	loss	D	HCK				
P08631/D381E	P08631	HCK/D381E	HCK	Reviewed;	MUTAGEN	D	381	E	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15998323""	loss	D	HCK				
P08631/Y411A	P08631	HCK/Y411A	HCK	Reviewed;	MUTAGEN	Y	411	A	Reduced catalytic activity and higher affinity;for target peptides."";/evidence=""ECO:0000269|PubMed:10644735""	decrease	D	HCK				
Q86Z02/K219A	Q86Z02	HIPK1/K219A	HIPK1	Reviewed;	MUTAGEN	K	219	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19646965""	loss	D	HIPK1				
Q86Z02/D315N	Q86Z02	HIPK1/D315N	HIPK1	Reviewed;	MUTAGEN	D	315	N	Loss of kinase activity and impaired MAP3K5-;JNK inactivation."";/evidence=""ECO:0000269|PubMed:15701637""	loss	D	HIPK1				
Q9H422/K226R	Q9H422	HIPK3/K226R	HIPK3	Reviewed;	MUTAGEN	K	226	R	Loss of kinase activity and impaired;activation of SF1."";/evidence=""ECO:0000269|PubMed:17210646""	loss	D	HIPK3				
P08069/R138Q	P08069	IGF1R/R138Q	IGF1R	Reviewed;	VARIANT	R	138	Q	(in IGF1RES; has decreased IGF1R function;;dbSNP:rs121912426)"";/evidence=""ECO:0000269|PubMed:14657428"";/id=""VAR_034891""	decrease	D	IGF1R				
P08069/K145N	P08069	IGF1R/K145N	IGF1R	Reviewed;	VARIANT	K	145	N	(in IGF1RES; has decreased IGF1R function;;dbSNP:rs121912427)"";/evidence=""ECO:0000269|PubMed:14657428"";/id=""VAR_034892""	decrease	D	IGF1R				
P08069/N359Y	P08069	IGF1R/N359Y	IGF1R	Reviewed;	VARIANT	N	359	Y	(in IGF1RES; significant decrease in IGF1-;induced DNA synthesis and AKT1 phosphorylation in patient;fibroblasts)"";/evidence=""ECO:0000269|PubMed:25040157"";/id=""VAR_076247""	decrease	D	IGF1R				
P08069/Y865C	P08069	IGF1R/Y865C	IGF1R	Reviewed;	VARIANT	Y	865	C	(in IGF1RES; significant decrease in IGF1-;induced DNA synthesis and AKT1 phosphorylation in patient;fibroblasts)"";/evidence=""ECO:0000269|PubMed:25040157"";/id=""VAR_076248""	decrease	D	IGF1R				
P08069/R1256S	P08069	IGF1R/R1256S	IGF1R	Reviewed;	VARIANT	R	1256	S	(in IGF1RES; significant decrease in IGF1-;induced DNA synthesis and AKT1 phosphorylation in patient;fibroblasts)"";/evidence=""ECO:0000269|PubMed:25040157"";/id=""VAR_076249""	decrease	D	IGF1R				
O15111/T23A	O15111	CHUK/T23A	CHUK	Reviewed;	MUTAGEN	T	23	A	Loss of phosphorylation and decrease of kinase;activity."";/evidence=""ECO:0000269|PubMed:10485710""	decrease	D	IKKA				
O15111/K44A	O15111	CHUK/K44A	CHUK	Reviewed;	MUTAGEN	K	44	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9244310,;ECO:0000269|PubMed:9346484""	loss	D	IKKA				
O15111/K44M	O15111	CHUK/K44M	CHUK	Reviewed;	MUTAGEN	K	44	M	Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:9244310,;ECO:0000269|PubMed:9346484""	loss	D	IKKA				
O15111/S176A	O15111	CHUK/S176A	CHUK	Reviewed;	MUTAGEN	S	176	A	Loss of phosphorylation and of activity."";/evidence=""ECO:0000269|PubMed:9346484,;ECO:0000269|PubMed:9520446""	loss	D	IKKA				
O14920/D166A	O14920	IKBKB/D166A	IKBKB	Reviewed;	MUTAGEN	D	166	A	Loss of protein kinase activity."";/evidence=""ECO:0000269|PubMed:25326418""	loss	D	IKKB				
O14920/S177A	O14920	IKBKB/S177A	IKBKB	Reviewed;	MUTAGEN	S	177	A	Decrease of activity."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	decrease	D	IKKB				
O14920/S181A	O14920	IKBKB/S181A	IKBKB	Reviewed;	MUTAGEN	S	181	A	Decrease of activity."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	decrease	D	IKKB				
Q14164/K38A	Q14164	IKBKE/K38A	IKBKE	Reviewed;	MUTAGEN	K	38	A	Loss of kinase activity and loss of nuclear;import."";/evidence=""ECO:0000269|PubMed:10421793""	loss	D	IKKE				
Q14164/E168A	Q14164	IKBKE/E168A	IKBKE	Reviewed;	MUTAGEN	E	168	A	Slight decrease of kinase activity."";/evidence=""ECO:0000269|PubMed:10421793""	decrease	D	IKKE				
Q14164/S172A	Q14164	IKBKE/S172A	IKBKE	Reviewed;	MUTAGEN	S	172	A	Loss of autophosphorylation and of kinase;activity."";/evidence=""ECO:0000269|PubMed:10421793""	loss	D	IKKE				
Q14164/S172E	Q14164	IKBKE/S172E	IKBKE	Reviewed;	MUTAGEN	S	172	E	Decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:10421793""	decrease	D	IKKE				
P06213/E1206D	P06213	INSR/E1206D	INSR	Reviewed;	VARIANT	E	1206	D	(in IRAN type A; accelerates degradation of;the protein and impairs kinase activity)"";/evidence=""ECO:0000269|PubMed:7983039"";/id=""VAR_015931""	decrease	D	INSR				
P06213/W1220L	P06213	INSR/W1220L	INSR	Reviewed;	VARIANT	W	1220	L	(in IRAN type A; accelerates degradation of;the protein and impairs kinase activity; dbSNP:rs52800171)"";/evidence=""ECO:0000269|PubMed:7983039,;ECO:0000269|PubMed:8390949"";/id=""VAR_004100""	decrease	D	INSR				
P06213/K1057M	P06213	INSR/K1057M	INSR	Reviewed;	MUTAGEN	K	1057	M	R: Abolishes the kinase activity."";/evidence=""ECO:0000269|PubMed:10803466,;ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""	loss	D	INSR		K->R missing		
P06213/D1159N	P06213	INSR/D1159N	INSR	Reviewed;	MUTAGEN	D	1159	N	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11598120""	loss	D	INSR				
P06213/R1163Q	P06213	INSR/R1163Q	INSR	Reviewed;	MUTAGEN	R	1163	Q	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11598120""	loss	D	INSR				
P51617/T209A	P51617	IRAK1/T209A	IRAK1	Reviewed;	MUTAGEN	T	209	A	Completely abolishes auto-phosphorylation in;the kinase domain."";/evidence=""ECO:0000269|PubMed:14625308""	loss	D	IRAK1				
P51617/K239S	P51617	IRAK1/K239S	IRAK1	Reviewed;	MUTAGEN	K	239	S	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15084582""	loss	D	IRAK1				
P51617/D340N	P51617	IRAK1/D340N	IRAK1	Reviewed;	MUTAGEN	D	340	N	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18691762""	loss	D	IRAK1				
P51617/T387A	P51617	IRAK1/T387A	IRAK1	Reviewed;	MUTAGEN	T	387	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14625308""	loss	D	IRAK1				
Q9NWZ3/K213A	Q9NWZ3	IRAK4/K213A	IRAK4	Reviewed;	MUTAGEN	K	213	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15084582""	loss	D	IRAK4				
P23458/K908A	P23458	JAK1/K908A	JAK1	Reviewed;	MUTAGEN	K	908	A	Loss of protein tyrosine kinase activity."";/evidence=""ECO:0000269|PubMed:32750333""	loss	D	JAK1				
P52333/Y785F	P52333	JAK3/Y785F	JAK3	Reviewed;	MUTAGEN	Y	785	F	Strong decrease of JAK3 phosphorylation."";/evidence=""ECO:0000269|PubMed:15121872""	decrease	D	JAK3				
P52333/K855A	P52333	JAK3/K855A	JAK3	Reviewed;	MUTAGEN	K	855	A	More than 90% loss of STAT5a activation."";/evidence=""ECO:0000269|PubMed:18250158""	loss	D	JAK3				
P52333/Y904F	P52333	JAK3/Y904F	JAK3	Reviewed;	MUTAGEN	Y	904	F	About 40% loss of STAT5a activation."";/evidence=""ECO:0000269|PubMed:18250158""	decrease	D	JAK3				
P52333/Y939F	P52333	JAK3/Y939F	JAK3	Reviewed;	MUTAGEN	Y	939	F	About 80% loss of STAT5a activation."";/evidence=""ECO:0000269|PubMed:18250158""	loss	D	JAK3				
O60229/K2713A	O60229	KALRN/K2713A	KALRN	Reviewed;	MUTAGEN	K	2713	A	Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:10023074""	loss	D	KALRN				
P22612/I74M	P22612	PRKACG/I74M	PRKACG	Reviewed;	VARIANT	I	74	M	(in BDPLT19; patient platelets show impaired;activation; dbSNP:rs724159972)"";/evidence=""ECO:0000269|PubMed:25061177"";/id=""VAR_072672""	decrease	D	KAPCG				
P48730/T44A	P48730	CSNK1D/T44A	CSNK1D	Reviewed;	VARIANT	T	44	A	(in FASPS2; strongly reduces kinase activity;;dbSNP:rs104894561)"";/evidence=""ECO:0000269|PubMed:15800623,;ECO:0000269|PubMed:23636092"";/id=""VAR_029075""	decrease	D	KC1D				
P48730/H46R	P48730	CSNK1D/H46R	CSNK1D	Reviewed;	VARIANT	H	46	R	(in FASPS2; strongly reduces kinase activity;;dbSNP:rs397514693)"";/evidence=""ECO:0000269|PubMed:23636092"";/id=""VAR_069801""	decrease	D	KC1D				
P48730/K38M	P48730	CSNK1D/K38M	CSNK1D	Reviewed;	MUTAGEN	K	38	M	Impaired kinase activity and abnormal;subcellular localization with exclusive accumulation to the;nucleus."";/evidence=""ECO:0000269|PubMed:11161704""	decrease	D	KC1D				
P48730/T176I	P48730	CSNK1D/T176I	CSNK1D	Reviewed;	MUTAGEN	T	176	I	Impaired kinase activity and abnormal;subcellular localization with exclusive accumulation to the;nucleus."";/evidence=""ECO:0000269|PubMed:11161704""	decrease	D	KC1D				
P49674/K38R	P49674	CSNK1E/K38R	CSNK1E	Reviewed;	MUTAGEN	K	38	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:29222110""	loss	D	KC1E				
Q9HCP0/N169A	Q9HCP0	CSNK1G1/N169A	CSNK1G1	Reviewed;	MUTAGEN	N	169	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:21680713""	loss	D	KC1G1				
Q14012/T177A	Q14012	CAMK1/T177A	CAMK1	Reviewed;	MUTAGEN	T	177	A	Loss of activation by CaMKK1."";/evidence=""ECO:0000269|PubMed:7641687""	loss	D	KCC1A				
Q6P2M8/T179A	Q6P2M8	PNCK/T179A	PNCK	Reviewed;	MUTAGEN	T	179	A	Loss of activation by cmkC."";/evidence=""ECO:0000269|PubMed:10988293""	loss	D	KCC1B				
Q8IU85/T180A	Q8IU85	CAMK1D/T180A	CAMK1D	Reviewed;	MUTAGEN	T	180	A	Loss of ionomycin-induced activation."";/evidence=""ECO:0000269|PubMed:12935886,;ECO:0000269|PubMed:16324104""	loss	D	KCC1D				
Q16566/S12A	Q16566	CAMK4/S12A	CAMK4	Reviewed;	MUTAGEN	S	12	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:8702940""	loss	D	KCC4				
Q16566/S13A	Q16566	CAMK4/S13A	CAMK4	Reviewed;	MUTAGEN	S	13	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:8702940""	loss	D	KCC4				
Q16566/K75E	Q16566	CAMK4/K75E	CAMK4	Reviewed;	MUTAGEN	K	75	E	Loss of activity; dominant negative form."";/evidence=""ECO:0000269|PubMed:10617605""	loss	D	KCC4				
Q16566/T200A	Q16566	CAMK4/T200A	CAMK4	Reviewed;	MUTAGEN	T	200	A	Loss of activation by CaMKK1 or CaMKK2."";/evidence=""ECO:0000269|PubMed:8855261""	loss	D	KCC4				
P10721/E839K	P10721	KIT/E839K	KIT	Reviewed;	VARIANT	E	839	K	(in MASTC; sporadic case; somatic mutation;;dominant negative mutation; loss of autophosphorylation;;dbSNP:rs121913509)"";/evidence=""ECO:0000269|PubMed:9990072"";/id=""VAR_033136""	loss	D	KIT				
P10721/R381A	P10721	KIT/R381A	KIT	Reviewed;	MUTAGEN	R	381	A	Reduces autophosphorylation in response to;KITLG/SCF."";/evidence=""ECO:0000269|PubMed:17662946""	decrease	D	KIT				
P10721/E386A	P10721	KIT/E386A	KIT	Reviewed;	MUTAGEN	E	386	A	Reduces autophosphorylation in response to;KITLG/SCF."";/evidence=""ECO:0000269|PubMed:17662946""	decrease	D	KIT				
Q15139/Y502E	Q15139	PRKD1/Y502E	PRKD1	Reviewed;	MUTAGEN	Y	502	E	Loss of activation."";/evidence=""ECO:0000269|PubMed:12637538""	loss	D	KPCD1				
Q15139/K612W	Q15139	PRKD1/K612W	PRKD1	Reviewed;	MUTAGEN	K	612	W	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12637538""	loss	D	KPCD1				
Q9BZL6/D695A	Q9BZL6	PRKD2/D695A	PRKD2	Reviewed;	MUTAGEN	D	695	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:23503467""	loss	D	KPCD2				
Q9BZL6/Y717F	Q9BZL6	PRKD2/Y717F	PRKD2	Reviewed;	MUTAGEN	Y	717	F	Abolishes phosphorylation. Decreases substrate;affinity and increases catalytic efficiency. Increases Ser-;706 or/and Ser-710 phosphorylation. Increases NF-kappa-B;activation in response to oxidative stress."";/evidence=""ECO:0000269|PubMed:28428613""	decrease	D	KPCD2	loss	loss		
Q05655/S299A	Q05655	PRKCD/S299A	PRKCD	Reviewed;	MUTAGEN	S	299	A	Loss of phosphorylation."";/evidence=""ECO:0000269|PubMed:17603046""	loss	D	KPCD				
Q02156/K437W	Q02156	PRKCE/K437W	PRKCE	Reviewed;	MUTAGEN	K	437	W	Abolishes activity and S-729 phosphorylation."";/evidence=""ECO:0000269|PubMed:11964154""	loss	D	KPCE				
Q02156/T566A	Q02156	PRKCE/T566A	PRKCE	Reviewed;	MUTAGEN	T	566	A	Abolishes phosphorylation by PDK1, and S-729;phosphorylation."";/evidence=""ECO:0000269|PubMed:11964154""	loss	D	KPCE				
P41743/K274W	P41743	PRKCI/K274W	PRKCI	Reviewed;	MUTAGEN	K	274	W	Abolishes activity."";/evidence=""ECO:0000269|PubMed:10906326""	loss	D	KPCI				
Q04759/K409A	Q04759	PRKCQ/K409A	PRKCQ	Reviewed;	MUTAGEN	K	409	A	E: Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10652356""	loss	D	KPCT		K->E missing		
Q04759/T538A	Q04759	PRKCQ/T538A	PRKCQ	Reviewed;	MUTAGEN	T	538	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11772397,;ECO:0000269|PubMed:16252004""	loss	D	KPCT				
Q04759/S676A	Q04759	PRKCQ/S676A	PRKCQ	Reviewed;	MUTAGEN	S	676	A	Reduction in kinase activity."";/evidence=""ECO:0000269|PubMed:16252004""	decrease	D	KPCT				
Q04759/S695A	Q04759	PRKCQ/S695A	PRKCQ	Reviewed;	MUTAGEN	S	695	A	Reduction in kinase activity."";/evidence=""ECO:0000269|PubMed:11772397,;ECO:0000269|PubMed:16252004""	decrease	D	KPCT				
P51812/R383W	P51812	RPS6KA3/R383W	RPS6KA3	Reviewed;	VARIANT	R	383	W	(in XLID19; kinase activity is decreased but;not abolished; dbSNP:rs122454129)"";/evidence=""ECO:0000269|PubMed:10319851"";/id=""VAR_065897""	decrease	D	KS6A3				
O75582/D195A	O75582	RPS6KA5/D195A	RPS6KA5	Reviewed;	MUTAGEN	D	195	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9687510""	loss	D	KS6A5				
O75582/S360A	O75582	RPS6KA5/S360A	RPS6KA5	Reviewed;	MUTAGEN	S	360	A	Decreases kinase activity by 60% in response;to PMA and UV-C."";/evidence=""ECO:0000269|PubMed:15568999""	decrease	D	KS6A5				
O75582/S376A	O75582	RPS6KA5/S376A	RPS6KA5	Reviewed;	MUTAGEN	S	376	A	Loss of kinase activity, and decreases the;phosphorylation of S-360 and T-581."";/evidence=""ECO:0000269|PubMed:15568999""	decrease	D	KS6A5	loss	loss		
O75582/D565A	O75582	RPS6KA5/D565A	RPS6KA5	Reviewed;	MUTAGEN	D	565	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9687510""	loss	D	KS6A5				
O75582/T581A	O75582	RPS6KA5/T581A	RPS6KA5	Reviewed;	MUTAGEN	T	581	A	Loss of kinase activity, and blocks;phosphorylation of S-212; S-376 and S-381 in response to;PMA and UV-C."";/evidence=""ECO:0000269|PubMed:15568999""	loss	D	KS6A5				
O75582/T700A	O75582	RPS6KA5/T700A	RPS6KA5	Reviewed;	MUTAGEN	T	700	A	D: Strongly reduces phosphorylation of T-581 in;response to PMA and UV-C."";/evidence=""ECO:0000269|PubMed:17117922""	decrease	D	KS6A5		T->D missing		
Q9UK32/S389A	Q9UK32	RPS6KA6/S389A	RPS6KA6	Reviewed;	MUTAGEN	S	389	A	Strongly decreases activity."";/evidence=""ECO:0000269|PubMed:15632195""	decrease	D	KS6A6				
P23443/K167N	P23443	RPS6KB1/K167N	RPS6KB1	Reviewed;	MUTAGEN	K	167	N	Greatly reduces activity. Greatly reduces;phosphorylation at T-412 and moderately reduces;phosphorylation at T-252."";/evidence=""ECO:0000269|PubMed:17446865""	decrease	D	KS6B1				
P23443/S394A	P23443	RPS6KB1/S394A	RPS6KB1	Reviewed;	MUTAGEN	S	394	A	Loss of activity. Loss of phosphorylation at;T-412."";/evidence=""ECO:0000269|PubMed:17446865""	loss	D	KS6B1				
Q8IVT5/E72K	Q8IVT5	KSR1/E72K	KSR1	Reviewed;	MUTAGEN	E	72	K	Loss of interaction with BRAF and MAP2K1 and;severe decrease in MAP2K1 phosphorylation levels."";/evidence=""ECO:0000269|PubMed:29433126""	decrease	D	KSR1				
Q6VAB6/D786A	Q6VAB6	KSR2/D786A	KSR2	Reviewed;	MUTAGEN	D	786	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:21441910""	loss	D	KSR2				
O95835/S464A	O95835	LATS1/S464A	LATS1	Reviewed;	MUTAGEN	S	464	A	Abolishes phosphorylation by NUAK1 and NUAK2."";/evidence=""ECO:0000269|PubMed:19927127""	loss	D	LATS1				
O95835/K734A	O95835	LATS1/K734A	LATS1	Reviewed;	MUTAGEN	K	734	A	Loss of kinase activity, autophosphorylation,;increased ploidy, prolonged duration of mitosis and lack of;p53 expression."";/evidence=""ECO:0000269|PubMed:15122335""	loss	D	LATS1				
Q9NRM7/K697A	Q9NRM7	LATS2/K697A	LATS2	Reviewed;	MUTAGEN	K	697	A	Loss of kinase activity, autophosphorylation;and tumor suppressor activity."";/evidence=""ECO:0000269|PubMed:10871863,;ECO:0000269|PubMed:12853976""	loss	D	LATS2				
Q9NRM7/S872A	Q9NRM7	LATS2/S872A	LATS2	Reviewed;	MUTAGEN	S	872	A	Loss of tumor suppressor activity."";/evidence=""ECO:0000269|PubMed:12853976""	loss	D	LATS2				
P53667/T508A	P53667	LIMK1/T508A	LIMK1	Reviewed;	MUTAGEN	T	508	A	Abolishes activation by ROCK1."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	loss	D	LIMK1		Missing: D460N, D460A ('Abrogates kinase activity')		
P53667/T508V	P53667	LIMK1/T508V	LIMK1	Reviewed;	MUTAGEN	T	508	V	Reduces kinase activity."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	decrease	D	LIMK1				
P53671/T505V	P53671	LIMK2/T505V	LIMK2	Reviewed;	MUTAGEN	T	505	V	Abolishes cofilin phosphorylation and;enhancement of stress fiber formation."";/evidence=""ECO:0000269|PubMed:11018042""	loss	D	LIMK2		Missing: D451A ('Abrogates kinase activity')		
Q38SD2/K1270W	Q38SD2	LRRK1/K1270W	LRRK1	Reviewed;	MUTAGEN	K	1270	W	Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:16243488""	loss	D	LRRK1				
Q5S007/L760D	Q5S007	LRRK2/L760D	LRRK2	Reviewed;	MUTAGEN	L	760	D	Decreased kinase activity and loss of RAB29-;mediated activation."";/evidence=""ECO:0000269|PubMed:29212815""	decrease	D	LRRK2				
Q5S007/L761D	Q5S007	LRRK2/L761D	LRRK2	Reviewed;	MUTAGEN	L	761	D	Decreased kinase activity and loss of RAB29-;mediated activation."";/evidence=""ECO:0000269|PubMed:29212815""	decrease	D	LRRK2				
Q5S007/L762D	Q5S007	LRRK2/L762D	LRRK2	Reviewed;	MUTAGEN	L	762	D	Decreased kinase activity and loss of RAB29-;mediated activation."";/evidence=""ECO:0000269|PubMed:29212815""	decrease	D	LRRK2				
Q5S007/D1994A	Q5S007	LRRK2/D1994A	LRRK2	Reviewed;	MUTAGEN	D	1994	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:28720718""	loss	D	LRRK2				
P29376/K544M	P29376	LTK/K544M	LTK	Reviewed;	MUTAGEN	K	544	M	Loss of interaction with PLCG1, PI3-kinase;subunit p85, Ras GTPase-activating protein and RAF1."";/evidence=""ECO:0000269|PubMed:8084603""	loss	D	LTK				
P29376/Y862F	P29376	LTK/Y862F	LTK	Reviewed;	MUTAGEN	Y	862	F	Impairs phosphorylation of CBLC (demonstrated;with chimeric EGFR-LTK)."";/evidence=""ECO:0000269|PubMed:9223670""	decrease	D	LTK				
P07948/K275L	P07948	LYN/K275L	LYN	Reviewed;	MUTAGEN	K	275	L	R: Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11435302,;ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188,;ECO:0000269|PubMed:18817770""	loss	D	LYN		Also K->R and K->A		
P07948/Y397F	P07948	LYN/Y397F	LYN	Reviewed;	MUTAGEN	Y	397	F	Strongly reduced kinase activity."";/evidence=""ECO:0000269|PubMed:16920712""	decrease	D	LYN				
Q16584/K144A	Q16584	MAP3K11/K144A	MAP3K11	Reviewed;	MUTAGEN	K	144	A	Greatly reduced autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:11053428,;ECO:0000269|PubMed:8195146""	decrease	D	M3K11				
Q16584/K144R	Q16584	MAP3K11/K144R	MAP3K11	Reviewed;	MUTAGEN	K	144	R	Loss of kinase activity. Prevents activation;of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428,;ECO:0000269|PubMed:8195146""	loss	D	M3K11				
Q16584/E164A	Q16584	MAP3K11/E164A	MAP3K11	Reviewed;	MUTAGEN	E	164	A	Greatly reduced autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:8195146""	decrease	D	M3K11				
Q16584/T277A	Q16584	MAP3K11/T277A	MAP3K11	Reviewed;	MUTAGEN	T	277	A	Severely reduced autophosphorylation activity.;Prevents phosphorylation of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428""	decrease	D	M3K11				
Q16584/S281A	Q16584	MAP3K11/S281A	MAP3K11	Reviewed;	MUTAGEN	S	281	A	Reduced autophosphorylation activity. Reduced;activation of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428""	decrease	D	M3K11				
Q9NYL2/K45M	Q9NYL2	MAP3K20/K45M	MAP3K20	Reviewed;	MUTAGEN	K	45	M	Loss of kinase activity. Does not affect;ability to activate EIF2AK4/GCN2 in response to mild;ribosome collision."";/evidence=""ECO:0000269|PubMed:11836244,;ECO:0000269|PubMed:32610081, ECO:0000269|PubMed:35857590""	loss	D	M3K20				
Q9NYL2/T161A	Q9NYL2	MAP3K20/T161A	MAP3K20	Reviewed;	MUTAGEN	T	161	A	Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	loss	D	M3K20				
Q9NYL2/T162A	Q9NYL2	MAP3K20/T162A	MAP3K20	Reviewed;	MUTAGEN	T	162	A	Slight loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	decrease	D	M3K20				
Q9NYL2/S165A	Q9NYL2	MAP3K20/S165A	MAP3K20	Reviewed;	MUTAGEN	S	165	A	Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	loss	D	M3K20				
Q9Y6R4/K1372R	Q9Y6R4	MAP3K4/K1372R	MAP3K4	Reviewed;	MUTAGEN	K	1372	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:12052864,;ECO:0000269|PubMed:9305639""	loss	D	M3K4				
Q99683/K709M	Q99683	MAP3K5/K709M	MAP3K5	Reviewed;	MUTAGEN	K	709	M	Loss of kinase activity. Inhibits activation;of JNK and apoptosis mediated by TNFRSF6 and DAXX. Does not;affect interaction with TRIM48."";/evidence=""ECO:0000269|PubMed:17210579,;ECO:0000269|PubMed:29186683, ECO:0000269|PubMed:9743501""	loss	D	M3K5				
Q99683/K709R	Q99683	MAP3K5/K709R	MAP3K5	Reviewed;	MUTAGEN	K	709	R	Loss of kinase activity. Abolishes DAXX-;mediated apoptosis. Loss of RC3H2-mediated ubiquitination."";/evidence=""ECO:0000269|PubMed:17210579,;ECO:0000269|PubMed:24448648, ECO:0000269|PubMed:9743501""	loss	D	M3K5				
O43318/K63W	O43318	MAP3K7/K63W	MAP3K7	Reviewed;	MUTAGEN	K	63	W	Loss of kinase activity. Loss of;autophosphorylation."";/evidence=""ECO:0000269|PubMed:12589052,;ECO:0000269|PubMed:22802624""	loss	D	M3K7				
P80192/K171A	P80192	MAP3K9/K171A	MAP3K9	Reviewed;	MUTAGEN	K	171	A	Loss of kinase activity and threonine;phosphorylation."";/evidence=""ECO:0000269|PubMed:15610029""	loss	D	M3K9				
P80192/T304A	P80192	MAP3K9/T304A	MAP3K9	Reviewed;	MUTAGEN	T	304	A	Reduces threonine phosphorylation. Impairs JNK;activation."";/evidence=""ECO:0000269|PubMed:15610029""	decrease	D	M3K9				
P80192/S308A	P80192	MAP3K9/S308A	MAP3K9	Reviewed;	MUTAGEN	S	308	A	Impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	decrease	D	M3K9				
P80192/T312A	P80192	MAP3K9/T312A	MAP3K9	Reviewed;	MUTAGEN	T	312	A	Loss of threonine phosphorylation. Strongly;impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	loss	D	M3K9				
Q8IVH8/K48E	Q8IVH8	MAP4K3/K48E	MAP4K3	Reviewed;	MUTAGEN	K	48	E	Loss of kinase activity and ability to;activate JNK family."";/evidence=""ECO:0000269|PubMed:9275185""	loss	D	M4K3				
Q9Y4K4/K49R	Q9Y4K4	MAP4K5/K49R	MAP4K5	Reviewed;	MUTAGEN	K	49	R	Loss of kinase activity and ability to;activate JNK family."";/evidence=""ECO:0000269|PubMed:9038372""	loss	D	M4K5				
P20794/G13S	P20794	MAK/G13S	MAK	Reviewed;	VARIANT	G	13	S	(in RP62; results in a complete loss of;kinase activity compared to wild-type; dbSNP:rs387906647)"";/evidence=""ECO:0000269|PubMed:21835304"";/id=""VAR_066988""	loss	D	MAK				
P20794/N130H	P20794	MAK/N130H	MAK	Reviewed;	VARIANT	N	130	H	(in RP62; results in a complete loss of;kinase activity compared to wild-type; dbSNP:rs387906646)"";/evidence=""ECO:0000269|PubMed:21835304"";/id=""VAR_066990""	loss	D	MAK				
P20794/K33R	P20794	MAK/K33R	MAK	Reviewed;	MUTAGEN	K	33	R	Abolishes autophosphorylation."";/evidence=""ECO:0000269|PubMed:12084720""	loss	D	MAK				
P20794/T157A	P20794	MAK/T157A	MAK	Reviewed;	MUTAGEN	T	157	A	Abolishes autophosphorylation and impairs;kinase activity."";/evidence=""ECO:0000269|PubMed:21986944""	loss	D	MAK				
P49137/K93R	P49137	MAPKAPK2/K93R	MAPKAPK2	Reviewed;	MUTAGEN	K	93	R	Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:14517288""	loss	D	MAPK2				
P49137/D207A	P49137	MAPKAPK2/D207A	MAPKAPK2	Reviewed;	MUTAGEN	D	207	A	Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:8846784""	loss	D	MAPK2				
P49137/T222A	P49137	MAPKAPK2/T222A	MAPKAPK2	Reviewed;	MUTAGEN	T	222	A	Strong decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	decrease	D	MAPK2				
P49137/S272A	P49137	MAPKAPK2/S272A	MAPKAPK2	Reviewed;	MUTAGEN	S	272	A	Strong decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:8846784""	decrease	D	MAPK2				
P49137/T334A	P49137	MAPKAPK2/T334A	MAPKAPK2	Reviewed;	MUTAGEN	T	334	A	Slight decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	decrease	D	MAPK2				
P49137/K353R	P49137	MAPKAPK2/K353R	MAPKAPK2	Reviewed;	MUTAGEN	K	353	R	Induces decreased sumoylation and increase in;protein kinase activity."";/evidence=""ECO:0000269|PubMed:21131586""	decrease	D	MAPK2				
Q8IW41/K51M	Q8IW41	MAPKAPK5/K51M	MAPKAPK5	Reviewed;	MUTAGEN	K	51	M	Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:12808055""	loss	D	MAPK5				
Q7KZI7/S219A	Q7KZI7	MARK2/S219A	MARK2	Reviewed;	MUTAGEN	S	219	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14517247,;ECO:0000269|PubMed:9108484""	loss	D	MARK2				
Q14680/D150A	Q14680	MELK/D150A	MELK	Reviewed;	MUTAGEN	D	150	A	Abolishes enzymatic activity."";/evidence=""ECO:0000269|PubMed:14699119,;ECO:0000269|PubMed:16216881, ECO:0000269|PubMed:17280616""	loss	D	MELK				
Q14680/T167A	Q14680	MELK/T167A	MELK	Reviewed;	MUTAGEN	T	167	A	Abolishes activation of serine/threonine-;protein kinase activity and has only weak activity."";/evidence=""ECO:0000269|PubMed:14976552""	loss	D	MELK				
Q14680/S171A	Q14680	MELK/S171A	MELK	Reviewed;	MUTAGEN	S	171	A	Abolishes activation of serine/threonine-;protein kinase activity and has only weak activity."";/evidence=""ECO:0000269|PubMed:16216881""	loss	D	MELK				
P45983/K55D	P45983	MAPK8/K55D	MAPK8	Reviewed;	MUTAGEN	K	55	D	Abolished protein kinase activity."";/evidence=""ECO:0000269|PubMed:22966201""	loss	D	MK08				
P53778/Y185F	P53778	MAPK12/Y185F	MAPK12	Reviewed;	MUTAGEN	Y	185	F	Loss of activity."";/evidence=""ECO:0000269|PubMed:8633070""	loss	D	MK12				
O15264/T180A	O15264	MAPK13/T180A	MAPK13	Reviewed;	MUTAGEN	T	180	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9374491""	loss	D	MK13				
O15264/Y182A	O15264	MAPK13/Y182A	MAPK13	Reviewed;	MUTAGEN	Y	182	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9374491""	loss	D	MK13				
Q16539/A34V	Q16539	MAPK14/A34V	MAPK14	Reviewed;	MUTAGEN	A	34	V	Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	decrease	D	MK14				
Q16539/K53R	Q16539	MAPK14/K53R	MAPK14	Reviewed;	MUTAGEN	K	53	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	D	MK14				
Q16539/K54R	Q16539	MAPK14/K54R	MAPK14	Reviewed;	MUTAGEN	K	54	R	Impairs MAP2K6/MKK6-dependent;autophosphorylation."";/evidence=""ECO:0000269|PubMed:11010976""	decrease	D	MK14				
Q16539/Y69H	Q16539	MAPK14/Y69H	MAPK14	Reviewed;	MUTAGEN	Y	69	H	Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	decrease	D	MK14				
Q16539/D168A	Q16539	MAPK14/D168A	MAPK14	Reviewed;	MUTAGEN	D	168	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	D	MK14				
Q16539/D177A	Q16539	MAPK14/D177A	MAPK14	Reviewed;	MUTAGEN	D	177	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	loss	D	MK14				
Q16539/T180E	Q16539	MAPK14/T180E	MAPK14	Reviewed;	MUTAGEN	T	180	E	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	D	MK14				
Q16539/Y182F	Q16539	MAPK14/Y182F	MAPK14	Reviewed;	MUTAGEN	Y	182	F	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	D	MK14				
Q16539/A320T	Q16539	MAPK14/A320T	MAPK14	Reviewed;	MUTAGEN	A	320	T	Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	decrease	D	MK14				
Q16539/W337R	Q16539	MAPK14/W337R	MAPK14	Reviewed;	MUTAGEN	W	337	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	loss	D	MK14				
Q8TD08/K42R	Q8TD08	MAPK15/K42R	MAPK15	Reviewed;	MUTAGEN	K	42	R	Loss of autophosphorylation and activity. Does;not increase dopamine transporter activity. Impairs kinase;activity. Does not rescue cilium assembly in MAPK15-;depleted cells."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:28842414, ECO:0000269|PubMed:29021280""	loss	D	MK15				
Q8TD08/R59Q	Q8TD08	MAPK15/R59Q	MAPK15	Reviewed;	MUTAGEN	R	59	Q	Does not increase dopamine transporter;activity. Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:28842414""	decrease	D	MK15	loss	loss		
Q8TD08/Y177A	Q8TD08	MAPK15/Y177A	MAPK15	Reviewed;	MUTAGEN	Y	177	A	Loss of autophosphorylation and activity.;Heavily phosphorylated at Thr-175."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:16336213""	loss	D	MK15				
Q9HBH9/D228G	Q9HBH9	MKNK2/D228G	MKNK2	Reviewed;	MUTAGEN	D	228	G	Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:16917500""	decrease	D	MKNK2				
Q02750/K97A	Q02750	MAP2K1/K97A	MAP2K1	Reviewed;	MUTAGEN	K	97	A	Loss of catalytic activity. Strongly reduces;phosphorylation upon UV irradiation."";/evidence=""ECO:0000269|PubMed:20956560""	decrease	D	MP2K1	loss	loss		
Q5VT25/K106A	Q5VT25	CDC42BPA/K106A	CDC42BPA	Reviewed;	MUTAGEN	K	106	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	D	MRCKA		missing muts preventing CASP3 cleavage, which is required for activation (thus inactivating)		
Q5VT25/S234A	Q5VT25	CDC42BPA/S234A	CDC42BPA	Reviewed;	MUTAGEN	S	234	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	D	MRCKA				
Q5VT25/T240A	Q5VT25	CDC42BPA/T240A	CDC42BPA	Reviewed;	MUTAGEN	T	240	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	D	MRCKA				
Q5VT25/T403A	Q5VT25	CDC42BPA/T403A	CDC42BPA	Reviewed;	MUTAGEN	T	403	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	D	MRCKA				
P42345/H2340A	P42345	MTOR/H2340A	MTOR	Reviewed;	MUTAGEN	H	2340	A	Barely detectable kinase activity."";/evidence=""ECO:0000269|PubMed:23636326""	loss	D	MTOR		Missing several inactivating: S2159A, T2164A, D2357E, V2364I		
O15146/I575T	O15146	MUSK/I575T	MUSK	Reviewed;	VARIANT	I	575	T	(in FADS1; reduces agrin-dependent AChR;aggregation and tyrosine kinase activity in developing;neuromuscular junction; dbSNP:rs751889864)"";/evidence=""ECO:0000269|PubMed:25537362"";/id=""VAR_072787""	decrease	D	MUSK				
O15146/M605I	O15146	MUSK/M605I	MUSK	Reviewed;	VARIANT	M	605	I	(in CMS9; affects interaction with DOK7 and;impairs MUSK phosphorylation; altered AChR clustering;;dbSNP:rs766640370)"";/evidence=""ECO:0000269|PubMed:20371544"";/id=""VAR_066604""	decrease	D	MUSK				
O15146/A727V	O15146	MUSK/A727V	MUSK	Reviewed;	VARIANT	A	727	V	(in CMS9; affects interaction with DOK7 and;impairs MUSK phosphorylation; altered AChR clustering;;dbSNP:rs397515450)"";/evidence=""ECO:0000269|PubMed:20371544"";/id=""VAR_066605""	decrease	D	MUSK				
O15146/V790M	O15146	MUSK/V790M	MUSK	Reviewed;	VARIANT	V	790	M	(in CMS9; does not affect catalytic kinase;activity; reduces protein expression and stability;;dbSNP:rs199476083)"";/evidence=""ECO:0000269|PubMed:15496425"";/id=""VAR_023046""	decrease	D	MUSK				
O15146/G584C	O15146	MUSK/G584C	MUSK	Reviewed;	MUTAGEN	G	584	C	D: Mild decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	decrease	D	MUSK		Also G->D		
O15146/K609R	O15146	MUSK/K609R	MUSK	Reviewed;	MUTAGEN	K	609	R	Severe loss of kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	loss	D	MUSK				
Q15746/A1491S	Q15746	MYLK/A1491S	MYLK	Reviewed;	VARIANT	A	1491	S	(in AAT7; decreases kinase activity;;dbSNP:rs1576422965)"";/evidence=""ECO:0000269|PubMed:29544503"";/id=""VAR_083425""	decrease	D	MYLK				
Q15746/A1754T	Q15746	MYLK/A1754T	MYLK	Reviewed;	VARIANT	A	1754	T	(in AAT7; 4-fold reduced affinity for;calmodulin; decreased kinase activity compared to wild-type;protein)"";/evidence=""ECO:0000269|PubMed:21055718"";/id=""VAR_065576""	decrease	D	MYLK				
Q15746/K608A	Q15746	MYLK/K608A	MYLK	Reviewed;	MUTAGEN	K	608	A	Loss of acetylation and no kinase activity;repression by NAA10/ARD1."";/evidence=""ECO:0000269|PubMed:19826488""	loss	D	MYLK				
Q6ZWH5/K548R	Q6ZWH5	NEK10/K548R	NEK10	Reviewed;	MUTAGEN	K	548	R	Catalytically inactive. Impaired mucociliary;transport."";/evidence=""ECO:0000269|PubMed:20956560,;ECO:0000269|PubMed:31959991""	decrease	D	NEK10				
P51955/K37R	P51955	NEK2/K37R	NEK2	Reviewed;	MUTAGEN	K	37	R	Loss of kinase activity and of ability to;activate NEK11. Loss of phosphorylation of CCDC102B."";/evidence=""ECO:0000269|PubMed:15161910,;ECO:0000269|PubMed:17197699, ECO:0000269|PubMed:30404835""	loss	D	NEK2				
P51955/D141A	P51955	NEK2/D141A	NEK2	Reviewed;	MUTAGEN	D	141	A	Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:17197699""	loss	D	NEK2				
P51955/T175A	P51955	NEK2/T175A	NEK2	Reviewed;	MUTAGEN	T	175	A	Kinase activity decreased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	decrease	D	NEK2				
P51955/T179A	P51955	NEK2/T179A	NEK2	Reviewed;	MUTAGEN	T	179	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	D	NEK2				
P51955/T179E	P51955	NEK2/T179E	NEK2	Reviewed;	MUTAGEN	T	179	E	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	D	NEK2				
P51955/S241A	P51955	NEK2/S241A	NEK2	Reviewed;	MUTAGEN	S	241	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	D	NEK2				
P51955/S241D	P51955	NEK2/S241D	NEK2	Reviewed;	MUTAGEN	S	241	D	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	D	NEK2				
Q8TDX7/N33D	Q8TDX7	NEK7/N33D	NEK7	Reviewed;	MUTAGEN	N	33	D	Significant decrease in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	decrease	D	NEK7		Many deactivating are missing, check		
Q8TD19/K81M	Q8TD19	NEK9/K81M	NEK9	Reviewed;	MUTAGEN	K	81	M	Loss of activity and autophosphorylation."";/evidence=""ECO:0000269|PubMed:12101123""	loss	D	NEK9				
Q8TD19/T210A	Q8TD19	NEK9/T210A	NEK9	Reviewed;	MUTAGEN	T	210	A	Significant reduction of autophosphorylation."";/evidence=""ECO:0000269|PubMed:11864968""	decrease	D	NEK9				
Q8IY84/T229A	Q8IY84	NIM1K/T229A	NIM1K	Reviewed;	MUTAGEN	T	229	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15733851""	loss	D	NIM1				
P04629/G577R	P04629	NTRK1/G577R	NTRK1	Reviewed;	VARIANT	G	577	R	(in CIPA; loss of function; processed as;wild-type but shows significantly diminished;autophosphorylation in both neuronal and non-neuronal;cells; dbSNP:rs121964866)"";/evidence=""ECO:0000269|PubMed:10567924,;ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935,;ECO:0000269|PubMed:8696348"";/id=""VAR_004103""	loss	D	NTRK1				
P04629/D596N	P04629	NTRK1/D596N	NTRK1	Reviewed;	VARIANT	D	596	N	(in CIPA; abolishes autophosphorylation)"";/evidence=""ECO:0000269|PubMed:28177573"";/id=""VAR_079404""	loss	D	NTRK1				
P04629/R780P	P04629	NTRK1/R780P	NTRK1	Reviewed;	VARIANT	R	780	P	(in CIPA; loss of function;;dbSNP:rs35669708)"";/evidence=""ECO:0000269|PubMed:10090906"";/id=""VAR_009635""	loss	D	NTRK1				
P04629/K544N	P04629	NTRK1/K544N	NTRK1	Reviewed;	MUTAGEN	K	544	N	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:1281417,;ECO:0000269|PubMed:8155326""	loss	D	NTRK1				
Q16620/Y706C	Q16620	NTRK2/Y706C	NTRK2	Reviewed;	VARIANT	Y	706	C	(in OBHD; expressed normally on the cell;surface; results in markedly impaired ligand-induced;phosphorylation as well as impaired downstream MAPK1;phosphorylation; dbSNP:rs121434633)"";/evidence=""ECO:0000269|PubMed:15494731"";/id=""VAR_065890""	decrease	D	NTRK2				
Q16288/K572N	Q16288	NTRK3/K572N	NTRK3	Reviewed;	MUTAGEN	K	572	N	Loss of autophosphorylation and loss of NTRK3;signaling."";/evidence=""ECO:0000269|PubMed:25196463""	loss	D	NTRK3				
O60285/K84A	O60285	NUAK1/K84A	NUAK1	Reviewed;	MUTAGEN	K	84	A	Abolishes kinase activity and ability to;induce senescence."";/evidence=""ECO:0000269|PubMed:19927127,;ECO:0000269|PubMed:21317932""	loss	D	NUAK1				
O60285/T211A	O60285	NUAK1/T211A	NUAK1	Reviewed;	MUTAGEN	T	211	A	Prevents phosphorylation and activation by;STK11/LKB1 complex. Abolishes ability to induce;senescence."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:21317932""	loss	D	NUAK1				
Q9H093/K81R	Q9H093	NUAK2/K81R	NUAK2	Reviewed;	MUTAGEN	K	81	R	Loss of autophosphorylation, kinase activity;and of anti-apoptotic activity."";/evidence=""ECO:0000269|PubMed:15345718""	loss	D	NUAK2				
O95747/K46A	O95747	OXSR1/K46A	OXSR1	Reviewed;	MUTAGEN	K	46	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:14707132,;ECO:0000269|PubMed:16389068""	loss	D	OXSR1				
O95747/K46M	O95747	OXSR1/K46M	OXSR1	Reviewed;	MUTAGEN	K	46	M	Loss of RELT, RELL1 and RELL2 phosphorylation.;Retention of some autophosphorylation activity may be due;to complex formation with other endogenous kinases in the;assay."";/evidence=""ECO:0000269|PubMed:14707132,;ECO:0000269|PubMed:16389068""	loss	D	OXSR1				
Q13153/L107F	Q13153	PAK1/L107F	PAK1	Reviewed;	MUTAGEN	L	107	F	Abolishes autoinhibition, leading to;constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	loss	D	PAK1	activating	Should be activating		
Q13153/D393A	Q13153	PAK1/D393A	PAK1	Reviewed;	MUTAGEN	D	393	A	Abolishes autophosphorylation at Thr-423."";/evidence=""ECO:0000269|PubMed:22153498""	loss	D	PAK1				
Q13153/T423A	Q13153	PAK1/T423A	PAK1	Reviewed;	MUTAGEN	T	423	A	Decreases CDC42-stimulated activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:10551809""	decrease	D	PAK1				
Q13177/K278R	Q13177	PAK2/K278R	PAK2	Reviewed;	MUTAGEN	K	278	R	Abolishes kinase activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:9786869""	loss	D	PAK2				
Q13177/T402A	Q13177	PAK2/T402A	PAK2	Reviewed;	MUTAGEN	T	402	A	Abolishes kinase activity and greatly inhibits;autophosphorylation of PAK-2p27 and PAK-2p34."";/evidence=""ECO:0000269|PubMed:9786869""	loss	D	PAK2				
Q96RG2/K1028R	Q96RG2	PASK/K1028R	PASK	Reviewed;	MUTAGEN	K	1028	R	Loss of autophosphorylating activity."";/evidence=""ECO:0000269|PubMed:11459942,;ECO:0000269|PubMed:20943661""	loss	D	PASK				
Q96RG2/R1058A	Q96RG2	PASK/R1058A	PASK	Reviewed;	MUTAGEN	R	1058	A	Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	decrease	D	PASK				
Q96RG2/A1151K	Q96RG2	PASK/A1151K	PASK	Reviewed;	MUTAGEN	A	1151	K	Induces lower protein kinase activity and;ability to autophosphorylate."";/evidence=""ECO:0000269|PubMed:20943661""	decrease	D	PASK				
Q96RG2/Y1152F	Q96RG2	PASK/Y1152F	PASK	Reviewed;	MUTAGEN	Y	1152	F	Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	decrease	D	PASK				
Q96RG2/T1161A	Q96RG2	PASK/T1161A	PASK	Reviewed;	MUTAGEN	T	1161	A	Loss of catalytic activity (PubMed:11459942).;According to another report, does not affect the protein;kinase activity (PubMed:20943661). Does not affect protein;translation."";/evidence=""ECO:0000269|PubMed:11459942,;ECO:0000269|PubMed:17595531, ECO:0000269|PubMed:20943661""	loss	D	PASK				
Q96RG2/T1165A	Q96RG2	PASK/T1165A	PASK	Reviewed;	MUTAGEN	T	1165	A	Loss of catalytic activity. Does not affect;protein translation."";/evidence=""ECO:0000269|PubMed:11459942,;ECO:0000269|PubMed:17595531""	loss	D	PASK				
Q16654/Y157F	Q16654	PDK4/Y157F	PDK4	Reviewed;	MUTAGEN	Y	157	F	Loss of activity."";/evidence=""ECO:0000269|PubMed:18658136""	loss	D	PDK4				
Q16654/R161A	Q16654	PDK4/R161A	PDK4	Reviewed;	MUTAGEN	R	161	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:18658136""	loss	D	PDK4				
O15530/Y9F	O15530	PDPK1/Y9F	PDPK1	Reviewed;	MUTAGEN	Y	9	F	Slight reduction in pervanadate-stimulated;tyrosine phosphorylation."";/evidence=""ECO:0000269|PubMed:11481331""	decrease	D	PDPK1		Missing 'decrease': Y373F, Y376F. Missing 'loss': S241A		
O15530/T354A	O15530	PDPK1/T354A	PDPK1	Reviewed;	MUTAGEN	T	354	A	Abolishes phosphorylation by MELK."";/evidence=""ECO:0000269|PubMed:22544756""	loss	D	PDPK1	increase	Phosphorylation at Thr-354 by MELK partially inhibits kinase activity, the inhibition is cooperatively enhanced by phosphorylation at Ser-394 and Ser-398 by MAP3K5		
P11309/P81S	P11309	PIM1/P81S	PIM1	Reviewed;	MUTAGEN	P	81	S	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	decrease	D	PIM1				
P11309/N82K	P11309	PIM1/N82K	PIM1	Reviewed;	MUTAGEN	N	82	K	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	decrease	D	PIM1				
P11309/L193F	P11309	PIM1/L193F	PIM1	Reviewed;	MUTAGEN	L	193	F	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	decrease	D	PIM1				
Q9BXM7/T313M	Q9BXM7	PINK1/T313M	PINK1	Reviewed;	VARIANT	T	313	M	(in PARK6; decreases PRKN and SNCAIP;ubiquitination and degradation; slightly decreases Drp1;phosphorylation; dbSNP:rs74315359)"";/evidence=""ECO:0000269|PubMed:17030667,;ECO:0000269|PubMed:18785233, ECO:0000269|PubMed:19229105,;ECO:0000269|PubMed:32484300"";/id=""VAR_046589""	decrease	D	PINK1				
Q9BXM7/G386A	Q9BXM7	PINK1/G386A	PINK1	Reviewed;	VARIANT	G	386	A	(in PARK6; abolishes kinase activity)"";/evidence=""ECO:0000269|PubMed:16401616,;ECO:0000269|PubMed:24784582"";/id=""VAR_062776""	loss	D	PINK1				
Q16512/K644E	Q16512	PKN1/K644E	PKN1	Reviewed;	MUTAGEN	K	644	E	Abolishes Serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:18066052,;ECO:0000269|PubMed:8135837""	loss	D	PKN1				
Q16512/K644R	Q16512	PKN1/K644R	PKN1	Reviewed;	MUTAGEN	K	644	R	Substantial reduction of autophosphorylation."";/evidence=""ECO:0000269|PubMed:18066052,;ECO:0000269|PubMed:8135837""	decrease	D	PKN1				
Q16513/T816A	Q16513	PKN2/T816A	PKN2	Reviewed;	MUTAGEN	T	816	A	Reduces catalytic activity."";/evidence=""ECO:0000269|PubMed:18835241""	decrease	D	PKN2				
Q16513/T958A	Q16513	PKN2/T958A	PKN2	Reviewed;	MUTAGEN	T	958	A	Abolishes catalytic activity."";/evidence=""ECO:0000269|PubMed:18835241""	loss	D	PKN2				
Q16513/F977W	Q16513	PKN2/F977W	PKN2	Reviewed;	MUTAGEN	F	977	W	Y: Reduces catalytic activity by 50%."";/evidence=""ECO:0000269|PubMed:10226025,;ECO:0000269|PubMed:18835241""	decrease	D	PKN2		Also F->Y		
Q16513/Y979A	Q16513	PKN2/Y979A	PKN2	Reviewed;	MUTAGEN	Y	979	A	Reduces catalytic activity by 50%."";/evidence=""ECO:0000269|PubMed:10226025,;ECO:0000269|PubMed:18835241""	decrease	D	PKN2				
Q16513/Y979F	Q16513	PKN2/Y979F	PKN2	Reviewed;	MUTAGEN	Y	979	F	L,W: Reduces catalytic activity by 25%."";/evidence=""ECO:0000269|PubMed:10226025,;ECO:0000269|PubMed:18835241""	decrease	D	PKN2		Also Y->L and Y->W		
Q6P5Z2/K588E	Q6P5Z2	PKN3/K588E	PKN3	Reviewed;	MUTAGEN	K	588	E	Abolishes autophosphorylation and catalytic;activity."";/evidence=""ECO:0000269|PubMed:10441506,;ECO:0000269|PubMed:15282551""	loss	D	PKN3				
Q6P5Z2/K588R	Q6P5Z2	PKN3/K588R	PKN3	Reviewed;	MUTAGEN	K	588	R	Abolishes catalytic activity."";/evidence=""ECO:0000269|PubMed:10441506,;ECO:0000269|PubMed:15282551""	loss	D	PKN3				
Q6P5Z2/T718A	Q6P5Z2	PKN3/T718A	PKN3	Reviewed;	MUTAGEN	T	718	A	Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:15282551""	loss	D	PKN3				
P53350/D176N	P53350	PLK1/D176N	PLK1	Reviewed;	MUTAGEN	D	176	N	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:18615013""	loss	D	PLK1	loss	Also 'loss': K82M, K82R		
P53350/T210A	P53350	PLK1/T210A	PLK1	Reviewed;	MUTAGEN	T	210	A	Abolishes activity. Abolishes checkpoint;recovery."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,;ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	loss	D	PLK1		Missing 'decrease': T210V		
Q9NYY3/N210A	Q9NYY3	PLK2/N210A	PLK2	Reviewed;	MUTAGEN	N	210	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19001868""	loss	D	PLK2				
Q9H4B4/K91R	Q9H4B4	PLK3/K91R	PLK3	Reviewed;	MUTAGEN	K	91	R	Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:11447225,;ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:17804415,;ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:19490146,;ECO:0000269|PubMed:20889502, ECO:0000269|PubMed:20940307""	loss	D	PLK3				
Q9H4B4/D203A	Q9H4B4	PLK3/D203A	PLK3	Reviewed;	MUTAGEN	D	203	A	Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:11156373""	loss	D	PLK3				
O00444/K41M	O00444	PLK4/K41M	PLK4	Reviewed;	MUTAGEN	K	41	M	Abolishes ability to phosphorylate CDC25C and;CHEK2."";/evidence=""ECO:0000269|PubMed:18239451,;ECO:0000269|PubMed:19164942""	loss	D	PLK4	loss	Also 'loss': D154A		
Q99640/N238A	Q99640	PKMYT1/N238A	PKMYT1	Reviewed;	MUTAGEN	N	238	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10373560""	loss	D	PMYT1				
Q99640/D251A	Q99640	PKMYT1/D251A	PKMYT1	Reviewed;	MUTAGEN	D	251	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10504341""	loss	D	PMYT1				
P78527/A3574V	P78527	PRKDC/A3574V	PRKDC	Reviewed;	VARIANT	A	3574	V	(in IMD26; shows impaired function in;response to irradiation and a less severe defect in V(D)J;end-joining suggesting that the missense mutation retained;some functional capacity; consistent with a loss of;function mutation; dbSNP:rs587777686)"";/evidence=""ECO:0000269|PubMed:23722905"";/id=""VAR_072570""	loss	D	PRKDC				
P51817/K78R	P51817	PRKX/K78R	PRKX	Reviewed;	MUTAGEN	K	78	R	Loss of function."";/evidence=""ECO:0000269|PubMed:12082174""	loss	D	PRKX				
Q13882/W44A	Q13882	PTK6/W44A	PTK6	Reviewed;	MUTAGEN	W	44	A	Strong decrease in STAP2 phosphorylation.;Markedly decreased interaction between SH3 domain the;linker region."";/evidence=""ECO:0000269|PubMed:10980601,;ECO:0000269|PubMed:17822667""	decrease	D	PTK6				
Q13882/Y66A	Q13882	PTK6/Y66A	PTK6	Reviewed;	MUTAGEN	Y	66	A	Decrease in STAP2 phosphorylation."";/evidence=""ECO:0000269|PubMed:10980601""	decrease	D	PTK6				
Q13882/R105L	Q13882	PTK6/R105L	PTK6	Reviewed;	MUTAGEN	R	105	L	Decrease in STAP2 phosphorylation."";/evidence=""ECO:0000269|PubMed:10980601""	decrease	D	PTK6				
Q13882/K219M	Q13882	PTK6/K219M	PTK6	Reviewed;	MUTAGEN	K	219	M	Abolishes kinase activity and cell;transformation, and phosphorylation of STAP2."";/evidence=""ECO:0000269|PubMed:10980601,;ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083""	loss	D	PTK6				
Q13882/K219R	Q13882	PTK6/K219R	PTK6	Reviewed;	MUTAGEN	K	219	R	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:27480927""	loss	D	PTK6				
P04049/D486N	P04049	RAF1/D486N	RAF1	Reviewed;	VARIANT	D	486	N	(in NS5; has reduced or absent kinase;activity; dbSNP:rs80338798)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037817""	decrease	D	RAF1	loss	loss (DFG); also loss: K375W		
P04049/T491I	P04049	RAF1/T491I	RAF1	Reviewed;	VARIANT	T	491	I	(in NS5; has reduced or absent kinase;activity; dbSNP:rs80338799)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037818""	decrease	D	RAF1	loss	loss (p-mimic in Aloop)		
P04049/L603P	P04049	RAF1/L603P	RAF1	Reviewed;	VARIANT	L	603	P	(in CMD1NN; shows impaired kinase activity;and reduced MAPK3 activation with this mutation;;dbSNP:rs587777586)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071847""	decrease	D	RAF1				
P07949/Y1062F	P07949	RET/Y1062F	RET	Reviewed;	MUTAGEN	Y	1062	F	Abolishes GFRAL-mediated MAPK1/MAPK2;phosphorylation."";/evidence=""ECO:0000269|PubMed:28953886""	loss	D	RET		Also loss: K758R		
Q13546/S25D	Q13546	RIPK1/S25D	RIPK1	Reviewed;	MUTAGEN	S	25	D	Phophomimetic mutant. Significant loss of;kinase activity."";/evidence=""ECO:0000269|PubMed:30988283""	loss	D	RIPK1		interesting case where StoD deactivates the kinase hence Activark is wrong coz it assumes Sp->D is immer activating	http://activark.russelllab.org/result?uniqID=S9YDA&kinase=Q13546&mutation=S25D	http://127.0.0.1:5000/output/DHVO6
Q13546/K45A	Q13546	RIPK1/K45A	RIPK1	Reviewed;	MUTAGEN	K	45	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:30988283,;ECO:0000269|PubMed:8612133""	loss	D	RIPK1				
Q13546/S161A	Q13546	RIPK1/S161A	RIPK1	Reviewed;	MUTAGEN	S	161	A	Decreases RIPK1 kinase activity."";/evidence=""ECO:0000269|PubMed:18408713""	decrease	D	RIPK1				
O43353/K47A	O43353	RIPK2/K47A	RIPK2	Reviewed;	MUTAGEN	K	47	A	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9575181,;ECO:0000269|PubMed:9642260""	loss	D	RIPK2				
O43353/D146N	O43353	RIPK2/D146N	RIPK2	Reviewed;	MUTAGEN	D	146	N	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9705938""	loss	D	RIPK2				
O43353/Y381A	O43353	RIPK2/Y381A	RIPK2	Reviewed;	MUTAGEN	Y	381	A	Prevents phosphorylation. Reduces serine and;threonine phosphorylation of ARHGEF2."";/evidence=""ECO:0000269|PubMed:21887730""	decrease	D	RIPK2				
Q9Y572/K50D	Q9Y572	RIPK3/K50D	RIPK3	Reviewed;	MUTAGEN	K	50	D	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10339433,;ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:22265414""	loss	D	RIPK3				
Q9Y572/D142N	Q9Y572	RIPK3/D142N	RIPK3	Reviewed;	MUTAGEN	D	142	N	Abolishes kinase activity and ability to;mediate necroptosis."";/evidence=""ECO:0000269|PubMed:22265413""	loss	D	RIPK3				
P57078/I121N	P57078	RIPK4/I121N	RIPK4	Reviewed;	VARIANT	I	121	N	(in BPS; loss of function;;dbSNP:rs387906923)"";/evidence=""ECO:0000269|PubMed:22197489"";/id=""VAR_067332""	loss	D	RIPK4		interesting case which is not as much conserved in the kinase aln but conserved in orthologs	http://mechismox.russelllab.org/result?protein=P57078&mutation=I121N	http://activark.russelllab.org/result?uniqID=S9YDA&kinase=P57078&mutation=I121N
P57078/T184I	P57078	RIPK4/T184I	RIPK4	Reviewed;	VARIANT	T	184	I	(in BPS; loss of function)"";/evidence=""ECO:0000269|PubMed:22197489"";/id=""VAR_067333""	loss	D	RIPK4				
Q05823/R462Q	Q05823	RNASEL/R462Q	RNASEL	Reviewed;	VARIANT	R	462	Q	(risk factor for prostate cancer; reduced;enzymatic activity; dbSNP:rs486907)"";/evidence=""ECO:0000269|PubMed:11799394,;ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269,;ECO:0000269|PubMed:17344846"";/id=""VAR_012056""	decrease	D	RN5A				
Q05823/K392R	Q05823	RNASEL/K392R	RNASEL	Reviewed;	MUTAGEN	K	392	R	Complete loss of enzymatic activity and enzyme;dimerization. No change in binding to 2-5A and RNA."";/evidence=""ECO:0000269|PubMed:9862963""	loss	D	RN5A				
Q05823/D661A	Q05823	RNASEL/D661A	RNASEL	Reviewed;	MUTAGEN	D	661	A	Complete loss of enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	loss	D	RN5A				
Q05823/R667A	Q05823	RNASEL/R667A	RNASEL	Reviewed;	MUTAGEN	R	667	A	Complete loss of enzymatic activity. No change;in 2-5A binding and enzyme dimerization."";/evidence=""ECO:0000269|PubMed:11333017""	loss	D	RN5A				
Q05823/H672A	Q05823	RNASEL/H672A	RNASEL	Reviewed;	MUTAGEN	H	672	A	Complete loss of enzymatic activity. No change;in 2-5A binding activity and enzyme dimerization."";/evidence=""ECO:0000269|PubMed:11333017""	loss	D	RN5A				
P08922/K1980M	P08922	ROS1/K1980M	ROS1	Reviewed;	MUTAGEN	K	1980	M	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12661006""	loss	D	ROS1				
Q52WX2/K61R	Q52WX2	SBK1/K61R	SBK1	Reviewed;	MUTAGEN	K	61	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:16403448""	loss	D	SBK1				
P0C263/K73M	P0C263	SBK2/K73M	SBK2	Reviewed;	MUTAGEN	K	73	M	Loss of activity."";/evidence=""ECO:0000269|PubMed:11322885""	loss	D	SBK2				
Q9H5K3/L137R	Q9H5K3	POMK/L137R	POMK	Reviewed;	VARIANT	L	137	R	(in MDDGA12; loss of kinase activity;;dbSNP:rs397509385)"";/evidence=""ECO:0000269|PubMed:23519211,;ECO:0000269|PubMed:23929950"";/id=""VAR_069625""	loss	D	SG196				
O00141/K127M	O00141	SGK1/K127M	SGK1	Reviewed;	MUTAGEN	K	127	M	Abolishes enzymatic activity."";/evidence=""ECO:0000269|PubMed:11696533,;ECO:0000269|PubMed:12911626, ECO:0000269|PubMed:15040001""	loss	D	SGK1		Several 'decrease' variants missing		
Q96BR1/K191M	Q96BR1	SGK3/K191M	SGK3	Reviewed;	MUTAGEN	K	191	M	Abolishes activity."";/evidence=""ECO:0000269|PubMed:16790420""	loss	D	SGK3				
P57059/K56M	P57059	SIK1/K56M	SIK1	Reviewed;	MUTAGEN	K	56	M	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18348280,;ECO:0000269|PubMed:19622832""	loss	D	SIK1				
P57059/S135A	P57059	SIK1/S135A	SIK1	Reviewed;	MUTAGEN	S	135	A	Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	D	SIK1				
P57059/T182A	P57059	SIK1/T182A	SIK1	Reviewed;	MUTAGEN	T	182	A	Prevents phosphorylation and activation by;STK11/LKB1 complex. Reduced inhibition of CRTC3-mediated;transcriptional activity."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:29211348""	decrease	D	SIK1				
P57059/S186A	P57059	SIK1/S186A	SIK1	Reviewed;	MUTAGEN	S	186	A	D,C,G: Impaired autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	D	SIK1	loss	loss; also S->D, S->C and S->G		
P57059/S209A	P57059	SIK1/S209A	SIK1	Reviewed;	MUTAGEN	S	209	A	Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	D	SIK1				
P57059/S248A	P57059	SIK1/S248A	SIK1	Reviewed;	MUTAGEN	S	248	A	Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	D	SIK1				
P57059/S575E	P57059	SIK1/S575E	SIK1	Reviewed;	MUTAGEN	S	575	E	Strongly reduced but still present interaction;with 14-3-3 proteins in response to cAMP signaling and,;thus, still able to inhibit TORC activity."";/evidence=""ECO:0000269|PubMed:29211348""	decrease	D	SIK1				
Q9Y2K2/T469A	Q9Y2K2	SIK3/T469A	SIK3	Reviewed;	MUTAGEN	T	469	A	Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	D	SIK3				
Q9Y2K2/T469E	Q9Y2K2	SIK3/T469E	SIK3	Reviewed;	MUTAGEN	T	469	E	Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	D	SIK3				
Q9Y2K2/S551A	Q9Y2K2	SIK3/S551A	SIK3	Reviewed;	MUTAGEN	S	551	A	Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	D	SIK3				
Q9Y2K2/S551E	Q9Y2K2	SIK3/S551E	SIK3	Reviewed;	MUTAGEN	S	551	E	Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	D	SIK3				
Q9H2G2/K63R	Q9H2G2	SLK/K63R	SLK	Reviewed;	MUTAGEN	K	63	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:10699464""	loss	D	SLK				
Q96Q15/D2335A	Q96Q15	SMG1/D2335A	SMG1	Reviewed;	MUTAGEN	D	2335	A	Loss of function."";/evidence=""ECO:0000269|PubMed:11331269,;ECO:0000269|PubMed:11544179, ECO:0000269|PubMed:15175154""	loss	D	SMG1				
P12931/K298M	P12931	SRC/K298M	SRC	Reviewed;	MUTAGEN	K	298	M	Kinase inactive. Abolishes ubiquitination;promoted by CBLC."";/evidence=""ECO:0000269|PubMed:14661060""	loss	D	SRC				
P12931/Y419F	P12931	SRC/Y419F	SRC	Reviewed;	MUTAGEN	Y	419	F	Loss of kinase activity. Loss of interaction;with PDLIM4."";/evidence=""ECO:0000269|PubMed:19307596""	loss	D	SRC				
Q9H3Y6/W223A	Q9H3Y6	SRMS/W223A	SRMS	Reviewed;	MUTAGEN	W	223	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:23822091""	loss	D	SRMS				
Q96SB4/S51A	Q96SB4	SRPK1/S51A	SRPK1	Reviewed;	MUTAGEN	S	51	A	Protein phosphorylation impaired at this;position."";/evidence=""ECO:0000269|PubMed:12565829""	decrease	D	SRPK1				
Q96SB4/S555A	Q96SB4	SRPK1/S555A	SRPK1	Reviewed;	MUTAGEN	S	555	A	Protein phosphorylation impaired at this;position."";/evidence=""ECO:0000269|PubMed:12565829""	decrease	D	SRPK1				
Q9UEE5/K90A	Q9UEE5	STK17A/K90A	STK17A	Reviewed;	MUTAGEN	K	90	A	Loss of activity and of apoptotic function."";/evidence=""ECO:0000269|PubMed:9786912""	loss	D	ST17A				
O94768/K62A	O94768	STK17B/K62A	STK17B	Reviewed;	MUTAGEN	K	62	A	Loss of activity and of apoptotic function."";/evidence=""ECO:0000269|PubMed:9786912""	loss	D	ST17B				
Q9Y2H1/T75A	Q9Y2H1	STK38L/T75A	STK38L	Reviewed;	MUTAGEN	T	75	A	Decreased kinase activity. Reduced binding of;S100B."";/evidence=""ECO:0000269|PubMed:15037617""	decrease	D	ST38L				
Q9Y2H1/K119A	Q9Y2H1	STK38L/K119A	STK38L	Reviewed;	MUTAGEN	K	119	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15037617""	loss	D	ST38L				
Q9Y2H1/S282A	Q9Y2H1	STK38L/S282A	STK38L	Reviewed;	MUTAGEN	S	282	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15037617""	loss	D	ST38L				
Q9Y2H1/T442A	Q9Y2H1	STK38L/T442A	STK38L	Reviewed;	MUTAGEN	T	442	A	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15037617""	decrease	D	ST38L				
O94804/K65I	O94804	STK10/K65I	STK10	Reviewed;	MUTAGEN	K	65	I	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12639966""	loss	D	STK10				
Q15831/L67P	Q15831	STK11/L67P	STK11	Reviewed;	VARIANT	L	67	P	(in PJS; abolishes kinase activity, leading;to loss of autophosphorylation; dbSNP:rs137853077)"";/evidence=""ECO:0000269|PubMed:9428765,;ECO:0000269|PubMed:9837816"";/id=""VAR_006202""	loss	D	STK11				
Q15831/D176N	Q15831	STK11/D176N	STK11	Reviewed;	VARIANT	D	176	N	(in PJS; loss of kinase activity, leading to;greatly reduced autophosphorylation; fails to phosphorylate;PTEN in vitro; no significant effect on nucleocytoplasmic;localization; dbSNP:rs730881979)"";/evidence=""ECO:0000269|PubMed:15987703,;ECO:0000269|PubMed:9837816"";/id=""VAR_071058""	decrease	D	STK11	loss	loss		
Q15831/D176Y	Q15831	STK11/D176Y	STK11	Reviewed;	VARIANT	D	176	Y	(in sporadic cancer; somatic mutation; Loss;of kinase activity)"";/evidence=""ECO:0000269|PubMed:12805220,;ECO:0000269|PubMed:19892943"";/id=""VAR_065637""	loss	D	STK11				
Q15831/E199K	Q15831	STK11/E199K	STK11	Reviewed;	VARIANT	E	199	K	(in colorectal cancer; somatic mutation;;impaired kinase activity; dbSNP:rs121913317)"";/evidence=""ECO:0000269|PubMed:9731485"";/id=""VAR_065641""	decrease	D	STK11	loss	loss		
Q15831/W308C	Q15831	STK11/W308C	STK11	Reviewed;	VARIANT	W	308	C	(in PJS; abolishes kinase activity, leading;to loss of autophosphorylation; dbSNP:rs1057520042)"";/evidence=""ECO:0000269|PubMed:9837816"";/id=""VAR_071059""	loss	D	STK11				
Q15831/K78I	Q15831	STK11/K78I	STK11	Reviewed;	MUTAGEN	K	78	I	Loss of kinase activity, leading to greatly;reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:11430832,;ECO:0000269|PubMed:9837816""	decrease	D	STK11	loss	loss		
Q15831/K78M	Q15831	STK11/K78M	STK11	Reviewed;	MUTAGEN	K	78	M	Loss of kinase activity, leading to reduced;autophosphorylation and acting as a dominant-negative;mutant."";/evidence=""ECO:0000269|PubMed:11430832,;ECO:0000269|PubMed:9837816""	decrease	D	STK11	loss	loss		
Q15831/T189A	Q15831	STK11/T189A	STK11	Reviewed;	MUTAGEN	T	189	A	Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:11430832""	decrease	D	STK11				
Q15831/D194A	Q15831	STK11/D194A	STK11	Reviewed;	MUTAGEN	D	194	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14517248,;ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943""	loss	D	STK11				
O75716/T192A	O75716	STK16/T192A	STK16	Reviewed;	MUTAGEN	T	192	A	Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:8662877""	loss	D	STK16				
P49842/K300P	P49842	STK19/K300P	STK19	Reviewed;	MUTAGEN	K	300	P	Partial loss of activity."";/evidence=""ECO:0000269|PubMed:9812991""	decrease	D	STK19				
P49842/K315P	P49842	STK19/K315P	STK19	Reviewed;	MUTAGEN	K	315	P	Partial loss of activity."";/evidence=""ECO:0000269|PubMed:9812991""	decrease	D	STK19				
P49842/K317P	P49842	STK19/K317P	STK19	Reviewed;	MUTAGEN	K	317	P	Complete loss of activity."";/evidence=""ECO:0000269|PubMed:9812991""	loss	D	STK19				
Q9Y6E0/T18A	Q9Y6E0	STK24/T18A	STK24	Reviewed;	MUTAGEN	T	18	A	Loss of phosphorylation by PKA."";/evidence=""ECO:0000269|PubMed:10644707""	loss	D	STK24				
Q9Y6E0/K65A	Q9Y6E0	STK24/K65A	STK24	Reviewed;	MUTAGEN	K	65	A	Loss of activity and autophosphorylation."";/evidence=""ECO:0000269|PubMed:12107159""	loss	D	STK24				
Q9Y6E0/T190A	Q9Y6E0	STK24/T190A	STK24	Reviewed;	MUTAGEN	T	190	A	Loss of activity and autophosphorylation."";/evidence=""ECO:0000269|PubMed:17046825""	loss	D	STK24				
O00506/K49R	O00506	STK25/K49R	STK25	Reviewed;	MUTAGEN	K	49	R	Loss of kinase activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:15037601""	loss	D	STK25				
O00506/D158A	O00506	STK25/D158A	STK25	Reviewed;	MUTAGEN	D	158	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15037601""	loss	D	STK25				
Q9P289/K53E	Q9P289	STK26/K53E	STK26	Reviewed;	MUTAGEN	K	53	E	Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:29232556""	loss	D	STK26				
Q15208/T74A	Q15208	STK38/T74A	STK38	Reviewed;	MUTAGEN	T	74	A	Decreases autophosphorylation and kinase;activity. Reduced binding of S100B."";/evidence=""ECO:0000269|PubMed:12493777""	decrease	D	STK38				
Q15208/K118A	Q15208	STK38/K118A	STK38	Reviewed;	MUTAGEN	K	118	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777,;ECO:0000269|PubMed:7761441""	loss	D	STK38				
Q15208/S281A	Q15208	STK38/S281A	STK38	Reviewed;	MUTAGEN	S	281	A	Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777""	loss	D	STK38				
Q15208/T444A	Q15208	STK38/T444A	STK38	Reviewed;	MUTAGEN	T	444	A	Decreases autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777""	decrease	D	STK38				
Q13188/K56R	Q13188	STK3/K56R	STK3	Reviewed;	MUTAGEN	K	56	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:16930133""	loss	D	STK3				
Q13043/K59R	Q13043	STK4/K59R	STK4	Reviewed;	MUTAGEN	K	59	R	Loss of activity."";/evidence=""ECO:0000269|PubMed:15109305,;ECO:0000269|PubMed:16930133""	loss	D	STK4				
Q13043/T183A	Q13043	STK4/T183A	STK4	Reviewed;	MUTAGEN	T	183	A	Loss of activity."";/evidence=""ECO:0000269|PubMed:15109305""	loss	D	STK4				
Q13043/L444P	Q13043	STK4/L444P	STK4	Reviewed;	MUTAGEN	L	444	P	Loss of homodimerization, activation, and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:15109305""	loss	D	STK4				
Q7RTN6/T329A	Q7RTN6	STRADA/T329A	STRADA	Reviewed;	MUTAGEN	T	329	A	Loss of STK11/LKB1-mediated phosphorylation."";/evidence=""ECO:0000269|PubMed:12805220""	loss	D	STRAA				
Q7RTN6/T419A	Q7RTN6	STRADA/T419A	STRADA	Reviewed;	MUTAGEN	T	419	A	Loss of STK11/LKB1-mediated phosphorylation."";/evidence=""ECO:0000269|PubMed:12805220""	loss	D	STRAA				
P21675/S137A	P21675	TAF1/S137A	TAF1	Reviewed;	MUTAGEN	S	137	A	No decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:9660973""	decrease	D	TAF1	exclude	This should be neutral and other mutations are missing		
Q7L7X3/K57A	Q7L7X3	TAOK1/K57A	TAOK1	Reviewed;	MUTAGEN	K	57	A	Abolishes kinase activity, ability to activate;the MAPK8/JNK cascade and cleavage by caspase-3 (CASP3)."";/evidence=""ECO:0000269|PubMed:16407310""	loss	D	TAOK1				
Q7L7X3/D169A	Q7L7X3	TAOK1/D169A	TAOK1	Reviewed;	MUTAGEN	D	169	A	Loss of serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:17396146""	loss	D	TAOK1				
Q9H2K8/D165A	Q9H2K8	TAOK3/D165A	TAOK3	Reviewed;	MUTAGEN	D	165	A	Loss of serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:17396146""	loss	D	TAOK3				
Q9UHD2/R47H	Q9UHD2	TBK1/R47H	TBK1	Reviewed;	VARIANT	R	47	H	(in FTDALS4; loss of kinase activity)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073938""	loss	D	TBK1				
Q9UHD2/G159A	Q9UHD2	TBK1/G159A	TBK1	Reviewed;	VARIANT	G	159	A	(in IIAE8; loss of kinase activity; loss of;autophosphorylation at S-172; loss of IFNB induction;;dbSNP:rs1555202947)"";/evidence=""ECO:0000269|PubMed:22851595,;ECO:0000269|PubMed:32972995"";/id=""VAR_080518""	loss	D	TBK1				
Q9UHD2/R308Q	Q9UHD2	TBK1/R308Q	TBK1	Reviewed;	VARIANT	R	308	Q	(in FTDALS4; reduced kinase activity)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073941""	decrease	D	TBK1				
Q9UHD2/R357Q	Q9UHD2	TBK1/R357Q	TBK1	Reviewed;	VARIANT	R	357	Q	(in FTDALS4; reduced kinase activity;;dbSNP:rs758357594)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073942""	decrease	D	TBK1				
Q9UHD2/M559R	Q9UHD2	TBK1/M559R	TBK1	Reviewed;	VARIANT	M	559	R	(in FTDALS4; loss of kinase activity)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073944""	loss	D	TBK1				
Q9UHD2/E696K	Q9UHD2	TBK1/E696K	TBK1	Reviewed;	VARIANT	E	696	K	(in FTDALS4; loss of kinase activity; impairs;binding to OPTN; dbSNP:rs748112833)"";/evidence=""ECO:0000269|PubMed:25803835,;ECO:0000269|PubMed:25943890"";/id=""VAR_073948""	loss	D	TBK1				
Q9UHD2/D33A	Q9UHD2	TBK1/D33A	TBK1	Reviewed;	MUTAGEN	D	33	A	Decreases phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	D	TBK1				
Q9UHD2/K38A	Q9UHD2	TBK1/K38A	TBK1	Reviewed;	MUTAGEN	K	38	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10581243,;ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971,;ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:31709703""	loss	D	TBK1				
Q9UHD2/D135N	Q9UHD2	TBK1/D135N	TBK1	Reviewed;	MUTAGEN	D	135	N	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:21931631,;ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972,;ECO:0000269|PubMed:30842653""	loss	D	TBK1				
Q9UHD2/S172E	Q9UHD2	TBK1/S172E	TBK1	Reviewed;	MUTAGEN	S	172	E	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:11839743,;ECO:0000269|PubMed:23453972""	decrease	D	TBK1				
Q9UHD2/Y325E	Q9UHD2	TBK1/Y325E	TBK1	Reviewed;	MUTAGEN	Y	325	E	Abolishes phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453972""	loss	D	TBK1				
Q9UHD2/R547D	Q9UHD2	TBK1/R547D	TBK1	Reviewed;	MUTAGEN	R	547	D	Decreases phosphorylation and kinase activity.;Abolishes dimerization."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	D	TBK1				
Q9UHD2/Y577A	Q9UHD2	TBK1/Y577A	TBK1	Reviewed;	MUTAGEN	Y	577	A	Decreases kinase activity. Reduced;phosphorylation of STING1."";/evidence=""ECO:0000269|PubMed:23453971,;ECO:0000269|PubMed:30842653""	decrease	D	TBK1				
Q9UHD2/N578A	Q9UHD2	TBK1/N578A	TBK1	Reviewed;	MUTAGEN	N	578	A	Reduced phosphorylation of STING1."";/evidence=""ECO:0000269|PubMed:30842653""	decrease	D	TBK1				
Q9UHD2/E580A	Q9UHD2	TBK1/E580A	TBK1	Reviewed;	MUTAGEN	E	580	A	Decreases kinase activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	D	TBK1				
Q9UHD2/Q581A	Q9UHD2	TBK1/Q581A	TBK1	Reviewed;	MUTAGEN	Q	581	A	Reduced phosphorylation of STING1."";/evidence=""ECO:0000269|PubMed:30842653""	decrease	D	TBK1				
Q9UHD2/I582A	Q9UHD2	TBK1/I582A	TBK1	Reviewed;	MUTAGEN	I	582	A	Decreases kinase activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	D	TBK1				
Q9UHD2/K589D	Q9UHD2	TBK1/K589D	TBK1	Reviewed;	MUTAGEN	K	589	D	Decreases phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	D	TBK1				
P36897/T200V	P36897	TGFBR1/T200V	TGFBR1	Reviewed;	MUTAGEN	T	200	V	Loss of phosphorylation. Loss of response to;TGF-beta."";/evidence=""ECO:0000269|PubMed:7774578""	loss	D	TGFR1				
P36897/T204V	P36897	TGFBR1/T204V	TGFBR1	Reviewed;	MUTAGEN	T	204	V	Reduced phosphorylation. Reduced response to;TGF-beta."";/evidence=""ECO:0000269|PubMed:7774578""	decrease	D	TGFR1				
P37173/K277R	P37173	TGFBR2/K277R	TGFBR2	Reviewed;	MUTAGEN	K	277	R	Abolishes kinase activity, TGF-beta signaling;and interaction with DAXX."";/evidence=""ECO:0000269|PubMed:11483955""	loss	D	TGFR2				
Q02763/C224S	Q02763	TEK/C224S	TEK	Reviewed;	MUTAGEN	C	224	S	Reduces protein abundance."";/evidence=""ECO:0000269|PubMed:27270174""	decrease	D	TIE2				
Q02763/K855R	Q02763	TEK/K855R	TEK	Reviewed;	MUTAGEN	K	855	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12609966,;ECO:0000269|PubMed:15851516""	loss	D	TIE2				
Q9UKI8/D607A	Q9UKI8	TLK1/D607A	TLK1	Reviewed;	MUTAGEN	D	607	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10523312,;ECO:0000269|PubMed:11470414""	loss	D	TLK1				
Q9UKI8/S743A	Q9UKI8	TLK1/S743A	TLK1	Reviewed;	MUTAGEN	S	743	A	Loss of kinase inhibition in response to DNA;damage."";/evidence=""ECO:0000269|PubMed:12660173""	loss	D	TLK1				
Q9UKI8/S743D	Q9UKI8	TLK1/S743D	TLK1	Reviewed;	MUTAGEN	S	743	D	Loss of kinase inhibition in response to DNA;damage."";/evidence=""ECO:0000269|PubMed:12660173""	loss	D	TLK1				
Q9UKI8/S743E	Q9UKI8	TLK1/S743E	TLK1	Reviewed;	MUTAGEN	S	743	E	Loss of kinase inhibition in response to DNA;damage."";/evidence=""ECO:0000269|PubMed:12660173""	loss	D	TLK1				
Q86UE8/H493R	Q86UE8	TLK2/H493R	TLK2	Reviewed;	VARIANT	H	493	R	(in MRD57; reduced kinase activity;;dbSNP:rs1567974030)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081028""	decrease	D	TLK2				
Q86UE8/H518R	Q86UE8	TLK2/H518R	TLK2	Reviewed;	VARIANT	H	518	R	(in MRD57; severely reduced kinase activity;;dbSNP:rs1567995650)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081029""	decrease	D	TLK2				
Q86UE8/S617L	Q86UE8	TLK2/S617L	TLK2	Reviewed;	VARIANT	S	617	L	(in MRD57; exhibits abnormal perinuclear;localization instead of diffuse nuclear localization;;impairs kinase activity; reduced phosphorylation of ASF1A)"";/evidence=""ECO:0000269|PubMed:21572417,;ECO:0000269|PubMed:33323470"";/id=""VAR_087042""	decrease	D	TLK2				
Q86UE8/D629N	Q86UE8	TLK2/D629N	TLK2	Reviewed;	VARIANT	D	629	N	(in MRD57; reduced phosphorylation of ASF1A;;dbSNP:rs1568006217)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081032""	decrease	D	TLK2				
Q86UE8/H518N	Q86UE8	TLK2/H518N	TLK2	Reviewed;	MUTAGEN	H	518	N	Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	D	TLK2				
Q86UE8/D592V	Q86UE8	TLK2/D592V	TLK2	Reviewed;	MUTAGEN	D	592	V	Loss of kinase activity. No impact on;interaction with ASF1A."";/evidence=""ECO:0000269|PubMed:33323470,;ECO:0000269|PubMed:35136069""	loss	D	TLK2				
Q86UE8/D613A	Q86UE8	TLK2/D613A	TLK2	Reviewed;	MUTAGEN	D	613	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10523312,;ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:29955062""	loss	D	TLK2				
Q86UE8/S617D	Q86UE8	TLK2/S617D	TLK2	Reviewed;	MUTAGEN	S	617	D	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	loss	D	TLK2				
Q86UE8/S659A	Q86UE8	TLK2/S659A	TLK2	Reviewed;	MUTAGEN	S	659	A	Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	D	TLK2				
Q86UE8/S686A	Q86UE8	TLK2/S686A	TLK2	Reviewed;	MUTAGEN	S	686	A	Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	D	TLK2				
Q86UE8/S686D	Q86UE8	TLK2/S686D	TLK2	Reviewed;	MUTAGEN	S	686	D	Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	D	TLK2				
Q86UE8/T695A	Q86UE8	TLK2/T695A	TLK2	Reviewed;	MUTAGEN	T	695	A	Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	D	TLK2				
Q86UE8/R720A	Q86UE8	TLK2/R720A	TLK2	Reviewed;	MUTAGEN	R	720	A	Reduced phosphorylation of ASF1A."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	D	TLK2				
Q59H18/G526D	Q59H18	TNNI3K/G526D	TNNI3K	Reviewed;	VARIANT	G	526	D	(in CCDD; the mutation results in decreased;protein solubility; causes abnormal aggregation; markedly;reduced protein expression is observed in the sarcoplasm;and nuclei of patient cardiomyocytes; dbSNP:rs606231469)"";/evidence=""ECO:0000269|PubMed:24925317"";/id=""VAR_072650""	decrease	D	TNI3K				
Q59H18/K490R	Q59H18	TNNI3K/K490R	TNNI3K	Reviewed;	MUTAGEN	K	490	R	Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:12721663""	loss	D	TNI3K				
Q9UKE5/K54A	Q9UKE5	TNIK/K54A	TNIK	Reviewed;	MUTAGEN	K	54	A	Kinase dead. Loss of autophosphorylation and;loss of function in cytoskeleton regulation."";/evidence=""ECO:0000269|PubMed:15342639,;ECO:0000269|PubMed:19816403""	loss	D	TNIK				
O75962/E1299K	O75962	TRIO/E1299K	TRIO	Reviewed;	VARIANT	E	1299	K	(in MRD44; severely decreased activation of;RAC1-mediated signaling; severely decreased neurite;outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083920""	decrease	D	TRIO				
O75962/R1428Q	O75962	TRIO/R1428Q	TRIO	Reviewed;	VARIANT	R	1428	Q	(in MRD44; severely decreased activation of;RAC1-mediated signaling; severely decreased neurite;outgrowth; dbSNP:rs879255626)"";/evidence=""ECO:0000269|PubMed:27418539,;ECO:0000269|PubMed:32109419"";/id=""VAR_077096""	decrease	D	TRIO				
O75962/H1469R	O75962	TRIO/H1469R	TRIO	Reviewed;	VARIANT	H	1469	R	(in MRD44; decreased activation of RAC1-;mediated signaling; severely decreased neurite outgrowth;;dbSNP:rs1554070777)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083922""	decrease	D	TRIO				
O75962/E1299A	O75962	TRIO/E1299A	TRIO	Reviewed;	MUTAGEN	E	1299	A	50% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/T1303A	O75962	TRIO/T1303A	TRIO	Reviewed;	MUTAGEN	T	1303	A	40% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/V1426A	O75962	TRIO/V1426A	TRIO	Reviewed;	MUTAGEN	V	1426	A	90% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/Q1427A	O75962	TRIO/Q1427A	TRIO	Reviewed;	MUTAGEN	Q	1427	A	80% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/R1428A	O75962	TRIO/R1428A	TRIO	Reviewed;	MUTAGEN	R	1428	A	80% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/T1430A	O75962	TRIO/T1430A	TRIO	Reviewed;	MUTAGEN	T	1430	A	80% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/K1431A	O75962	TRIO/K1431A	TRIO	Reviewed;	MUTAGEN	K	1431	A	Loss of nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	loss	D	TRIO				
O75962/L1434A	O75962	TRIO/L1434A	TRIO	Reviewed;	MUTAGEN	L	1434	A	40% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
O75962/E1438A	O75962	TRIO/E1438A	TRIO	Reviewed;	MUTAGEN	E	1438	A	30% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	D	TRIO				
Q9BX84/K1804R	Q9BX84	TRPM6/K1804R	TRPM6	Reviewed;	MUTAGEN	K	1804	R	Abolishes kinase activity but does not affect;expression levels or binding to RACK1."";/evidence=""ECO:0000269|PubMed:18258429""	loss	D	TRPM6				
Q9BX84/T1851A	Q9BX84	TRPM6/T1851A	TRPM6	Reviewed;	MUTAGEN	T	1851	A	Significantly decreases autophosphorylation.;Does not alter binding to RACK1 but prevents inhibition by;RACK1."";/evidence=""ECO:0000269|PubMed:18258429""	decrease	D	TRPM6				
Q96QT4/K1648R	Q96QT4	TRPM7/K1648R	TRPM7	Reviewed;	MUTAGEN	K	1648	R	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12887921""	loss	D	TRPM7				
Q96QT4/G1799D	Q96QT4	TRPM7/G1799D	TRPM7	Reviewed;	MUTAGEN	G	1799	D	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12887921""	loss	D	TRPM7				
Q9BXA7/T174A	Q9BXA7	TSSK1B/T174A	TSSK1B	Reviewed;	MUTAGEN	T	174	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15733851""	loss	D	TSSK1				
Q6SA08/K54M	Q6SA08	TSSK4/K54M	TSSK4	Reviewed;	MUTAGEN	K	54	M	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15964553""	loss	D	TSSK4				
Q9BXA6/K41M	Q9BXA6	TSSK6/K41M	TSSK6	Reviewed;	MUTAGEN	K	41	M	Loss of kinase activity. Loss of binding to;TSACC."";/evidence=""ECO:0000269|PubMed:15870294,;ECO:0000269|PubMed:20829357""	loss	D	TSSK6				
Q6IQ55/D163A	Q6IQ55	TTBK2/D163A	TTBK2	Reviewed;	MUTAGEN	D	163	A	Abolishes serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	loss	D	TTBK2				
Q6IQ55/R181E	Q6IQ55	TTBK2/R181E	TTBK2	Reviewed;	MUTAGEN	R	181	E	A: Impaired serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	decrease	D	TTBK2	loss	loss; also R181A missing		
Q6IQ55/A184E	Q6IQ55	TTBK2/A184E	TTBK2	Reviewed;	MUTAGEN	A	184	E	G: Impaired serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	decrease	D	TTBK2	loss	loss; also A184G missing		
P33981/D664A	P33981	TTK/D664A	TTK	Reviewed;	MUTAGEN	D	664	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18243099,;ECO:0000269|PubMed:18480048""	loss	D	TTK				
P33981/T686A	P33981	TTK/T686A	TTK	Reviewed;	MUTAGEN	T	686	A	Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18480048""	loss	D	TTK				
P42681/K299A	P42681	TXK/K299A	TXK	Reviewed;	MUTAGEN	K	299	A	Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:9813138""	decrease	D	TXK	loss	loss		
P29597/K930R	P29597	TYK2/K930R	TYK2	Reviewed;	MUTAGEN	K	930	R	Complete loss of catalytic activity."";/evidence=""ECO:0000269|PubMed:8702790""	loss	D	TYK2				
P29597/D1023N	P29597	TYK2/D1023N	TYK2	Reviewed;	MUTAGEN	D	1023	N	Complete loss of catalytic activity."";/evidence=""ECO:0000269|PubMed:24843152""	loss	D	TYK2				
O75385/K46I	O75385	ULK1/K46I	ULK1	Reviewed;	MUTAGEN	K	46	I	Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:20921139,;ECO:0000269|PubMed:28821708""	loss	D	ULK1				
Q8IYT8/K39R	Q8IYT8	ULK2/K39R	ULK2	Reviewed;	MUTAGEN	K	39	R	Decreased kinase activity and decreased;autophosphorylation."";/evidence=""ECO:0000269|PubMed:18936157""	decrease	D	ULK2				
Q6PHR2/K44R	Q6PHR2	ULK3/K44R	ULK3	Reviewed;	MUTAGEN	K	44	R	Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:19878745""	decrease	D	ULK3				
Q6PHR2/K139R	Q6PHR2	ULK3/K139R	ULK3	Reviewed;	MUTAGEN	K	139	R	Loss of kinase activity. Does not promote GLI1;nuclear localization."";/evidence=""ECO:0000269|PubMed:19878745,;ECO:0000269|PubMed:20643644""	loss	D	ULK3				
P17948/Y914F	P17948	FLT1/Y914F	FLT1	Reviewed;	MUTAGEN	Y	914	F	Reduces phosphorylation at other tyrosine;residues."";/evidence=""ECO:0000269|PubMed:9722576""	decrease	D	VGFR1				
P17948/Y1242F	P17948	FLT1/Y1242F	FLT1	Reviewed;	MUTAGEN	Y	1242	F	Loss of phosphorylation site."";/evidence=""ECO:0000269|PubMed:9722576""	loss	D	VGFR1		Missing 'loss/decrease': K861M, Y1169F (abolish phosphorylation by PLCG), Y1213F (abolish phosphorylation by PIK3R1), Y1333F (abolish phosphorylation by CBL)		
P17948/Y1327F	P17948	FLT1/Y1327F	FLT1	Reviewed;	MUTAGEN	Y	1327	F	Loss of phosphorylation site."";/evidence=""ECO:0000269|PubMed:9722576""	loss	D	VGFR1				
P35968/V848E	P35968	KDR/V848E	KDR	Reviewed;	VARIANT	V	848	E	(strongly reduced autophosphorylation and;kinase activity; dbSNP:rs1139776)"";/evidence=""ECO:0000269|PubMed:10037737,;ECO:0000269|PubMed:1656371"";/id=""VAR_046679""	decrease	D	VGFR2				
P35968/R726A	P35968	KDR/R726A	KDR	Reviewed;	MUTAGEN	R	726	A	Strongly reduced autophosphorylation and;activation of MAP kinases."";/evidence=""ECO:0000269|PubMed:20080685""	decrease	D	VGFR2				
P35968/D731A	P35968	KDR/D731A	KDR	Reviewed;	MUTAGEN	D	731	A	Strongly reduced autophosphorylation and;activation of MAP kinases."";/evidence=""ECO:0000269|PubMed:20080685""	decrease	D	VGFR2				
P35968/K868M	P35968	KDR/K868M	KDR	Reviewed;	MUTAGEN	K	868	M	Loss of enzyme activity."";/evidence=""ECO:0000269|PubMed:11387210""	loss	D	VGFR2				
P35968/Y996F	P35968	KDR/Y996F	KDR	Reviewed;	MUTAGEN	Y	996	F	Strongly reduced autophosphorylation. Reduces;phosphorylation of PLCG1."";/evidence=""ECO:0000269|PubMed:10102632""	decrease	D	VGFR2				
P35968/Y1175F	P35968	KDR/Y1175F	KDR	Reviewed;	MUTAGEN	Y	1175	F	Abolishes phosphorylation of PLCG1 and MAP;kinases in response to VEGFA."";/evidence=""ECO:0000269|PubMed:11387210""	loss	D	VGFR2				
P35968/Y1214F	P35968	KDR/Y1214F	KDR	Reviewed;	MUTAGEN	Y	1214	F	Loss of phosphorylation site. Abolishes;reorganization of the actin cytoskeleton in response to;VEGFA."";/evidence=""ECO:0000269|PubMed:16966330""	loss	D	VGFR2				
P35916/A855T	P35916	FLT4/A855T	FLT4	Reviewed;	VARIANT	A	855	T	(in LMPHM1; recessive form; results in;reduced autophosphorylation; results in impaired ligand-;induced receptor internalization and downstream signaling;;dbSNP:rs121909657)"";/evidence=""ECO:0000269|PubMed:19289394"";/id=""VAR_074044""	decrease	D	VGFR3				
P35916/G857R	P35916	FLT4/G857R	FLT4	Reviewed;	VARIANT	G	857	R	(in LMPHM1; loss of kinase activity;;dbSNP:rs267606818)"";/evidence=""ECO:0000269|PubMed:10835628,;ECO:0000269|PubMed:15102829"";/id=""VAR_018409""	loss	D	VGFR3				
P35916/H1035R	P35916	FLT4/H1035R	FLT4	Reviewed;	VARIANT	H	1035	R	(in LMPHM1; loss of kinase activity;;dbSNP:rs121909653)"";/evidence=""ECO:0000269|PubMed:10856194"";/id=""VAR_018412""	loss	D	VGFR3				
P35916/R1041P	P35916	FLT4/R1041P	FLT4	Reviewed;	VARIANT	R	1041	P	(in LMPHM1; loss of kinase activity;;dbSNP:rs121909650)"";/evidence=""ECO:0000269|PubMed:10835628,;ECO:0000269|PubMed:12881528"";/id=""VAR_018413""	loss	D	VGFR3				
P35916/L1044P	P35916	FLT4/L1044P	FLT4	Reviewed;	VARIANT	L	1044	P	(in LMPHM1; loss of kinase activity;;dbSNP:rs121909651)"";/evidence=""ECO:0000269|PubMed:10835628"";/id=""VAR_018414""	loss	D	VGFR3				
P35916/P1114L	P35916	FLT4/P1114L	FLT4	Reviewed;	VARIANT	P	1114	L	(in LMPHM1; loss of kinase activity;;dbSNP:rs121909652)"";/evidence=""ECO:0000269|PubMed:10835628,;ECO:0000269|PubMed:9817924"";/id=""VAR_018415""	loss	D	VGFR3				
P35916/K879G	P35916	FLT4/K879G	FLT4	Reviewed;	MUTAGEN	K	879	G	Abolishes enzyme activity."";/evidence=""ECO:0000269|PubMed:12881528""	loss	D	VGFR3				
P35916/Y1068F	P35916	FLT4/Y1068F	FLT4	Reviewed;	MUTAGEN	Y	1068	F	Global loss of autophosphorylation. Abolishes;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:16076871,;ECO:0000269|PubMed:20431062""	loss	D	VGFR3				
P35916/Y1230F	P35916	FLT4/Y1230F	FLT4	Reviewed;	MUTAGEN	Y	1230	F	Loss of phosphorylation site. Strongly reduces;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:16076871""	decrease	D	VGFR3				
P35916/Y1231F	P35916	FLT4/Y1231F	FLT4	Reviewed;	MUTAGEN	Y	1231	F	Loss of phosphorylation site. Strongly reduces;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:16076871""	decrease	D	VGFR3				
P35916/Y1333F	P35916	FLT4/Y1333F	FLT4	Reviewed;	MUTAGEN	Y	1333	F	Loss of phosphorylation site. Reduced;autophosphorylation."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:7675451""	decrease	D	VGFR3				
P35916/Y1337F	P35916	FLT4/Y1337F	FLT4	Reviewed;	MUTAGEN	Y	1337	F	Reduced autophosphorylation. Strongly reduces;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:7675451""	decrease	D	VGFR3				
P35916/Y1363F	P35916	FLT4/Y1363F	FLT4	Reviewed;	MUTAGEN	Y	1363	F	Loss of phosphorylation site. Slightly reduced;autophosphorylation."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:7675451""	decrease	D	VGFR3				
Q99986/S342A	Q99986	VRK1/S342A	VRK1	Reviewed;	MUTAGEN	S	342	A	Abolishes phosphorylation by PLK3 and;induction of Golgi fragmentation during mitosis. Strongly;reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:19103756,;ECO:0000269|PubMed:21543316""	decrease	D	VRK1				
Q99986/T353A	Q99986	VRK1/T353A	VRK1	Reviewed;	MUTAGEN	T	353	A	Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:21543316""	decrease	D	VRK1				
Q86Y07/K179E	Q86Y07	VRK2/K179E	VRK2	Reviewed;	MUTAGEN	K	179	E	Abolished protein serine/threonine kinase;activity."";/evidence=""ECO:0000269|PubMed:33076429""	loss	D	VRK2				
P30291/K328R	P30291	WEE1/K328R	WEE1	Reviewed;	MUTAGEN	K	328	R	Abolishes activity."";/evidence=""ECO:0000269|PubMed:8428596""	loss	D	WEE1				
P30291/S642A	P30291	WEE1/S642A	WEE1	Reviewed;	MUTAGEN	S	642	A	Abolishes phosphorylation by BRSK1 and BRSK2."";/evidence=""ECO:0000269|PubMed:20026642""	loss	D	WEE1				
P0C1S8/D234H	P0C1S8	WEE2/D234H	WEE2	Reviewed;	VARIANT	D	234	H	(in OOMD5; decreased WEE2 phosphorylation at;serine residues; decreased CDK1/CDC2 phosphorylation at 'Y-;15'; dbSNP:rs1554415096)"";/evidence=""ECO:0000269|PubMed:29606300"";/id=""VAR_080992""	decrease	D	WEE2				
P43403/D461N	P43403	ZAP70/D461N	ZAP70	Reviewed;	MUTAGEN	D	461	N	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	loss	D	ZAP70				
P43403/D479N	P43403	ZAP70/D479N	ZAP70	Reviewed;	MUTAGEN	D	479	N	Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15292186""	loss	D	ZAP70				
P43403/Y493F	P43403	ZAP70/Y493F	ZAP70	Reviewed;	MUTAGEN	Y	493	F	Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:7781602""	decrease	D	ZAP70	loss	loss		